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Initial HIV-1 therapy selection is informed by sequencing of a bulk PCR product 
to screen for antiretroviral resistance mutations. However, this method does not reliably 
sample drug resistant variants that occur in <20% of the viral population, and these may 
re-emerge and impair treatment response once therapy is administered. Alternatively, 
ultra deep sequencing can detect minority drug resistant variants, but it is difficult to 
distinguish very low abundance mutations from error. To address deep sequencing 
error, two regions of the HIV-1 genome spanning reverse transcriptase (RT) codons 34-
245 were tagged with a random 8-nucleotide sequence (Primer ID) prior to PCR and 
sequencing. Primer ID allowed us to use resampled raw sequences sharing the same 
Primer ID to construct consensus sequences, each representing an original viral 
template within that sample.  
We first established a residual error rate for Primer ID using known sequences 
for both the Roche 454 and Illumina MiSeq deep sequencing platforms. Primer ID 
reduced 454 and MiSeq errors from 71 to 2.6 and from 24 to 1.2 errors/10,000 
nucleotides, respectively. Applying Primer ID corrected 454 deep sequencing to 184 
therapy-naïve patients from North Carolina that went on to receive RT inhibitor based 
combination therapy, we found that 14% of had at least one RT inhibitor mutation, 
compared to 2.7% using standard bulk sequence analysis. Nearly 10% of 184 patients 
received regimens that contained fewer than 3 active antiretrovirals, according to the 
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Stanford resistance algorithm. While patients on suboptimal therapy failed faster than 
patients on fully-active regimens, the effect was driven by resistance detected by 
standard methods rather than previously undetected minority variants. Overall, the use 
of Primer ID revealed limited template utilization, limiting the depth of deep sequencing 
sampling. Primer ID addresses important limitations of deep sequencing and produces 
less biased estimates of low level resistance mutations in the viral population, which may 
allow us to more accurately define a threshold at which minority drug resistant variants 
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CHAPTER 1     SPECIFIC AIMS 
 
1.1     STATEMENT OF PURPOSE 
HIV-related morbidity and mortality have declined significantly since the 
introduction of highly active antiretroviral therapy (HAART) [1, 2]. However, the benefits 
of potent combination antiretroviral therapy may be offset by the development of 
resistance and cross-resistance to these drugs [3]. Furthermore, HIV-1 variants with 
antiretroviral (ARV) resistance mutations may be transmitted to others, possibly limiting 
efficacy of HAART among patients initiating antiretroviral therapy [4, 5]. 
US Department of Health and Human Services (DHHS) Guidelines recommend 
resistance testing combined with expert opinion in patients failing therapy [6]. However, 
DHHS recommendations have only recently favored testing all patients prior to initiating 
therapy, irrespective of duration of HIV infection. DHHS’s caution stems from the fact 
that commercially-available genotypic antiretroviral resistance tests (GART) are unable 
to reliably detect minority HIV-1 variants present in below 20% of the population [7, 8]. 
Low sensitivity for minority variants could be problematic for testing chronically infected 
therapy-naïve patients, since resistant variants may have been overgrown by HIV-1 
variants with better replicative capacity in the absence of drug pressure. However, once 
corresponding drugs are administered, it is presumed that these minority drug resistant 
variants would quickly re-emerge [9], warranting further exploration into the prevalence, 
diversity, and clinical impact of minority resistance populations [10].  
The clinical utility of resistance testing in therapy-naïve patients is complex and 
depends on some key factors: transmissibility of resistance mutations; prevalence of 
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resistance in treated and untreated populations; persistence of resistance over time 
without drug pressure; and clinical relevance of minority drug-resistant HIV variants. 
Prevalence estimated using standard bulk sequence analysis indicates the burden of 
pre-therapy drug resistance is substantial in populations where ARV drugs have been 
historically more available, with an estimated 10-15% of untreated individuals having 
evidence of resistance [4, 5, 11, 12]. Moreover, transmitted HIV-1 variants with 
resistance mutations may persist as major circulating viral populations in therapy-naïve 
individuals for long periods of time [13-16]. While it is generally accepted that dominant 
resistant variants lead to adverse clinical outcomes in patients initiating therapy [5, 17], 
the impact of minority resistant variants on clinical outcomes is not as well characterized.  
Recent studies have implicated minority non-nucleoside reverse transcriptase 
inhibitor (NNRTI) resistant variants in shorter time to virologic rebound [18], but a 
threshold at which resistance mutations are clinically relevant has not been clearly 
defined. Difficulty in defining a clinical cut-point for variants with resistance mutations is 
partly due to complications associated with their measurement. Specifically, rare HIV-1 
RNA must be enriched in patient samples before sequencing, first by reverse 
transcription of HIV-1 RNA into cDNA followed by polymerase chain reaction (PCR) 
mediated amplification of the cDNA template. While both steps may introduce errors into 
the HIV sequence, PCR amplification in particular is associated with nucleotide 
misincorporation, recombination of viral sequences by template switching, biased 
amplification, and resampling of viral templates due to low template input [19, 20]. 
Further, HIV-1 replicates rapidly without a proofreading mechanism so that, theoretically, 
any mutation may be present in the viral population at any one time [21]. It is therefore 
critical to accurately estimate each individual’s viral population, which may be highly 
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variable and contain very low abundance resistance mutations, before a clinically 
relevant threshold can be defined. 
Ultra deep sequencing (UDS) is a high throughput technique that promises 
sampling depths capable of detecting minority drug resistant variants of HIV-1 [22, 23]. 
For this collection of highly sensitive sequencing platforms, patient-derived HIV-1 nucleic 
acids are amplified, pooled, and sequenced in a massively parallel fashion. Sensitivity is 
mainly limited by the number of HIV-1 RNA templates input and the efficiency with which 
they are reverse transcribed and amplified. However, UDS, like all other methods that 
rely on HIV-1 amplification, is subject to errors associated with PCR. UDS platforms in 
which a single nucleotide is added at one time (e.g., the 454 sequencing platform) are 
additionally prone to nucleotide miscalls within nucleotide repeats (homopolymeric 
regions) [24].  
Errors accumulated during UDS impede estimation of the highly diverse viral 
populations, since these must be distinguished from genuine mutations. Typically, 
known control sequences are used to inform statistical models that correct estimates 
skewed by nucleotide misincorporation, but not PCR re-sampling [25]. Alternatively, 
Jabara et al. introduced a method to address errors stemming from the PCR step 
forward, including PCR re-sampling [26]. With this approach, a random 8-nucleotide 
sequence is incorporated during cDNA synthesis so that each individual viral template is 
tagged with a unique Primer ID. After amplification and sequencing, majority-rules 
consensus sequences are constructed from sequences sharing the same Primer ID so 
that, collectively, these consensus sequences reflect the true viral population sampled 
rather than what was best amplified. Nucleotide miscalls are also filtered out by Primer 
ID consensus sequences since random nucleotide errors are more likely to be 
represented among the minority of raw sequences. 
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In this study, we estimated the prevalence of minority reverse transcriptase 
inhibitor (RTI)-resistant HIV-1 variants among therapy-naïve patients seeking HIV care 
at the University of North Carolina Infectious Disease Clinic and examined the influence 
of these resistant variants on response to early RTI-based HAART. For the latter 
question, we attempted to articulate relationships between the distribution of resistant 
variant within the individual and time-to-virologic failure (VF). To measure minority 
variants, we used an assay that is more sensitive than standard bulk sequence analysis 
to detect and quantify resistance in archived plasma samples from HIV-1-positive North 
Carolinians enrolled in the University of North Carolina Center for AIDS Research HIV 
Clinical Cohort (UCHCC). This assay was based on analysis of ultra deep sequencing 
(UDS) data generated by the 454 sequencing platform with the Primer ID method to 
allow more accurate estimation of the viral population [26]. We first established a 
baseline error rate for deep sequencing using both the 454 and less homopolymeric 
error prone Illumina platforms in a series of control experiments (Aim 1). We compared 
the results of resistance testing by deep sequencing with the 454 platform and standard 
bulk sequencing in samples from 184 patients obtained prior to therapy initiation (Aims 
2A and 2B). Among a subset of 19 patients with the greatest number of Primer ID 
consensus sequences generated using the 454 platform, we compared results obtained 
using the 454 platform to those obtained using the Illumina MiSeq platform, which is not 
susceptible to homopolymeric errors (Aim 2C). Last, we estimated the association of 
pre-therapy RT inhibitor resistant HIV-1 variants with virologic response to early RT 
inhibitor-based HAART (Aim 3).  
1.2     SPECIFIC AIM 1 
Using a known HIV-1 reverse transcriptase sequence, define a baseline error rate for the 
454 and MiSeq deep sequencing platforms. For each platform, compare results 
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estimated using Primer ID consensus sequences to those estimated using raw 
sequences. 
Hypothesis 1.1: Using Primer ID to create consensus sequences will 
reduce PCR and sequencing errors compared to raw sequences.  
Hypothesis 1.2: Error rates estimated using data from the 454 
sequencing platform will be higher in homopolymeric tracts compared to 
stretches of heterogeneous nucleotides. 
1.3     SPECIFIC AIM 2   
(A) Using the 454 FLX platform to sequence HIV-1 RT codons 34-138 and 149-236, 
estimate the prevalence and relative abundance of RT inhibitor resistance among 184 
therapy-naïve patients with concurrent bulk sequencing results. (B) Compare estimates 
obtained using the 454 platform to estimates obtained using bulk sequencing. (C) 
Among a subset of 19 patients with the greatest depth of sampling of viral templates, 
compare mutations detected within HIV-1 RT codons 34-73 and 111-138 between the 
Illumina MiSeq and Roche 454 platforms. 
Hypothesis 2A: Some drug resistance mutations will be detected more 
often as minority variants, particularly those associated with a reduction in fitness 
or those that are in homopolymeric regions (false positives), than other resistant 
variants. 
Hypothesis 2B.1: A larger proportion of the population will have 
evidence of RT inhibitor associated resistance mutations using deep sequencing 
compared to standard bulk sequence analysis. 
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Hypothesis 2B.2: Deep sequencing and bulk sequencing results will 
agree for drug resistance mutations that occur frequently on Primer ID 
consensus sequences within a patient sample. 
Hypothesis 2C.1: Results obtained using both ultra deep sequencing 
platforms will be highly concordant for mutations that occur on the majority of 
Primer ID consensus sequences. 
Hypothesis 2C.2: Results obtained using both platforms will be 
discordant for mutations that lie within stretches of homopolymeric sequence, 
and for mutations that occur in very low abundance. 
1.4     SPECIFIC AIM 3  
Among study participants with HIV-1 RT sequences obtained using both bulk 
sequencing and the 454 deep sequencing platform, estimate the association of pre-
therapy resistance to one or more antiretroviral agents within their first regimen on time-
to-first virologic failure (VF). 
Hypothesis 3.1: Participants harboring pre-therapy mutations conferring 
resistance to at least one ARV agent in their first HAART regimen will experience 
a shorter time-to-virologic failure compared to patients without any evidence of 
resistance at baseline. 
Hypothesis 3.2: The magnitude of the association of ARV with 





CHAPTER 2     BACKGROUND 
 
2.1     EPIDEMIOLOGY OF HIV INFECTION 
The HIV epidemic has vastly altered the global infectious disease landscape 
since five patients were first identified with Pneumocystis carinii pneumonia in Los 
Angeles in October 1980 [27]. Over more than 30 years since, an estimated 34 million 
persons are living with HIV/AIDS worldwide, about 0.8% of the world’s reproductive aged 
population [28]. Some regions of the world are disproportionately affected, such as sub-
Saharan Africa, which accounts for 64% of the infected population [28]; however, even in 
the United States, over 600,000 people have died from AIDS and over 1 million people 
are living with HIV/AIDS [29] 
Persons living with HIV in the US represent a paradigm shift in the course of 
infection. This shift occurred as HIV underwent a transition from an illness of long clinical 
latency leading inevitably to AIDS and death into a manageable chronic illness of 
unknown duration. This shift, which is unequally distributed within the US population of 
HIV-infected individuals, was primarily due to the advent of combinations of powerful 
antiretroviral drugs with different mechanisms of action against the HIV virus, or highly 
active antiretroviral therapy (HAART) [1, 2, 30]. More people with HIV/AIDS are living 
longer as increasingly potent and tolerable regimens have become available (Figure 
2.1), but patients are completely dependent on HAART for remainder of their lives to 




Figure 2.1. AIDS cases, deaths, and persons living with AIDS, 1985-2009, US [31]. Data is 
adjusted for reporting delays. In 1993, the Centers for Disease Control and Prevention 
revised the definition of AIDS to include persons with CD4 cell counts <200 cells/µL [32]. In 
1996, widespread use of HAART began. HAART=highly active antiretroviral therapy. 
After HIV was eliminated from the blood supply, HIV/AIDS was thought to be 
confined to high risk groups, particularly men who have sex with men (MSM) and 
injection drug users (IDU) [33]. Since peaking at 31% in 1993, the proportion of AIDS 
diagnoses attributable to IDU declined to 13% in 2011, while MSM accounted for about 
half of diagnoses during that same period [29]. AIDS cases among persons reporting 
high risk heterosexual contact, while decreasing since 2008, have increased 
proportionately overall from 11% in 1993 to 31% in 2011 [29]. The most striking shift in 
the US epidemic, however, is the widening disparity between whites and racial and 
ethnic minorities. Minorities accounted for fewer than half of all new AIDS diagnoses in 
1985, but this proportion climbed to 74% in 2011 [29].  
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The Deep South, which includes Louisiana, Mississippi, Alabama, Georgia, 
South Carolina, and North Carolina [34], is a high priority region for HIV research, since 
the burden of AIDS is disproportionately high in that locale and changes in racial 
disparity and mode of transmission in the Deep South are at least as extreme as in any 
other region in the US. Nearly 17% of persons living with AIDS reside in these 5 states, 
which only account for 11% of the US population [29]. The Deep South has experienced 
a slower decline in AIDS cases since the introduction of HAART compared to other 
southern states and the remainder of the US: the Deep South experienced about a 19% 
decrease in AIDS diagnoses since 1996, while the remaining southern and non-southern 
states saw 38% and 52% declines [29, 35-45]. African Americans made up 70-77% of 
new AIDS cases in the Deep South in 2000-2004, which was higher than any other US 
region [46]. Further, the HIV epidemic in this region is driven by sexual transmission with 
heterosexual transmission playing an important role, particularly among women. 
Through 2002, 53% of all AIDS cases in the region were attributed to heterosexual 
transmission, with the majority of which were women [47].  
2.2     HIV VIROLOGY 
Acquired Immunodeficiency Syndrome (AIDS) was first recognized in 1980, but 
the causative pathogen, human immunodeficiency virus (HIV), was not identified until 
1983, when scientists at the Pasteur Institute in Paris isolated a retrovirus from a lymph 
node of a patient with AIDS [48]. Since this discovery, HIV virology has been vigorously 
studied in hopes of developing effective vaccines, powerful treatments, and a potential 
cure.  
Human immunodeficiency virus (HIV) belongs to the genus Lentivirus of the 
family Retroviridae based on shared morphology and similar mode of replication [49]. 
HIV is further classified into HIV-1 and HIV-2 based on genetic variability. HIV-1, which 
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originated in eastern and central Africa, and HIV-2 from western Africa, were both 
important in the early epidemic long before the 1980’s [50], but the current pandemic is 
due to HIV-1, and in particular HIV-1 Group M [50, 51]. While HIV-1 Group M subtype C 
is the most prevalent in the world given its dominance in Africa, subtype B, which is most 
prevalent in North America and Western Europe, has traditionally been the most 
frequently studied.   
HIV-1 is an enveloped virus with a matrix protein that surrounds a nucleoid 
structure in the center of the viral particle [49]. The nucleoid structure of mature HIV-1 
contains the viral dimeric RNA genome surrounded by a nucleocapsid core, which in 
turn is housed in the viral capsid. This nucleoid structure also contains viral enzymes 
integrase, reverse transcriptase (RT), and protease (PR). Surrounding the virion is a 
host-derived envelope, which is embedded with numerous spike-like glycoproteins that 
are responsible for host cell attachment and fusion [52]. Each glycoprotein is composed 
of three transmembrane gp41 subunits (trimer) plus a gp120 trimer that binds to the host 
cell’s CD4 receptor and CCR5 or CXCR4 coreceptor [53]. 
The HIV genome is approximately 9 kb in length and encodes ten genes: 
regulatory genes tat and rev; accessory genes vpu, vpr, vif, and nef; and structural 
genes gag, pro, pol, env (Figure 2.2). In addition, the HIV DNA genome includes non-
coding regulatory sequences, including two flanking long terminal repeats (LTR). Among 
the coding regions, regulatory gene rev encodes a protein that shuttles incompletely 
spliced RNA transcripts from cellular nucleus to cytoplasm for translation and packaging, 
while tat encodes a transcription factor that upregulates HIV DNA expression [54]. 
Accessory genes vpu, vpr, vif, and nef, encode proteins that likely inhibit cellular 
retroviral defenses [49]. Gag and env encode proteins that make up the nucleoid 
structure and envelope, respectively, while pro encodes HIV-1 PR. Finally, pol encodes 
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enzymes necessary for reverse transcription of viral RNA into DNA (RT and 
ribonuclease H, RNAse H) and integration (integrase, IN) of viral DNA into the host 
genome. In this study, HIV-1 pol is the region of interest since the most widespread 
therapeutic strategies target its products.   
 
Figure 2.2. HIV-1-encoded proteins (reprinted from [49]). Location of HIV-1 genes, sizes of 
primary translation products, and processed mature viral proteins are indicated. LTR=long 
terminal repeat; MA=matrix protein; CA=capsid protein; NC=nucleocapsid protein; 
IN=integrase. 
 
2.3     NATURAL HISTORY OF HIV INFECTION 
The classic model for the course of HIV infection in an untreated individual can 
be divided into three distinct phases: acute infection; chronic infection; and AIDS (Figure 
2.3) [55-57]. Typically, initial HIV infection is followed by a steep rise in plasma viral load 
and a drop in peripheral CD4+ T lymphocytes. This acute stage is followed by a partial 
rebound of CD4 cell count and a decline of plasma viral load to a relatively stable set-
point. This period of stable HIV-1 RNA concentration is generally marked by the near 
absence of overt clinical illness; however, dynamic immunologic changes are taking 
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place within the infected individual. Eventually, CD4 cell count falls below a threshold, 
plasma HIV-1 RNA concentration slowly rises, and the individual begins to experience 
opportunistic infections. Immune function continues to deteriorate over time and death 
follows, usually within 2 years of the onset of opportunistic infections. 
 
Figure 2.3. Classic model of HIV disease progression in the untreated HIV-infected adult. 
(adapted from [55-57]). 
 
2.3.1     TRANSMISSION AND ACUTE/EARLY INFECTION 
HIV disease begins with the transmission of the virus to a susceptible individual 
(time 0, Figure 2.3). HIV may be transmitted sexually, parenterally though exposure to 
infected blood products, or from mother to child. The probability of HIV transmission per 
exposure is highly variable and depends on exposure route, infectiousness of the 
transmitter, and susceptibility of the uninfected individual. Infectiousness of the 
transmitter is influenced by factors that alter the dose of virus to the susceptible 
individual. For example, acutely-infected individuals have higher viral loads in plasma, 
semen, and cervicovaginal fluids compared to persons with chronic HIV infection and 
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are therefore more likely to transmit HIV [58-60]. Conversely, infectiousness decreases 
with suppressive HAART, which lowers viral replication in these same fluids [61], and its 
use among discordant couples reduces HIV transmission [62, 63].  
Susceptibility may be influenced by factors that disrupt the mucosal barrier of the 
susceptible individual (concurrent infection with other sexually transmitted diseases 
(STD)), that are related to or modify the number of susceptible cells at the site of 
infection, (male circumcision, CCR5 Δ32 allele), or that modulate immune response 
(human leukocyte antigen class I alleles) [64-67]. Individual effects of each of these co-
factors on the probability of transmission are difficult to distinguish, given uncertain 
timing of events in the transmission process and high correlation between HIV, other 
STD, and high-risk behaviors [67]. How these co-factors might affect the transmission 
and acquisition of different variants of HIV-1, including those harboring drug resistance 
mutations, is even less certain.     
Once HIV is successfully transmitted, the acute stage of infection begins. During 
the first 2 weeks of acute infection, the virus disseminates from local to peripheral 
lymphatic tissues, creating a reservoir from which the virus can persist and replicate for 
the duration of disease [68]. Establishment of this viral reservoir within the peripheral 
lymphatic tissues is accompanied by irreversible and massive depletion of effector 
memory CCR5+ CD4+ T cells, particularly within the gastrointestinal tract [69, 70]. 
Massive die off of CCR5+ CD4+ T cells is not reflected in peripheral CD4 cell counts, 
since CCR5+ CD4+ T cells are not as common in peripheral blood and lymphatic tissues 
where central memory CCR5- CD4+ T cells dominate [71]. 
Within infected CCR5+ CD4+ T cells, HIV replication increases exponentially 
without significant control by an adaptive immune response, resulting in a burst in 
plasma virus concentration often higher than 10 million copies/mL [72]. As the adaptive 
14 
 
immune system becomes activated, many individuals with acute HIV may experience a 
constellation of non-specific, flu-like symptoms, collectively called acute retroviral 
syndrome [73, 74]. The onset of acute retroviral syndrome and the steep rise in viral 
titers coincides with the initiation of a CD8+ cytotoxic T lymphocyte response that is 
ultimately insufficient to eliminate HIV infection [75], but often allows reduction of viral 
load to a lower, somewhat more stable set-point [76]. Both lower viral load set-point and 
more rapid viral decay after reaching peak viral load during acute HIV infection have 
been linked to increased duration of the chronic stage of infection [76]. 
2.3.2     CHRONIC INFECTION AND AIDS 
The chronic stage of HIV disease begins with the establishment of the viral load 
set-point and detection of antibodies by standard clinical assays (seroconversion), but 
the duration of this relatively asymptomatic stage differs substantially among individuals. 
Some fast progressors experience AIDS onset within 2-3 years of seroconversion, while 
some long term non-progressors maintain high CD4 cell counts, lower viral loads, and 
remain asymptomatic for greater than 15 years after seroconversion [77]. However, on 
average, the time between seroconversion and the onset of AIDS-defining clinical 
conditions is around 10 years [78]. Although chronic infection of any duration is a period 
of clinical latency, in the absence of therapy, immunologic changes occur within the 
infected host that ultimately lead to the collapse of the immune system and the onset of 
AIDS. 
Once an infected person’s CD4 cell count has declined below 200 cells/µL, the 
individual meets the CDC laboratory definition of AIDS onset [32]. At this level of 
immunodeficiency, there is profound damage to the architecture of the lymphatic 
structures [55, 79], probably resulting from both indirect damage caused by general 
chronic immune activation and direct  damage due to cytopathic effects of HIV 
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replication and immunologic responses specific to HIV [56]. By the time HIV-infected 
individuals have met this definition of AIDS onset, many will already have begun 
experiencing symptoms such as oral candidiasis, herpes zoster outbreaks, recurrent oral 
ulcers, or constitutional symptoms such as prolonged fever, weight loss, or chronic 
diarrhea [32]. However, usually within 2 years after the laboratory threshold is reached, 
most begin experiencing the opportunistic illnesses that are listed in CDC category C, 
known as AIDS-defining clinical conditions [80, 81]. The number, duration, and severity 
of opportunistic infections vary among individuals, as does the prognosis. In one study, 
median survival for systemic illnesses such as progressive multifocal 
leukoencephalopathy was only 2 months (inter-quartile range, IQR: 1-5), while median 
survival for more superficial infections such as extrapulmonary tuberculosis was 19 
months (IQR: 7-37) [82].  
2.4     TREATMENT STRATEGIES FOR HIV INFECTION 
Potent combinations of ARV agents (HAART) have lengthened the chronic stage 
of HIV infection, reduced mortality [1, 2, 30, 83, 84], and improved AIDS survival time 
[85]. The expanding ARV repertoire in clinical use now includes 26 drugs from five 
classes distinguished by their mechanism of action against HIV (Figure 2.4) [86]. The 
five classes are: nucleoside and nucleotide reverse transcriptase inhibitors (NRTI); non-
NRTI (NNRTI); protease inhibitors (PI); entry inhibitors (EI), including fusion and CCR5 
inhibitors; and integrase strand transfer inhibitors (InSTI). Development of newer, better 
ARV is guided by our increasing understanding of the life cycle of HIV-1 and fueled by 
our need to outpace the development of resistance and cross-resistance within classes 




Figure 2.4. Antiretrovirals approved by the US Food and Drug Administration for the 
treatment of HIV-1 infection, 1987-2011 [86]. NRTI=nucleoside reverse transcriptase 
inhibitor; PI=protease inhibitor; NNRTI=non-NRTI; EI=entry inhibitor; InSTI=integrase 
strand transfer inhibitor; AZT=zidovudine; ddI=didanosine; ddC=zalcitabine; 
d4T=stavudine=3TC=lamivudine; ABC=abacavir; TDF=tenofovir; SQV=saquinavir; 
RTV=ritonavir; IDV=indinavir; NFV=nelfinavir=APV=amprenavir; LPV=lopinavir; 
ATV=atazanavir; FPV=fosamprenavir; TPV=tipranavir; DRV=darunavir; NVP=nevirapine; 
DLV=delavirdine; EFV=efavirenz; ETR=etravirine; RPV=rilpivirine; T20=enfuvirtide; 
MVC=maraviroc; RAL=raltegravir. 
The primary goals of HAART, as listed in DHHS treatment guidelines, are to: (1) 
reduce HIV-related morbidity and mortality; (2) improve quality of life; (3) restore and 
preserve immune function; (4) maximally and durably suppress viral load to below the 
limits of detection; and (5) prevent HIV transmission [6]. Modern HAART regimens 
include two NRTI as a “backbone,” along with a single NNRTI, a PI boosted with a low 
dose of the PI ritonavir (PI/r), an additional NRTI, or an InSTI [6, 87]; however, 
individuals may also maintain virologic suppression with a combination of an NNRTI and 
PI/r without a nucleoside backbone [88]. HAART is an effective and durable inhibitor of 
HIV replication since the combination of drugs from different ARV classes with different 
mechanisms of action minimizes the possibility of resistance to all three agents that 
make up the HAART regimen. 
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2.4.1     INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE 
Since the focus of this study is on reverse transcriptase inhibitor (RTI) resistance 
mutations, this discussion will focus on drugs within the NRTI and NNRTI classes. NRTI 
(Figure 2.4, black bars) are chain terminators of reverse transcription that halt reverse 
transcription of viral RNA when incorporated into the nascent DNA strand [89]. NRTI are 
the least potent inhibitors of viral replication because they are competitive inhibitors of 
naturally occurring cellular nucleotides and must be processed by the cell into an active 
form. Nucleoside reverse transcriptase inhibitors, including zidovudine (AZT), didanosine 
(ddI), discontinued zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir 
(ABC), and emtricitabine (FTC) [86], lack all three phosphate groups that are needed for 
incorporation into a DNA molecule and must have 3 phosphates added by cellular 
kinases. In contrast, the nucleotide reverse transcriptase inhibitor, tenofovir (TDF) [86], 
already has 1 phosphonate group prior to cell entry and require only 2 intracellular 
phosphorylation steps [90]. Once converted into an active form, NRTI halt DNA 
synthesis since they lack a 3’ hydroxyl group needed to connect the next nucleotide.  
NNRTI (Figure 2.4, medium gray bars) are a more structurally diverse group of 
compounds that inhibit HIV-1 RT by binding a hydrophobic pocket near the active site of 
this enzyme [91]; thus, NNRTI are allosteric inhibitors of HIV-1 RT. Once bound to RT, 
NNRTI induce a conformational change at the active site of RT that prevents the enzyme 
from binding correctly to nucleotides, the RT primer, and the RNA template [91]. NNRTI 
are highly specific to HIV-1 RT, which allows the inhibitory concentration of NNRTI to be 
lower than the amount that would be toxic to the individual [91]. NNRTI have higher oral 
bioavailability compared to nucleoside analogs since they do not have to be converted 
by the body into an active form, and these compounds have longer serum half-lives than 
nucleoside analogues (NRTI). Currently-approved NNRTI include delavirdine (DLV), 
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nevirapine (NVP), efavirenz (EFV), etravirine (ETV), and most recently, rilpivirine (RPV) 
[86]. 
2.4.2     TIMING OF INITIAL ANTIRETROVIRAL THERAPY 
When to initiate HAART and which ARV to combine is a complicated decision 
that is made based on individual and clinician considerations, including the presence of 
pre-existing resistance mutations [87]. Deferring HAART may benefit patients by: 
reducing the risk of treatment related toxicities and side effects; preserving and 
increasing future treatment options; decreasing the risk of treatment fatigue; and 
allowing patients to better understand the demands of HAART [6, 87]. On the other 
hand, deferring HAART may harm patients and their susceptible partners by: allowing 
irreversible damage to the immune system; increasing the risk of disease progression 
and death; and increasing the risk of HIV transmission to uninfected partners [6, 63, 87]. 
Given the risks and benefits of initiating HAART, current guidelines generally endorse 
initiation of therapy in all individuals with HIV infection, irrespective of disease stage [6]. 
All treatment guidelines recommend therapy initiation when individuals become 
symptomatic, regardless of CD4 cell count or HIV-1 RNA level. In asymptomatic 
patients, however, CD4 cell count is favored over HIV-1 RNA level in determining 
antiretroviral therapy initiation. Individuals with CD4 cell counts 200 cells/µL or below are 
offered therapy since initiation below this threshold increases the risk of disease 
progression or death and reduces the efficacy of treatment [92]. Therapy initiation at 
CD4 cell counts between 200 and 350 cells/µL is also recommended, since deferring 
therapy until CD4 cell counts dip below 200 cells/µL is associated with increased 
mortality and incidence of opportunistic infections [6, 87, 93]. Finally, for patients with 
CD4 cell counts ranging between 351 and 500 cells/µL, initiation of therapy is also 
recommended since there is good evidence that disease progression is delayed among 
these individuals, even if mortality is not clearly reduced [6]. CD4 cell count driven 
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recommendations underscore the importance of earlier diagnosis, which unfortunately is 
not the norm in the Southeastern US setting [94]. 
2.4.3     VIROLOGIC RESPONSE TO INITIAL ANTIRETROVIRAL THERAPY 
Once HIV-infected individuals begin HAART, plasma HIV-1 RNA decays in at 
least biphasic fashion. Patients first experience a 2 to 3 log10 decrease in HIV-1 RNA 
plasma concentration within 2 to 4 weeks of starting therapy [95, 96].  This first phase of 
rapid decline is followed by a slower, second phase of decay in which plasma HIV-1 
RNA levels fall below detection limits within an additional 2 to 24 weeks of suppressive 
therapy [97-101]. It is now clear that this second phase lasts indefinitely, since even in 
the presence of potent HAART, there is evidence of ongoing viremia below the limits of 
detection in clinical HIV-1 RNA quantification assays [98, 102, 103]. Also, many patients 
who achieve HIV-1 RNA levels below detection limits experience transient episodes of 
detectible HIV-1 RNA, or “blips.”  Each viral blip is probably associated with its own 
biphasic decline [104], but since blips are usually detected in the context of clinical care, 
where HIV-1 RNA level is measured every 4 to 8 weeks, only a single point on the curve 
is captured. Intermittent viremia may have important implications for drug resistance, 
since ongoing replication of virus under antiretroviral pressure may select for resistant 
variants that may be archived in resting cells or compartmentalized in tissues where viral 
dissemination is restricted, allowing for persistence of drug resistant variants within the 
treated individual [105, 106]. Episodes of intermittent viremia after initial suppression 
occur in 20-40% of patients in clinical care within the first year of therapy [107-109], and 
most of these patients return to suppressed levels upon their next viral load 
measurement. However, a small proportion of patients with intermittent viremia (7-15%) 
do not return to previously suppressed HIV-1 RNA levels by their next HIV-1 RNA 
measurement and experience virologic failure, a form of treatment failure [107-109]. 
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2.4.4     TREATMENT FAILURE 
Treatment failure occurs when patients on therapy do not experience expected 
improvements in terms of virologic response, immune reconstitution, and/or HIV disease 
progression [6]. Treatment failure may be the result of poor adherence, insufficient drug 
concentration, advanced AIDS or other comorbid conditions, or drug resistance. Failure 
often leads to modification or discontinuation of ART, which is common in the clinical 
setting: an estimated 48% of patients in routine clinical care in the UK switched one ARV 
in their regimen within two years of HAART initiation [110]. In a Southeastern US cohort, 
55% of patients discontinued their first HAART regimen within one year; however, most 
of these were associated with drug toxicity rather than treatment failure [111, 112]. 
For this study, one type of treatment failure will be defined – virologic failure (VF). 
Although virologic and immunologic response are highly correlated, there are many 
cases in which patients achieving virologic suppression fail to achieve immunologic 
benefits from HAART [113]. Also, there are many cases in clinical care where patients 
may experience immunological benefits despite persistent viremia while on HAART 
[114]. In most settings, patients experiencing VF include individuals who either fail to 
achieve a significant decline in viral load within the first 6 months of HAART (0.5 to 1 
log10 copies/mL) or have detectible HIV-1 RNA levels after 6 months of HAART. HIV-1 
RNA assay detection limits have evolved over time, and this cut-off is usually set for the 
highest detection limit of all assays used. This definition of failure is flexible since it 
allows for differential viral decay after initiation of HAART that occurs between 
individuals [95]; it includes those individuals who never achieve suppression as well as 
those experiencing virologic rebound; and it allows for viral load blips, which may not be 
clinically important [108, 115].  
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2.5     SELECTION OF RESISTANCE MUTATIONS WITH ANTIRETROVIRAL THERAPY 
Treatment guidelines emphasize the importance of viral suppression to below the 
limits of detection primarily to prevent evolution of antiretroviral resistance mutations [6]. 
With selective pressure of non-suppressive therapy, resistant viral variants may acquire 
additional mutations that increase resistance to a single drug or lead to cross resistance 
to other drugs within that class.  Alternatively, resistant variants may acquire mutations 
that compensate for penalties to viral fitness incurred with initial drug resistance 
mutations [116]. Variants with resistance mutations may also recombine, producing 
populations with additional resistance mutations on the same genome [117, 118]. 
Following convention, resistance mutations are indicated using single letter 
amino acid abbreviations and the codon number; for example, M184V indicates a 
change from wild type methionine (M) to resistant valine (V) at codon 184 of HIV-1 RT 
(Appendix 2.1). Most known amino acid changes and insertions or deletions associated 
with NRTI or NNRTI resistance fall within codons 41 and 225 of HIV-1 RT [119]. The 
accumulation of resistance mutations within these regions is no accident: changes in 
these codons often confer structural changes that disrupt substrate binding and 
processing, not only for natural substrates, but also for inhibitors. 
2.5.1     ANTIRETROVIRAL RESISTANCE AND VIRAL FITNESS 
Viral fitness is defined as the virus’s capacity to replicate in a given environment 
[120]. Since fitness is contextual, the microenvironment in which HIV replicates must be 
well defined. Further, the concept of fitness is so broad that it may be altered at virtually 
any stage in the viral life cycle.  Multiple genes may be in play, thus complicating 
comparisons of viral fitness across studies that use different methods to measure viral 
fitness. However, the concept of viral fitness is central to determining the relative 
abundance of different viral variants in the individual; it is expected that in a given 
microenvironment, such as the presence of non-suppressive therapy, variants with a 
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fitness advantage allowing them to replicate more efficiently will emerge as the dominant 
population.  
In the absence of ARV, many viruses with resistance mutations are less fit than 
the wild type virus, since many of the mutations introduce conformational changes to the 
target enzymes that negatively impact function. The fitness difference between resistant 
and wild type variants differs substantially by ARV class, location, type and number of 
resistance mutations, and the methods and environment in which fitness is measured 
[121]. Because of the fitness cost associated with many drug resistance mutations, the 
more fit, drug sensitive virus tends to re-emerge as the dominant population once drug 
pressure is removed, assuming the patient was initially infected with sensitive virus [9]. 
Such re-emergence includes replacement of resistant variants with archived sensitive 
variants, but reversion of resistance through back mutation is also possible.  
NRTI mutations accumulate under suboptimal therapy, primarily increasing 
resistance rather than compensating for a loss in fitness. Many NRTI mutations (A62V, 
K65R, T69ins, V75I, L74V, F77L, Y115F, F116Y, and Q151M) accumulate near primer 
binding site of RT, impairing the function of the enzyme. For example, the K65R amino 
acid change is associated with decreased incorporation of natural nucleoside substrates 
by HIV-1 RT, especially dATP [122]. RT function may also be impaired by a mutation 
within the polymerase active site, M184V/I, which increases fidelity and reduces 
processivity of the enzyme [123]. A separate class of mutations, selected by AZT and 
d4T, occur outside the primer binding site in “palm” and “finger” subdomains of RT, and 
may have less of an effect on fitness than mutations occurring near the polymerase 
active site [124]. These are collectively called thymidine analogue mutations (TAM), and 
include M41L, D67N, K70R, L210W, T215Y/F and K219Q/E. During non-suppressive 
AZT or d4T therapy, TAM tend to accumulate in two exclusive patterns, with an 
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increasing number of mutations associated with increased resistance and eventually 
cross-resistance to other nucleoside or nucleotide analogues within the NRTI class [125, 
126]: (1) M41L/L210W/T215Y (TAM-1); or (2) D67N/K70R/T215F/K219Q (TAM-2). 
Clustering of TAM into these two patterns has been attributed to changes in fitness 
determined largely by T215Y and L210W [126]. 
Unlike many NRTI resistance mutations, amino acid changes conferring 
resistance to NNRTI are not often associated with large fitness reduction in the absence 
of drug. NNRTI mutations, including K103N, Y181C, and Y188L, are selected rapidly 
under failing NNRTI-based therapy. They may be associated with high-level, class-wide 
resistance, and they may persist for lengthy amounts of time once drug pressure is 
removed [127, 128]. NNRTI mutations cluster near the hydrophobic pocket of RT that is 
the target for NNRTI, and most do not interfere with RT function. However, some NNRTI 
associated resistance mutations, including V106A, G190S/E, and P236L, are associated 
with a significant decline in replicative capacity in the absence of NNRTI; these effects 
on fitness are believed to be due to a decline in RNase H activity of mutant RT [129].   
2.6     MECHANISMS OF REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE 
Pathways of ARV resistance vary by drug class, by ARV within the class, and by 
individual mutation. Many of the best characterized mechanisms were first described 
under monotherapy, but mutations may accumulate and interact in more complex ways 
under combinations of ARV from multiple classes (HAART) [130]. Further, many 
resistance mutations to one class may interact in unexpected ways with mutations to 
another class, complicating expectations about the evolution of resistance mutations 
under suboptimal therapy.  
NRTI resistance mutations were reported almost immediately after the earliest 
NRTI became available [131]. However, as other analogues were introduced, the 
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spectrum of NRTI mutations also broadened, revealing two mechanisms of NRTI 
resistance: (1) reduced incorporation of the NRTI and (2) ATP-mediated excision of the 
NRTI from the terminated DNA strand [116]. The first mechanism, whereby RT shows a 
reduced capacity to add NRTI to the DNA chain, is associated with M184V/I, K65R, and 
the Q151M complex. M184V/I decreases incorporation of 3TC/FTC since the side chains 
of I/V sterically hinder binding of 3TC or FTC [132]. K65R, associated with ABC, ddI, and 
TDF resistance, occurs within the fingers domain of RT, where the wild type K residue 
forms a bridge with an incoming nucleotide; this bridge is disrupted by replacement of K 
with R [133, 134]. Q151M, which is associated with class-wide resistance upon 
accumulation of four additional mutations [135], appears to decrease binding of 
nucleoside analogues [136].  
The second mechanism of resistance to NRTI involves excision of the NRTI from 
the 3’ end of the DNA strand, or primer unblocking. This mechanism is associated with 
TAM, and involves the use of cellular ATP by mutant RT to attack the bond between the 
NRTI and the terminated DNA strand [116]. This second mechanism may be associated 
with cross-resistance to drugs within the NRTI class [137]. Excision of NRTI may also be 
less efficient in the presence of M184V, which may antagonize primer unblocking 
because of its position at the active site [138]. 
Pathways for NNRTI resistance mainly involve mutations that occur in the 
hydrophobic pocket of RT. This hydrophobic pocket, which is distal to the polymerase 
active site, is only formed once the NNRTI is bound to RT. In wild type unbound RT or 
RT bound with DNA, the side chains of tyrosine residues at codons 181 and 188 fill the 
pocket [139, 140]. Once the inhibitor binds, 181 and 188 side chains rotate toward the 
polymerase active site, and the hydrophobic pocket is formed. Mutations in this region 
confer resistance by: (1) blocking entry of the NNRTI; (2) inhibiting interactions between 
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the NNRTI and the amino acids within the pocket; and/or (3) changing the conformation 
of the pocket [141]. For example, the K103N substitution may prevent binding of NNRTI 
since the mutant N residue allows additional hydrogen bonds that prevent the 
hydrophobic pocket from opening [142]. Y181C, however, increases the size of the 
hydrophobic pocket of the enzyme, preventing first generation NNRTI, such as NVP and 
DLV, from making critical contacts with residues inside the pocket [143]. Newer NNRTI, 
such as RPV and ETR, are less affected by this mutation since they are more flexible 
and less dependent on interaction with 181 and 188. 
2.7     EPIDEMIOLOGY OF ACQUIRED ANTIRETROVIRAL RESISTANCE 
Accumulation of resistance mutations on therapy is a gradual process, leading to 
cross resistance and eventually exhaustion of drugs within a class, particularly as 
patients fail multiple HAART regimens [144]. Drug resistance that is acquired on therapy 
accounts for the majority of drug resistance in the HIV-infected population. The patterns 
of resistance among treated patients are somewhat reflected among therapy-naïve 
patients [145]. Comparing resistance across studies is difficult since only a fraction of 
patients at risk are tested, mutations considered relevant change over time or vary 
across mutations lists, and estimates must be updated as treatment strategies evolve. 
Further, standard resistance assays do not detect minority drug resistant variants [146], 
and resistance tests obtained at a single time point may not reflect the full spectrum of 
resistance within the individual, since mutations may have receded to undetectable 
levels in the absence of drug selection pressure [147]. 
2.7.1     PREVALENCE OF ACQUIRED REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE 
Even with the above caveats, multiple efforts have been made to estimate the 
burden of resistance among patients failing therapy, particularly in regions where HIV 
treatment is widely available. Among a representative sample of viremic patients 
receiving care in the United States through 1998, the overall prevalence of resistance 
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was estimated to be 76%; 71 and 25% of patients showed reduced susceptibility to at 
least one NRTI or NNRTI, respectively [148]. These estimates are from the early HAART 
era, when most patients in care initiated therapy with mono- or dual-NRTI regimens 
(non-HAART). Since then, the pool of patients on therapy is increasingly dominated by 
those who initiate treatment with HAART, changing the pattern of resistance over time.  
Temporal associations demonstrate that resistance trends coincide with changes 
in ARV usage [149-154]. For example, in British Columbia in 1996, nearly 90% of 
patients failing therapy harbored resistance to at least one ARV within one class [149]. 
By 2003, this number fell to 60%. However, while in 1996 only 14% of patients had 
evidence of dual class resistance, and virtually none had triple class resistance, these 
numbers rose to 39% and 7%, respectively, by 2003. These 2003 estimates of multi-
class resistance were still dominated by patients who started with non-HAART regimens.  
HAART initiators are expected to develop multi-class resistance less frequently 
than those initially treated with mono- or dual-NRTI therapy, since the former begin with 
a regimen with multiple mechanisms of inhibiting viral replication. For example, among 
viremic patients in North Carolina, 26% of patients who initiated therapy with a non-
HAART regimen had evidence of triple-class resistance, while the prevalence was only 
10% in those who started with HAART [155]. As more patients begin therapy with more 
potent and tolerable regimens, it is expected that complete class-wide resistance, in 
which patients have exhausted all options within a class, will remain rare (under 5%) 
[154, 156]. 
While the frequency of particular resistance mutations is strongly associated with 
ARV usage patterns, some unexpected patterns emerge, even if the agents known to 
select for rarer mutations are widely used. Among NRTI resistance mutations, the 
M184V amino acid substitution continues to be one of the most common mutations, 
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which is expected given pervasive use of 3TC and FTC in clinical care [149, 150, 155, 
157, 158]. TAM are also common, especially T215Y/F and M41L, with 30-60% having 
evidence of either mutation [149, 150, 155, 157, 158]. K65R, in contrast, is usually seen 
in 5% or fewer patients failing therapy [149, 150, 153, 157-159]. K65R did appear to be 
on the rise after the introduction of TDF in 2001; yet, since 2005, its frequency has 
declined with decreased co-administration of TDF with ddI and ABC [160, 161]. The 
Q151M complex and the 69 insertion complex, associated with broad NRTI resistance, 
are also extremely rare [116]: in an Italian cohort of patients failing HAART, fewer than 
3% and 1% had evidence of the Q151M and 69 insertion complex, respectively [156].  
For NNRTI associated resistance, the most common mutations detected among 
patients failing therapy are K103N and Y181C, and their frequency depends on the 
dominant NNRTI in use as well as the specific co-administered NRTI. In settings where 
EFV is dominant, K103N is the most common [150, 157], while in populations in which 
NVP is the NNRTI of choice, Y181C is detected more frequently or as much as K103N 
[149], which is only selected by NVP combined with d4T or AZT [162]. As EFV became 
more widespread in Italy, for example, accounting for 6% of ARV used in 1999 and 18% 
in 2003, the prevalence of K103N jumped from 17% to 29% [153].  
2.7.2     INCIDENCE OF ACQUIRED REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE 
Studies in which viremic patients were maintained on a failing ART regimen with 
two consecutive genotypic antiretroviral resistance tests (GART) have allowed 
estimation of the incidence of new drug resistance mutations as well as the identification 
of factors associated with their evolution. In a retrospective sample of 106 patients 
treated with a median of 6 ARV, 75% of patients maintained on a failing HAART regimen 
for a median of 14 months acquired a new resistance mutation, including 44% of those 
taking an NRTI, and 29% of those taking an NNRTI [163]. Results from the University of 
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North Carolina agree with these estimates: among 98 viremic patients with comparable 
ARV exposure history, 60% acquired a new drug resistance mutation over a median of 9 
months of stable HAART; 38% and 46% of patients receiving an NRTI or NNRTI, 
respectively, acquired at least one new mutation within that class [164]. New NRTI 
resistance was primarily the M184V substitution, detected among 42% of patients on a 
regimen containing 3TC or FTC. Among less heavily treated patients in a European 
cohort (median 5 ARV), 77% of patients maintained on failing HAART for a median of 11 
months acquired a new mutation [165]. At the other extreme, in a prospective sample of 
106 heavily treated patients (median 8 previous ARV), 44% had evidence of a new 
mutation at 12 months [166]. 
Different estimates of resistant mutation incidence among these studies could be 
due to differences in the amount of drug resistance patients had at baseline, since most 
studies reported increased incidence was associated with fewer mutations at baseline. 
The study reporting the lowest incidence, for example, included only patients with at ≥1 
major resistance mutation at baseline, while all other studies included a mixture of 
patients with and without evidence of resistance at baseline [166]. The effect of baseline 
mutations may be due to the evolutionary constraints on the virus, since additional 
mutations are often associated with a fitness cost to the virus and since a limited amount 
of selection pressure may be exerted by a particular regimen [21]. This ceiling effect may 
be critical for patients starting their first HAART regimen, since therapy-naïve individuals 
are expected to have fewer resistance mutations at baseline. 
Studies also identified the amount of time spent on the failing regimen [163], 
lower nadir CD4 cell count [165], increase in HIV-1 RNA level while on the stable 
regimen [164, 165], and average HIV-1 RNA level between 3-4 log10 copies/mL [164] as 
risk factors for acquiring new resistance. For the latter, an average HIV-1 RNA level 
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below 3 log10 copies/mL may be associated with sufficient suppression of replication to 
prevent the selection of mutations into the dominant population. In contrast, an average 
HIV-1 RNA level above 4 log10 copies/mL is probably a marker for poor adherence and 
thus insufficient ARV concentration to select for resistance mutations [164]. However, 
even among patients who achieve suppression well below 3 log10 copies/mL, there is 
evidence that drug resistance mutations that may not be detectible with standard GART 
still emerge in patients on HAART. Among a small number of therapy-naïve patients 
starting their first HAART regimen, 40% of patients developed minority drug resistant 
variants during the first phase of decay even though they eventually achieved viral loads 
below the limits of detection [167].  
2.7.3     CLINICAL IMPACT OF ACQUIRED ANTIRETROVIRAL RESISTANCE 
At least in the short term, the accumulation of resistance mutations may be 
associated with some level of immunologic benefit, although less so than observed 
under complete suppression [114, 158, 168]. In one observational study among women 
who experienced virologic failure, those with evidence of baseline NRTI resistance and 
NNRTI resistance at failure still achieved an average increase of 118 CD4 cells/µL (95% 
CI: 38-198) after one year of HAART [158]. However, those with baseline NRTI 
resistance alone showed some evidence of a decrease in mean CD4 cell count of 31 
cells/µL (95% CI: -82-20) at one year, while those who acquired NNRTI resistance alone 
experienced virtually no change. Increased benefit observed for women with both NNRTI 
and NRTI resistance could be due to the interaction between these mutations that 
causes hypersusceptibility to NNRTI [169]. 
In terms of virologic response, patients enrolled in a US clinical cohort (N=572) 
with fewer resistance mutations at baseline were more likely to achieve HIV-1 RNA <400 
copies/mL over follow-up: 28% of those with 0-2 mutations, 21% of those with 3-6 
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mutations, and 10% of those with ≥7 mutations achieved suppression at 6 months [170]. 
As the repertoire of available ARV expands, the number of mutations may become less 
important than the activity of ARV within the regimen. In two cohort studies of highly 
treated patients with baseline resistance, patients receiving regimens containing ≥3 
active ARV [171, 172] were more likely to achieve HIV-1 RNA <50 copies/mL within one 
year [173, 174].  
Finally, there is also evidence that resistance mutations acquired during early 
treatment are linked to an increase in mortality. Patients enrolled in a British Columbia 
cohort experienced an increased hazard of all cause mortality with the emergence of any 
major resistance compared to patients without emerging resistance (hazard ratio (HR): 
1.8, 95% CI: 1.3-2.4) [175]. Patients with emerging NNRTI resistance experienced the 
highest mortality rates (HR: 3.0, 95% CI: 2.0-4.6). These results were later confirmed in 
a randomized clinical trial estimating the effect of three different HAART strategies 
(NNRTI, PI, or NNRTI+PI) on the emergence of drug resistance over 5 years of follow-up 
among therapy-naïve patients [176]. Patients who failed and acquired NNRTI resistance 
were 2.4 times as likely to die or develop AIDS compared to patients who maintained 
suppression (95% CI: 1.5-3.7) [176]. Interestingly, patients who failed without any 
evidence of resistance also experienced excess mortality and AIDS incidence compared 
to patients who were suppressed (HR: 1.8, 95%CI: 1.2-2.7), which could be explained by 
their lower adherence scores and less time on therapy, indicating subtherapeutic 
exposure to HAART.  
2.8     EPIDEMIOLOGY OF TRANSMITTED REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE 
A major consequence of acquired drug resistance among patients with detectible 
viral load is the increased risk of transmission to susceptible individuals. Acquired 
resistance has been shown to be transmitted sexually [177], from mother to child [178], 
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and parenterally [179]. Drug resistance transmitted to an HIV negative individual may 
also be further spread to other susceptible individuals [180]. Transmitted drug resistance 
(TDR) represents not only a public health threat, but it is also detrimental to individuals 
starting HAART since it may compromise initial treatment and set the patient on an 
accelerated path to multiple HAART failures and exhaustion of future treatment options. 
Further, TDR has been shown in many studies to persist for long periods of time in the 
absence of therapy, meaning reversion to sensitive strains may be unlikely in those 
initially infected with TDR, particularly when the resistant virus must pass through a less 
fit intermediate phase [13-15, 105, 128]. Resistant variants may also be found in resting 
CD4 cells of therapy-naïve individuals, so even if the dominant population circulating in 
peripheral blood is sensitive, resistant variants may re-emerge once the patient is 
exposed to the relevant ARV [16].  
The epidemiology of TDR is complicated because there is no single standardized 
list of mutations or system of interpretation defining TDR. In fact, TDR may be thought of 
as a special case of pre-therapy resistance, since some mutations correlated with 
acquired resistance may be natural polymorphisms that have no effect on phenotypic 
resistance [181]. Other mutations may actually be markers for more extensive resistance 
among treated patients [182]. Consequently, estimates of TDR based on patients with 
acquired resistance, such as the list of mutations maintained by the International 
Antiviral Society-USA (IAS-USA) [183] or the online resistance database maintained by 
Stanford University [171, 184] may not reflect the true extent of TDR. For example, T215 
revertant mutations are not usually included in these algorithms since they do not affect 
phenotypic resistance in vitro; however, these variants rapidly evolve to AZT resistance 
under selective drug pressure and are associated with treatment failure. The presence of 
T215 revertants reflects either transmission of T215Y/F and then reversion to a non-wild 
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type amino acid in the absence of therapy, or transmission of the revertant [185, 186]. 
Also, some resistance algorithms include V118I, which among patients failing therapy 
occurs in tandem with TAM-1 mutations. However, among therapy-naïve individuals 
starting AZT or 3TC regimens, V118I alone has no effect on virologic or immunologic 
response compared to patients with sensitive virus [187].  
To address issues of TDR surveillance, a list of mutations has been developed 
by Shafer and colleagues, and implemented by the World Health Organization (WHO) 
(Appendix 2.2) [188, 189]. The selection process for this list begins with lists of known 
resistance mutations from expert opinion and available clinical data. Polymorphisms on 
these lists present in >5% of sequences from therapy-naïve individuals are excluded to 
preclude the inclusion of naturally occurring mutations that do not necessarily reflect 
transmission events. The list of surveillance drug resistance mutations (SDRM) is then 
simplified to maximize sensitivity and specificity for probable TDR. 
Even if resistance mutations detected among therapy-naïve individuals represent 
transmission events, TDR estimates are often plagued by selection bias, since 
resistance testing may be selectively applied to individuals perceived as more likely to 
harbor resistance, especially in resource poor settings [182]. Estimates may be 
influenced by the stage of infection at testing, since less fit resistant variants may wane 
over time to clinically-undetectable levels without ARV selective pressure [146]. 
However, even when resistant variants may still dominate, such as among those with 
recent HIV infection, approximations may be biased since these individuals often have 
symptomatic acute HIV infection, undergo frequent HIV testing, or are identified by their 




2.8.1     PREVALENCE OF TRANSMITTED DRUG RESISTANCE 
Given these challenges, some generalizations about TDR may still be drawn 
from available observational information. TDR, analogous to acquired resistance, is 
strongly correlated with ARV use in the treated population. TDR is more likely to be 
detected among whites, MSM, individuals with subtype B infections, and among those 
with partners on therapy [180, 191-194], reflecting a correlation with greater access to 
ARV and more frequent testing behaviors. TDR is most common where ARV use has 
been more widespread, while the prevalence remains low where antiretroviral coverage 
is lowest [182, 195]. TDR more common among individuals with recent HIV infection 
(Table 2.1) compared to individuals with chronic infection or infection of unknown 
duration (Table 2.2), probably reflecting both recession of less fit resistant variants over 
time and overrepresentation of groups more likely to carry TDR, such as white MSM 





Table 2.1. Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with recent HIV-1 
infection. 




Reference % NRTI % NNRTI 
Africa       
 Côte d’Ivoire 2002-2006 100 IAS-USA 3.0% 2.0% Toni et al.[196] 
 Kenya 2009-2010 68 SDRM§ 1.5% 7.4% Sigaloff et al.[197] 
 Uganda 2004-2010 72 SDRM§ 0.0% 1.4% Ssemwanga et al.[198] 
 Uganda 2007 70 SDRM§ 2.9% 4.3% Ndembi et al.[199] 
 Uganda 2009-2010 47 SDRM§ 0.0% 6.4% Nazziwa et al.[200] 
 Kenya 2006-2009 64 SDRM§ 1.6% 1.6% Price et al.[201] 
 Rwanda 2006-2009 78 SDRM§ 0.0% 3.8% Price et al.[201] 
 South Africa 2006-2009 5 SDRM§ 0.0% 20.0% Price et al.[201] 
 Uganda 2006-2009 92 SDRM§ 1.1% 2.2% Price et al.[201] 
 Zambia 2006-2009 169 SDRM§ 1.8% 1.2% Price et al.[201] 
Asia       
 China 2006 53 SDRM§ 0.0% 1.9% Zhang et al.[202] 
 Thailand 2003-2006 305 IAS-USA 2.0% 2.3% Apisarnthanarak et al.[203] 
Europe       
 7 Countries 1987-2003 438 IAS-USA† 10.5% 3.4% Masquelier et al.[204] 
 France 2001-2002 303 IAS-USA† 10.3% 3.3% Descamps et al.[12] 
 Germany 1996-2007 1,276 SDRM§ 7.5% 3.5% Bartmeyer et al.[205] 
 Italy 2000-2010 226 SDRM§ 7.0% 7.0% Colafigli et al.[206] 
 Romania 1997-2011 5 SDRM§ 0.0% 0.0% Temereanca et al.[207] 
 Slovenia 2005-2010 31 SDRM§ 6.5% 3.2% Lunar et al. [208] 
 Spain 1997-2004 198 IAS-USA† 9.6% 4.0% de Mendoza et al.[209] 
 Switzerland 1996-2005 822 SDRM‡ 5.5% 1.9% Yerly et al.[180] 
 United Kingdom 1996-2004 316 IAS-USA† 7.0% 4.1% UK et al.[210] 
 United Kingdom 2004-2006 85 IAS-USA† 4.7% 2.4% Booth et al.[211] 








Table 2.1 (continued). Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with recent 
HIV-1 infection. 




Reference % NRTI % NNRTI 
Latin America       
 Argentina 2003-2005 28 IAS-USA 3.6% 3.6% Dilernia et al.[213] 
 Brazil 1998-2002 55 IAS-USA† 9.1% 0.0% Barreto et al.[214] 
 Brazil 1999-2001 51 IAS-USA 2.0% 0.0% Varella et al.[215] 
 Cuba 2003-2011 194 SDRM§ 4.6% 3.6% Pérez et al.[216] 
 El Salvador 2008 19 SDRM§ 0.0% 10.5% Murillo et al.[217] 
 Mexico 2003-2005 10 IAS-USA 0.0% 0.0% Viani et al.[218] 
 Peru 2002 33 IAS-USA 3.0% 3.0% Lama et al.[219] 
North America       
 Canada 1996-2003 180 IAS-USA† 7.8% 3.9% Jayaraman et al.[191] 
 Canada 2000-2001 221 IAS-USA† 5.9% 1.8% Routy et al.[220] 
 United States       
  7 Cities 1995-2006 1,311 SDRM‡ 10.0% 7.0% Liu et al.[221] 
  6 Cities 1999-2003 195 SDRM‡ 8.7% 6.7% Eshleman et al.[222] 
  15 Sites 2004 55 IAS-USA 3.6% 14.5% Viani et al.[218] 
  Chapel Hill, NC 1999-2010 43 SDRM§ 0.0% 18.6% Yanik et al.[223] 
  New York 1995-2004 361 IAS-USA† 13.0% 8.0% Shet et al.[224] 
  New York 1995-2010 600 IAS-USA 8.3% 6.8% Castor et al.[225] 
NRTI=nucleoside(tide) reverse transcriptase inhibitor; PI=protease inhibitor; NNRTI=non-NRTI; IAS-USA=International Antiviral 
Society–USA Panel; SDRM=surveillance drug resistance mutations. *Estimate includes intermediate- and high-level resistance 
only. †Modified to include 215 revertant mutations and exclude V118I mutation of HIV-1 reverse transcriptase. ‡Based on 
transmitted resistance surveillance mutation list assembled by Shafer et al. [188]. §Based on surveillance drug resistance 








Table 2.2. Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with HIV-1 infection of 
unknown duration. 




Reference % NRTI % NNRTI 
Africa       
 
6 Sub-Saharan 
Countries 2007-2009 2,436 SDRM§ 2.5% 3.3% Hamers et al.[226] 
 Burkina Faso 2003 97 IAS-USA 2.1% 4.1% Vergne et al.[227] 
 Cameroon 2001 102 IAS-USA 2.9% 2.0% Vergne et al.[227] 
 DRC 2008 253 SDRM§ 3.2% 3.2% Muwonga et al.[228] 
 Ethiopia 2003 92 IAS-USA 1.1% 2.2% Kassu et al.[229] 
 Kenya 2008-2010 182 SDRM§ 0.6% 0.0% Hassan et al. [230] 
 Mali 2005-2006 198 IAS-USA 1.6% 1.1% Derache et al.[231] 
 Mali 2010 51 SDRM§ 3.9% 3.9% Maiga et al.[232] 
 Morocco 2005-2009 82 SDRM§ 4.9% 2.4% Annaz et al.[233] 
 Senegal 1998-2007 200 SDRM§ 2.0% 0.0% Diop-Ndiay et al.[234] 
 South Africa 2008 80 SDRM§ 1.2% 1.2% Nwobegahay et al.[235] 
 Uganda 2006-2007 37 IAS-USA 0.0% 0.0% Ndembi et al.[236] 
Asia       
 India NG 49 Stanford† 0.0% 2.0% Arora et al.[237] 
 India 2007 34 SDRM§ 0.0% 0.0% Chaturbhuj et al.[238] 
 India 2007-2009 47 SDRM§ 0.0% 2.1% Thorat et al.[239] 
 Iran 2010-2011 47 SDRM§ 4.3% 0.0% Jahanbakhsh et al.[240] 
 Israel 1999-2003 171 Stanford† 3.5% 3.5% Grossman et al.[241] 
 Japan 1996-2006 402 IAS-USA 1.5% 2.0% Ibe et al.[242] 
 Japan 2003-2008 2,573 SDRM§ 4.3% 0.8% Hattori et al.[243] 
 South Korea 2006 81 IAS-USA 1.2% 1.2% Bang et al.[244] 
 Malaysia 2003-2004 100 IAS-USA* 0.0% 1.0% Tee et al.[245] 
 Taiwan 1999-2006 786 IAS-USA 5.2% 4.1% Chang et al.[246] 
 Thailand 2005-2007 151 IAS-USA 4.0% 4.0% Apisarnthanarak et al.[247] 
 Thailand 2007-2010 466 SDRM§ 1.9% 2.8% Sungkanuparph et al.[248] 







Table 2.2 (continued). Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with HIV-1 
infection of unknown duration. 




Reference % NRTI % NNRTI 
Asia       
 Vietnam 2007-2008 47 SDRM§ 0.0% 2.3% Duc et al.[250] 
 Vietnam 2008-2009 92 SDRM§ 6.5% 6.5% Dean et al.[251] 
Europe       
 16 Countries 1996-2004 525 SDRM‡ 9.3% 1.0% Bannister et al.[252] 
 Belgium 2003-2006 285 SDRM‡ 7.0% 3.5% Vercauteren et al.[253] 
 Croatia 2006-2008 118 SDRM§ 19.5% 1.7% Grgic et al. [254] 
 Denmark 2001-2009 1,405 SDRM§ 2.9% 1.3% Audelin et al.[255] 
 Former USSR 1997-2004 278 Stanford† 2.5% 3.6% Vazquez de Parga et al.[256] 
 France 2001-2002 363 IAS-USA* 4.3% 0.8% Descamps et al.[12] 
 Germany 2001-2005 831 IAS-USA* 5.4% 3.0% Sagir et al.[257] 
 Greece 2002-2003 101 IAS-USA 5.0% 4.0% Paraskevis et al.[258] 
 Greece 2009-2011 238 SDRM§ 14.3% 18.9% Skoura et al.[259] 
 Italy 1996-2007 1,690 SDRM§ 11.0% 6.0% Bracciale et al.[260] 
 Italy 2000-2010 2,937 SDRM§ 7.4% 5.0% Colafigli et al.[206] 
 Italy 2001-2006 569 SDRM‡ 6.5% 6.0% Lapadula et al.[261] 
 Latvia 2005-2006 117 SDRM§ 0.9% 0.9% Balode et al.[262] 
 Romania 1997-2011 56 SDRM§ 14.3% 3.6% Temereanca et al.[207] 
 Slovenia 2000-2004 77 IAS-USA* 3.9% 0.0% Babic et al.[263] 
 Slovenia 2005-2010 131 SDRM§ 0.8% 1.5% Lunar et al. [208] 
 Spain 2004-2008 683 SDRM§ 4.4% 4.0% García et al.[264] 
 Spain 2007-2010 1,864 SDRM§ 3.9% 2.3% Monge et al.[265] 
 Sweden 2003-2010 1,463 SDRM§ 4.1% 2.7% Karlsson et al.[266] 
 United Kingdom 1996-2004 4,138 IAS-USA* 7.8% 4.7% UK Collaboration[210] 
 United Kingdom 1997-2005 8,272 SDRM‡ 5.8% 3.6% Green et al.[267] 
 United Kingdom 2004-2006 154 IAS-USA* 3.9% 1.3% Booth et al.[211] 
 United Kingdom 2005-2006 149 IAS-USA* 3.4% 4.7% Fox et al.[212] 







Table 2.2 (continued). Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with HIV-1 
infection of unknown duration. 




% NRTI % NNRTI  
Europe       
 United Kingdom 2002-2009 14,583 SDRM§ 6.9% 4.1% Dolling et al.[269] 
Latin America       
 Argentina 2003-2005 256 IAS-USA 1.6% 2.3% Dilernia et al.[213] 
 Brazil 1998-2002 280 IAS-USA* 3.2% 1.4% Barreto et al.[214] 
 Brazil 2000-2001 76 IAS-USA 1.3% 1.3% Rodrigues et al.[270] 
 Brazil 2008-2009 63 SDRM§ 4.8% 3.2% Arruda et al.[271] 
 Brazil 2008-2009 99 SDRM§ 15.0% 5.5% Bermúdez-Aza et al.[272] 
 Brazil 2008-2009 82 SDRM§ 5.0% 3.6% Gräf et al.[273] 
 Chile 2000-2005 79 IAS-USA 0.0% 0.0% Rios et al.[274] 
 Cuba 2003-2011 207 SDRM§ 7.2% 1.4% Pérez et al. [216] 
 DR 2007-2010 103 SDRM§ 1.0% 6.8% Myers et al.[275] 
 El Salvador 2008 98 SDRM§ 5.1% 5.1% Murillo et al.[217] 
 Honduras 2002-2003 336 SDRM‡ 7.7% 7.1% Lloyd et al.[276] 
 Honduras 2004-2007 200 SDRM§ 3.0% 5.0% Murillo et al.[277] 
 Mexico 2002-2003 96 IAS-USA* 12.5% 6.3% Escoto-Delgadillo et al.[278] 
 Mexico 2005-2010 1,655 SDRM§ 4.2% 1.9% Avila-Ríos et al. 
 Peru 2002 326 IAS-USA 2.1% 0.6% Lama et al.[219] 
North America       
 Canada 2000-2001 494 IAS-USA* 3.2% 1.2% Jayaraman et al.[191] 
 USA 1999-2001 491 IAS-USA* 7.8% 3.0% Novak et al.[192] 
  40 Cities 2003 317 IAS-USA 3.5% 6.0% Ross et al.[279] 
  10 Cities 1997-2001 1,082 IAS-USA* 6.4% 1.7% Weinstock et al.[194] 
  6 Cities NG-2008 1,585 SDRM§ 8.2% 8.3% Poon et al.[280] 
  7 Cities 2006-2009 145 SDRM§ 4.1% 12.4% Hightow-Weidman et al.[281] 
  10 States 2007 2,030 SDRM§ 7.8% 5.6% Wheeler et al.[282] 
  10 States 2005-2007 228 Stanford† 4.5% 9.8% Huang et al.[283] 







Table 2.2 (continued). Reverse transcriptase inhibitor resistance among antiretroviral-naïve individuals with HIV-1 
infection of unknown duration. 




Reference % NRTI % NNRTI 
North America       
 USA       
  Charlotte, NC 2008-2011 189 SDRM§ 2.6% 6.9% Klibanov et al.[284] 
  Detroit, MI 2006-2008 133 SDRM§ 9.8% 8.3% Huaman et al.[285] 
  Portland, OR 2003-2009 165 SDRM§ 9.1% 10.3% MacVeigh et al. [286] 
  Saint Louis, MO 2003-2005 192 IAS-USA* 6.3% 7.3% Grubb et al.[287] 
  Seattle, WA 2001-2009 801 SDRM§ 6.0% 12.0% Taniguchi et al.[288] 
  Washington, DC 2005 42 IAS-USA 2.4% 4.8% Boyd et al.[289] 
  New York State 2006-2008 4.032 SDRM§ 2.9% 6.3% Redhead et al.[290] 
NRTI=nucleoside(tide) reverse transcriptase inhibitor; PI=protease inhibitor; NNRTI=non-NRTI; IAS-USA=International Antiviral 
Society–USA Panel; SDRM=surveillance drug resistance mutations; NG=not given. *Includes 215 revertant mutations and 
exclude V118I mutation of HIV-1 reverse transcriptase. †Estimate includes intermediate- and high-level resistance only. ‡Based 
on transmitted resistance surveillance mutation list assembled by Shafer et al. [188]. §Based on surveillance drug resistance 
mutations list updated in 2009 [189]. 
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Even in areas with an extensive history of widespread ARV use, there are 
regional differences in transmitted resistance. TDR appears to be more common in 
North American cohorts compared to European cohorts: surveys including 19 European 
cohorts over 1996-2002 reported that 11% of individuals with recent HIV infection had ≥1 
major mutation [291], while in the United States and Canada, 15% of recently infected 
patients from 1995-2006 had evidence of TDR [221]. In a review of published literature 
through 2009, an estimated 12.9% (95% CI: 12.2-13.7%) of all therapy-naïve individuals 
in North America had evidence of any drug resistance, mostly driven by NRTI (7.4%, 
95% CI: 6.8-8.0%) and NNRTI resistance (5.7%, 95% CI: 5.2-6.2%) [292]. 
Corresponding European studies yielded regional estimates of overall, NRTI, and NNRTI 
resistance of 10.9% (95% CI: 10.6-11.4%), 7.4% (95% CI: 7.1-7.7%), and 3.4% (95% CI: 
3.2-3.6%), respectively [292].  
Temporal trends in these regions reflect more frequent NNRTI use and an 
increasing proportion of patients on HAART achieving durable virologic suppression 
[220]. Over time, TDR declined in Europe (11.5% to 7.7% before 2001 to after 2004), 
driven by decreases in NRTI resistance from 8.0% to 4.3%  and PI resistance from 3.3% 
to 1.4%  before 2001 to after 2004 [292]. NNRTI resistance peaked in 2001-2002 in 
Europe, but declined to 3.2% after 2004 [292]. These estimates agree with results from 
19 European countries, where TDR decreased from 12% to 8% from 1996-2004, and 
NRTI resistance decreased from 10% to 4% from 2001-2004 [193]. North America, in 
contrast, experienced an increase in TDR prevalence from 11.6% before 2001 to 14.3% 
after 2003, with increasing NNRTI resistance outpacing overall declines in transmitted 
NRTI and PI resistance [292].  
Since TDR is influenced by ARV usage patterns, it is not surprising that NRTI 
resistance has dominated in North America and Europe (Table 2.1 and Table 2.2). Most 
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NRTI resistance detected among therapy-naïve individuals from Europe and North 
America are TAM including M41L, K70R, and mutations in codon 215, which are present 
in nearly 5% of these populations; far fewer have evidence of M184V (<1%) or K65R 
(<0.5%) [12, 180, 191, 192, 194, 204, 279]. NNRTI-associated mutations are usually the 
second most common form of TDR resistance (1-15%), and many studies report K103N, 
Y181C, and G190A/S. Transmitted multi-drug resistance, though, remains rare, with 
dual-class and triple-class resistance present in 2.6% and 1.1% of individuals infected 
between 2004-2005 [180]. 
In contrast to developed regions, TDR estimates from resource-poor settings 
have been traditionally nonexistent, but the WHO implemented a strategy to monitor 
prevalence below 2 critical thresholds (5% and 15%) in settings where resistance testing 
is not routine but antiretroviral therapy was on schedule for expanded access [293]. 
Since the rollout of antiretrovirals starting in 2003, there is evidence of an increase in 
TDR prevalence, but changes are highly variable across different regions. Sub-Saharan 
Africa, for example, experienced an estimated annual increase of 14% (95% CI: 0-29%) 
since rollout started in 2004, with an overall estimated prevalence of 3.7% (95% CI: 2.5-
5.4%) by 2011 [294]. Eastern Africa experienced a steeper 29% annual increase (95% 
CI: 15-45%) since rollout, with an estimated overall prevalence of 7.4% (95% CI: 4.3-
12.7%) by 2011 [294]. Transmitted NNRTI resistance dominated these trends, reflecting 
their use in all first line options [294]. Latin American and Caribbean countries, in 
contrast, experienced no statistically significant increase in TDR prevalence since an 
estimated 6.9% of individuals had evidence of TDR at the start of and 8 years after 




2.8.2     TRANSMISSIBILITY AND PERSISTENCE OF DRUG RESISTANCE MUTATIONS 
The relatively high prevalence of TAM among therapy-naïve individuals is 
reflective of populations where mono- and dual-NRTI therapy as well as single PI-based 
HAART were once the standard of care [195], while the low prevalence of major PI 
mutations and some NRTI mutations may be due to a reduction in transmissibility of 
certain variants [295]. Transmission efficiencies of drug resistant variants relative to wild 
type strains have been estimated by several studies that have attempted to define 
populations of potential transmitters and recent seroconverters. One group estimated 
variants containing the M184V mutation alone were more than 10 times less likely to be 
transmitted than sensitive virus [296]. Dual-class and triple-class resistant variants were 
even less likely to be transmitted with a 20-fold reduction in transmission compared to 
sensitive virus [296]. Another group estimated that while the prevalence of TAM were 
similar between recently infected individuals and the pool of potential transmitters, 
M184V was underrepresented among recent infected individuals [297]. A third group 
estimated that M184I/V and T215Y/F had the lowest transmission efficiency relative to 
sensitive virus, while V118I, K219E/Q, and Y181C/I, had a higher transmission efficiency 
relative to sensitive virus [295]. Whether the underrepresentation of certain mutations 
among recently infected is due to outgrowth of more fit variants in the absence of ARV 
exposure [9, 13], reduction in viral load associated with these mutations among potential 
transmitters [297], or other factors, cannot be determined from these study designs.   
Specific mutations are also differentially distributed between recently infected 
and chronically infected individuals, possibly reflecting persistence or reversion of these 
variants in the absence of ARV selective pressure. For example M184V, T215Y/F, and 
K103N are found more frequently among those with recent infections, while other 
variants not associated with phenotypic resistance, such as T215 revertant mutations, 
are less likely to be found in recently infected individuals [194]. Reversion cannot be 
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confirmed from cross-sectional comparisons between therapy-naïve populations infected 
at different times and by potentially different sources.  
Longitudinal sampling of recent seroconverters with TDR has been applied to 
estimate the rate of reversion of drug resistant variants in the absence of therapy. 
Among 12 of 20 recently infected individuals with ≥2 pre-therapy samples available, the 
virus evolved at drug resistance positions without ARV pressure over a median 15 
months [298]. The variants that reverted to wild type, in order of increasing time since 
detection, were K70R, D67N, T215S, Y181C, and M184V [298]. T215Y/F variants 
evolved to revertant mutations rapidly in all cases, while M41L, T69D/N, L210W, K219Q, 
and G190S in were maintained over follow-up [298]. These observations agree with 
another study of 14 recently infected individuals: while M41L, T69N, K103N, and T215 
revertants persisted up to 3 years, Y181C and K219Q became undetectable in 27 
months and 9 months, respectively [299]. However, each of these studies detected 
resistance by population sequencing, which misses minority variants that make up <20% 
of the total [146], making it difficult to draw conclusions about the mechanism of resistant 
variant decline in the population. 
2.8.3     CLINICAL IMPACT OF TRANSMITTED RESISTANCE 
The general consensus is that resistant variants usually show a reduction in 
fitness compared to sensitive variants, as implied by in vivo studies of the decline of 
many of these mutations over time among untreated, recently infected individuals [13, 
128, 299], as well as by in vitro comparisons of  replicative capacity and infectivity 
between resistant and sensitive variants [10, 129, 300, 301]. It follows that TDR may be 
expected to have a beneficial impact on the natural course of infection. Several studies 
have observed lower HIV-1 RNA levels [302, 303] and higher CD4+ T cell counts [4, 
303, 304] near the time of HIV infection among individuals infected with drug resistant 
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virus compared to individuals infected with sensitive virus. These apparent advantages 
may not be preserved over time, however. One study estimated that an individual with 
500 CD4+ T cells/µL at seroconversion could expect a decline of 199 cells/µL or 73 
cells/µL in the first year without treatment if infected with resistant or sensitive virus, 
respectively [304].  
Once therapy is initiated, patients with TDR experience reduced virologic benefit 
compared to patients infected with fully susceptible virus. Among a cohort of patients on 
HAART for 6 months, time to suppression of HIV-1 RNA levels was longer and time to 
first failure was shorter for patients with high level phenotypic resistance compared to 
patients with sensitive virus [5]. Another study showed that patients with genotypic 
evidence of resistance to their initial regimen achieved suppression in a median of 3 
months compared to 5 weeks for patients without resistance [4]. In another cohort study, 
patients with resistant HIV experienced a slower decline in plasma HIV-1 RNA between 
1 and 6 months of HAART compared to patients with sensitive virus following a similar 
rate of decline in the first month of HAART [305]. Other studies have failed to detect 
statistically significant differential virologic response [17, 252, 303, 304, 306], but lack of 
statistical significance association could be due to the small number of exposed patients, 
shorter follow-up, decreased frequency of HIV-1 RNA level testing, or even definition of 
TDR. Most studies that reported “no effect” actually reported that fewer patients with 
TDR achieved virologic suppression within the study period compared to other patients. 
For example, virologic suppression within 6 months of HAART initiation was achieved in 
85% (49/58) of patients with susceptible virus and 64% (7/11) of patients with TDR in 
one study (p=0.2) [303].  
In terms of immunologic response, most studies have not demonstrated negative 
outcomes for patients with TDR, but these are difficult to interpret given the variable 
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definitions of immunologic outcomes. For example, one group reported that chronically 
infected patients with resistance to ≥1 ARV in their first regimen were more likely to 
achieve an increase of 100 CD4 cells/µL after 6-12 months of HAART compared to 
patients with >3 active ARV [252]. Similar observations were reported in an even smaller 
study in which patients with TDR experienced larger CD4 cell count gains at months 6 
and 12 after HAART compared to patients with wild type strains [154].  
2.9     MEASUREMENT OF ANTIRETROVIRAL ASSOCIATED RESISTANCE 
Because a single individual infected with HIV produces 109 viral particles with 
possibly 106 mutations per day [307], currently available technology cannot provide a full 
picture of evolving HIV populations in one compartment, such as plasma, over time, let 
alone simultaneous characterization of viral diversity within infected resting T cells or 
other compartments such as the genital tract or central nervous system. Given these 
limitations, the standard fluid tested for antiretroviral resistance is plasma because of its 
relative ease of collection, storage, and processing. However, the use of plasma allows 
characterization of HIV-1 RNA only from actively replicating virus, not integrated HIV 
DNA, which may contain archived drug resistance mutations. Also, HIV-1 RNA extracted 
from plasma must be reverse transcribed into cDNA and then amplified via PCR prior to 
resistance testing to enrich for rare viral sequences, which introduces error through 
multiple steps and probabilistically favors amplification of the dominant circulating viral 
population [7, 308]. Further, individuals must have >500 HIV-1 RNA copies/mL of 
plasma to allow sufficient HIV RNA templates for sampling for sequencing by 
commercial assays [308]. Thus, commercial resistance assays sample the most recently 
replicating, dominant viral variants among individuals with higher viral loads.  
2.9.1      GENOTYPIC ASSAYS USING POPULATION (BULK) SEQUENCING 
Standard genotypic antiretroviral resistance tests (GART) rely on population or 
bulk sequencing, where specific regions of HIV-1 pol are amplified and sequenced from 
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a sample of HIV genomes using the chain terminator method [309, 310]. For chain 
terminator sequencing, 4 deoxynucleotides (dNTP)  and 4 fluorescently labeled (1 
color/base) dideoxynucleotides (ddNTP) are used to extend DNA strands complimentary 
to amplified HIV DNA (dNTP) or to terminate DNA extension (ddNTP) [309]. As a result, 
each sample contains fragments of HIV DNA with a labeled ddNTP at each 3’ end. This 
population of HIV DNA fragments is separated by size, labeled fragments fluoresce as 
they pass through a laser light source, and the order of ddNTP is recorded on a 
chromatogram. The chromatogram consists of ordered, color-coded peaks for each 
incorporated ddNTP, representing the consensus HIV DNA nucleotide sequence. This 
sequence is then aligned with a reference HIV sequence to identify mutations associated 
with reduced ARV susceptibility. 
2.9.2      INTERPRETATION OF GENOTYPIC RESISTANCE DATA   
A variety of systems are available to interpret genotypic data, including 
proprietary systems such as  the VirtualPhenotype [311], publicly available algorithms 
including the Stanford University HIV Drug Resistance (HIVdb, Appendix 2.3) [171, 184] 
or Agence Nationale de Recherches sur le SIDA (ANRS) algorithms [312], and lists of 
mutations such as those published by the IAS-USA (Appendix Table  A.1) [313]. These 
algorithms are used to score a patient’s viral sequence with a given set of mutations as 
susceptible, possibly resistant, or resistant to a particular ARV, or in some cases they 
may predict a fold-change in susceptibility for each ARV. Different algorithms may use 
several sources of resistance to construct rules including [221]: (1) associations between 
mutations and ARV exposure (genotype-treatment correlations); (2) associations 
between mutations and phenotypic susceptibility (genotype-phenotype correlations); and 




For genotype-treatment correlations, in vitro passage experiments may be used 
in which mutations are selected in laboratory strains of HIV in the presence of a single 
ARV.  In vivo data may be used, in which  sequences derived from patient isolates are 
correlated with ARV exposure history [130]. However, these in vivo correlations cannot 
determine whether the mutations identified are merely markers for resistance in certain 
populations. Further, genotype-treatment correlations determined in vitro identify a 
fraction of mutations observed in a clinical setting in which people may have complex 
ARV exposure histories.  
Like genotype-treatment correlations, genotype-phenotype correlations may be 
derived from in vitro and in vivo sources. Mutations that arise from passage experiments 
or that are introduced into laboratory HIV strains may be tested with a phenotypic assay, 
or correlations between pairs of genotypic data and phenotypic data may be analyzed 
from patient sequence databases. Genotype-phenotype correlations may miss some 
clinically significant mutations such as T215 revertants, and clinical cut-offs for each 
ARV cannot be defined using this approach.  
Unlike the previous two correlation types, genotype-outcome correlations are 
only estimated in vivo. Genotype-outcome correlations are determined using data from 
clinical trials in which the effects of patient baseline genotypes on virologic response to 
new ARV are studied. Even this approach is limited, though, since various trials have 
different study designs and various patient populations with different ARV experience. 
Thus, each data source may be weighted very differently between algorithms and 
produce discordant interpretations of the same set of mutations. Also, interpretation 
algorithms must constantly be updated to be clinically relevant as new ARV and ARV 




2.9.3      GENOTYPIC ASSAYS TO DETECT MINORITY DRUG RESISTANT VARIANTS 
One of the major drawbacks of commercial resistance assays is their inability to 
detect and quantify minority HIV variants that make up <20% of the sample [146, 308]. It 
is clear that resistance detected by commercial assays adversely affects treatment 
outcomes [4, 5, 175], but the role of undetected minority resistant variants is less clear. 
In a pooled analysis of 985 therapy-naïve participants who received an NNRTI-
containing regimen, minority NNRTI resistant HIV was associated with an increased 
hazard of virologic failure (HR: 2.6, 95% CI: 1.9-3.5) [18]. This study also reported a 
dose-response relationship between the number of copies of reverse transcriptase 
inhibitor (RTI) resistant variant and virologic failure: 10-99 vs. 0 copies of resistant virus 
(HR: 2.2, 95% CI: 1.5-3.2); 100-999 vs. 0 copies (HR: 3.0, 95% CI: 2.0-4.5); ≥1000 vs. 0 
copies (HR: 4.1, 95% CI: 2.5-6.8) [18].  
Most studies included in the pooled analysis relied on allele-specific PCR (AS-
PCR) to measure minority variants [127, 314, 315], where HIV DNA amplicons from an 
initial RT-PCR reaction are subsequently amplified by real time PCR using codon 
specific primers. AS-PCR (Table 2.3) is quantitative, since primers specific to the target 
codon are combined with HIV-1 total copy primers. As primer sets extend across 
targeted sequence, probes annealed within the target template sequence fluoresce, 
producing signals for the mutant or wild type sequence and the total copy sequence. 
Intensity of the signals increases with each amplification cycle, producing curves for both 
total copy number and mutant or wild type sequences. By comparing the curves, the 
relative abundance of variants in the sample may be quantified down to 0.1% [127, 315]. 
However AS-PCR has several major limitations: (1) Only a limited number of a priori 
mutations are interrogated.; (2) Polymorphisms within the primer or probe binding sites 
may lead to false negative results.; (3) RT-PCR and real time PCR may introduce bias 
through nucleotide misincorporation and differential amplification [19]. (4)Linkage of 
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mutations to the same viral genome is not possible since AS-PCR queries single codons 
at one time [316].  
Another high throughput, low cost assay that detects minority point mutations 
includes the oligonucleotide ligation assay (OLA) (Table 2.3) [317]. The OLA relies on 
differential hybridization of mutant and wild type amplicons to specific oligonucleotide 
probes in a 96-well plate. Two oligonucleotide probes with different detection molecules, 
one for wild type, one for mutant, are added to wells along with a ligation enzyme and 
amplified HIV DNA. After ligation, two separate reactions are used to visualize 
hybridization complexes containing either wild type or mutant sequences. While OLA is 
more sensitive for detection of minority variants than bulk sequencing and can be 
performed rapidly on clinical samples, OLA is only quantitative if a standard of known 
relative abundance is run in parallel. Also, OLA is highly sensitive to polymorphisms in 
the regions queried by the probes, with incomplete binding leading to 2% of clinical 
samples negative for both wild type and mutant probes [317].  
The heteroduplex tracking assay (HTA) is more sensitive than the OLA, allows 
quantification of different viral populations, and is high throughput (Table 2.3). HTA 
probes are generated from labeled HIV-1 DNA clones with nucleotide changes proximal 
to the target nucleotides associated with resistance [318-320]. These changes allow 
greater mismatch between the HTA probe and wild type sequences relative to mutant 
sequences, and secondary structure of these heteroduplexes that results from 
mismatches may be resolved by polyacrylamide gel electrophoresis (PAGE). Using 
PAGE, HTA: wild type heteroduplexes shift upward from the probe: mutant 
heteroduplexes, forming two distinct bands. The relative intensity of these bands allows 
quantification of relative abundance of variants down to 1-3% [318, 319]. Bands may 
also be isolated and sequenced with less contamination [320]. However, the HTA is still 
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limited by: (1) errors introduced by an initial RT-PCR step to reverse transcribe and 
amplify HIV DNA sequences; (2) poor separation between mutant and wild type 
heteroduplexes; and (3) restriction to predetermined resistance mutations. 
All previously discussed technologies, while high throughput and low cost, rely on 
the detection of a priori resistance mutations. Other sensitive experimental technologies 
address this limitation, but many have been traditionally been limited by cost and labor. 
Clonal sequencing (Table 2.3) [321, 322], for example, is a technique in which an 
amplified HIV DNA insert is cloned into plasmid DNA and transformed into bacterial 
cells. Each bacterial colony originates from one cell carrying a single copy of the 
plasmid. By sequencing plasmids from multiple colonies, the relative abundance of HIV 
variants can be determined. However, clonal sequencing is still limited by the 
introduction of errors during the initial RT-PCR step [323], and by the loss of viral 
genomes during the cloning step. Also, there is the possibility of resampling of PCR 
template molecules, which can skew relative abundance estimates [19]. This last 
limitation has been addressed by taking a single colony from multiple PCR reactions, but 
this type of clonal sequencing is even more costly and labor-intensive [324]. 
Some limitations of clonal sequencing have been addressed by a method that 
relies on serial dilution of cDNA templates so that one molecule on average is amplified 
in each initial PCR reaction. This method, single genome sequencing (SGS) [146], 
employs multiple PCR reactions per cDNA dilution. PCR products are resolved on an 
agarose gel to determine the cDNA dilution that contains about 1 template per reaction 
based on the expected number of positives using the Poisson distribution. That cDNA 
dilution is then subjected to nested PCR, and products are bulk sequenced, allowing 
linkage of mutations on the same viral genome. However, sensitivity to detect minority 
variants is limited by the number of genomes or clones that are sequenced for both SGS 
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and clonal sequencing: 490 genomes/clones are required to detect a mutation present at 
1% abundance with 99% certainty [316]. 
Alternatively, massively parallel, ultra deep sequencing (UDS) techniques, 
including Illumina and 454 platforms, promise to deliver the advantages of SGS and 
clonal sequencing in a high throughput format [22, 23, 325, 326]. For HIV applications, a 
library of HIV DNA must be prepared for UDS in a series of amplification, purification, 
and quantification steps. Typically, HIV RNA preparations from clinical samples are 
independently reverse-transcribed with a sequence specific cDNA primer that includes 
preassigned barcode nucleotide sequence [23]. These are then amplified by nested 
PCR, purified, quantified, and pooled for UDS library preparation. 
For Roche’s 454 pyrosequencing platform (Table 2.3) [327], two proprietary 
adaptors are linked to each end of HIV DNA amplicons, either through incorporation 
during RT-PCR or ligation after RT-PCR. Both adaptors contain a nucleotide sequence 
for PCR and sequencing priming, but one adaptor also contains a tag that allows 
enrichment of single stranded DNA linked to one of each adaptor. Single stranded HIV 
DNA is diluted and captured by DNA beads, one molecule per bead. Beads are 
combined with PCR reagents and each HIV DNA is clonally amplified on the bead by 
emulsion PCR [328]. Clonally amplified HIV DNA is denatured and distributed across a 
picoliter plate, one bead per well [329]. Nucleotides are singly washed over the wells in 
limited concentration. Unincorporated nucleotides are degraded, but if a nucleotide is 
incorporated, pyrophosphate is released, converted into ATP, and used by an enzyme to 
generate a light signal. The signal is recorded as a series of ordered peaks proportional 
to the number of identical bases incorporated.  
The latest version of the 454 pyrosequencing platform, 454 GS FLX Titanium, 
allows for simultaneous interrogation of all known positions within 300-1,000 bp region, 
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producing up to 106 sequences per run. This enormous output allows 454 
pyrosequencing to detect minority sequences present in <0.1% of the population [330]. 
However, multiple PCR amplification steps and the initial RT step introduce a substantial 
amount of error [24]. Additional error may be introduced when more than three of the 
same nucleotide occur in a row [24], resulting in false calls of the third nucleotide, 
followed by partial incorporation of the next base [325]. These errors can make it difficult 
to distinguish actual base changes associated with drug resistance from errors 
introduced by reverse transcription or PCR amplification.  
Illumina UDS platforms, including MiSeq and HiSeq 2500 (Table 2.3), offer an 
alternative to the 454 sequencing platform. Similar to the 454 platform, proprietary 
adaptors are added to the ends of double stranded amplified HIV DNA to enrich single-
stranded HIV DNA with both adaptors. These templates are then immobilized on a 
surface coated with sequences complimentary adaptors [326]. Immobilized HIV DNA is 
clonally amplified by bridge PCR to form dense clusters of HIV DNA. One strand of the 
HIV DNA template is sequenced at a time, depending on which adaptor is cleaved prior 
to denaturation of amplified, double stranded HIV DNA products [326]. After sequencing 
the initial strand, the immobilized HIV DNA is again amplified, and double stranded DNA 
is nicked at the opposite end for paired end sequencing.  
For the sequencing using the Illumina platform, DNA polymerase and four 
labeled nucleotides are added to the surface containing clusters of clonally amplified, 
single stranded HIV DNA. The DNA polymerase incorporates only one nucleotide, since 
the nucleotide’s 3’ hydroxyl group of the nucleotide is blocked after its incorporation 
[331]. Unincorporated nucleotides are washed away, and the color of the incorporated 
nucleotide is captured for each immobilized HIV DNA cluster. A second enzyme then 
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cleaves the blocking group from the incorporated nucleotide, and these molecules are 
washed away following cleavage, allowing another single round of sequencing to begin. 
Compared to 454 platforms, the Illumina sequencing platforms are higher output, 
producing up to 6 billion 150 bp paired end sequences per run for HiSeq 2500 and 15 
million 250 bp paired end sequences for MiSeq. Illumina platforms are less prone to 
errors within homopolymeric stretches of sequence compared to 454 technologies [332], 
but the quality of the sequencing read declines rapidly towards the end of the run [333]. 
The decline in sequence quality over the run is due to incomplete cleavage of the 
nucleotide blocking site that accumulate over the run [334]. Also, low diversity 
sequences, such as might be expected among a pool of amplified, HIV DNA with 
predetermined barcodes, cause the Illumina platform data filters to count multiple 
clusters as the same sequence and bias estimates of sequence diversity [335].  
Table 2.3. Common genotypic assays to detect low abundance antiretroviral 
resistant HIV-1. 
Assay Avg. Length Threshold Main error source Cost Throughput 
AS-PCR point mutation 0.1% primer/probe mismatches $$ high 
OLA point mutation 10% sequence mismatches $ high 
HTA point mutation 1-3% band discrimination $$ medium 
Clonal  700 bp 5%* cloning efficiency $$$ low 
SGS 700 bp 5%* dilution $$$ low 
454 700 bp <1% homopolymeric regions $$$$ high 
Illumina  150-250 bp <1% phasing $$$$ very high 
AS-PCR=allele-specific polymerase chain reaction; OLA=oligonucleotide ligation assay; 
HTA=heteroduplex tracking assay; SGS=single genome sequencing. *Value for 
sequencing 60 genomes with 95% certainty; sequencing 490 genomes is necessary to 
obtain a 1% limit with 99% certainty. 
 
2.9.4      ADDRESSING MULTIPLE SOURCES OF SEQUENCING ERROR  
Despite rapidly advancing next generation sequencing techniques, estimating 
resistant HIV populations in plasma remains challenging because of the balance 
between the high diversity of rapidly evolving HIV within the individual [21] and errors 
introduced during multiple steps of viral enrichment and sequencing. These errors are 
first a function of the integrity of starting samples, which must be properly handled and 
 54 
 
stored to prevent loss of HIV RNA genomes [332]. Upon RNA extraction from these 
samples, genomes are inevitably lost, but various protocols may be used to enhance 
recovery. For example, plasma samples with low viral titers may be centrifuged prior to 
extraction to concentrate viral particles [333], or carrier RNA may be added to samples 
so that rare viral RNA sequences are less likely to be lost during extraction.  
Even if losses during RNA extraction are minimized, errors may be introduced 
when purified HIV RNA is reverse-transcribed into cDNA by an engineered RT enzyme,  
which introduces an error every 30,000 to 17,000 nucleotides [334]. Reverse 
transcription is also associated with template recombination, which occurs when cDNA 
strands are incompletely extended and serve as primers for downstream amplification. 
Reverse transcription errors may first be addressed by starting with the highest quality 
(full-length) RNA, and by increasing cDNA synthesis reaction times to allow complete 
extension of the cDNA [335]. 
The next step, PCR amplification, is a major source of sequencing error, but it is 
currently necessary to produce an adequate sequencing signal. PCR errors may be 
introduced through one or more of the following: (1) biased amplification due to 
mismatches between the primer and some HIV sequences [336]; (2) resampling of 
starting templates due to low number of input templates [19]; (3) nucleotide 
misincorporation by the DNA polymerase [337]; and (4) PCR recombination from 
incomplete extension of amplified DNA or template switching [338]. To alleviate biased 
amplification due to primer-template mismatches (1), primers may be designed to 
complement conserved sequence regions or degenerate nucleotides may be substituted 
where potential mismatches may occur. To address PCR resampling (2), the number of 
starting templates may be maximized by concentrating the virus before extraction, for 
example. To reduce nucleotide misincorporation (3), high fidelity DNA polymerases with 
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proofreading capability are often used, but there is usually a trade-off with PCR 
efficiency [337]. Finally, to prevent PCR recombination (4), PCR extension times must 
be optimized to prevent too-short products from priming subsequent amplifications or to 
reduce the opportunity for template switching by the DNA polymerase [338]. 
For next-generation sequencing platforms, errors introduced during PCR and 
some platform specific errors discussed previously (2.9.3) have been addressed using a 
method engineered into the cDNA synthesis step. Here, a randomized sequence (Primer 
ID) is tagged to each individual viral genome via the cDNA synthesis primer (Figure 
2.5A) [26]. The Primer ID and pre-assigned, sample specific nucleotide barcode are 
subsequently amplified along with the viral sequence (Figure 2.5B). Downstream, 
majority-rules consensus sequences may be constructed from 3 or more resampled 
sequences within a sample (barcode) sharing the same Primer ID sequence (Figure 
2.5C), so that concordant nucleotides at a given position are more likely to be genuine 
nucleotide calls and discordant nucleotides at a given position are more likely to be 
errors. Importantly, collapsing raw sequences into Primer ID consensus sequences 
allows estimation of the viral population that was originally sampled, rather than what 
was best amplified. Thus, tagging individual viral genomes with a Primer ID allows 







Figure 2.5. Primer ID method to estimate HIV-1 viral population [26]. Panel A demonstrates 
how a randomized nucleotide sequence (Primer ID, medium gray) is added to the HIV RNA 
genome (black) during cDNA synthesis. The cDNA primer consists of an HIV specific 
sequence (black), the sequence specific Primer ID (medium gray), the pre-assigned sample 
barcode (light gray), and the non-specific sequence for downstream PCR (dark gray with 
circle). Panel B shows differential amplification of different Primer ID (black circles, diagonal 
stripes, dark gray hatch on gray) tagged viral genomes within the same sample (light gray 
barcode). Panel C shows how multiple resampled raw sequences (dark gray) sharing the 
same Primer ID (black circles) and barcode (light gray) are collapsed into a single 




CHAPTER 3     RESEARCH DESIGN AND METHODS 
 
 3.1     OVERVIEW 
For this study, a new method (Primer ID) that simultaneously addresses many 
sources of PCR and ultra deep sequencing (UDS) errors [26] was used to estimate HIV-
1 reverse transcriptase (RT) inhibitor resistance among a population of therapy-naïve, 
HIV-infected patients who eventually received an RT inhibitor regimen (N=184). For the 
Primer ID method, each viral RNA template was tagged with a unique primer 
identification sequence prior to amplification (Figure 2.5). Downstream, consensus 
sequences made from sequences sharing the same Primer ID represented the viral 
templates input into cDNA synthesis, rather than what was most efficiently amplified.  
First, by sequencing known HIV-1 RT sequences spanning HIV-1 RT codons 34-
138 with the 454 and Illumina deep sequencing platforms, the amount of error 
associated with the Primer ID was quantified for each platform (Aim 1). The rate of 
nucleotide substitutions, insertions and deletions, and template recombination was 
estimated from both Primer ID consensus and raw sequences and compared by analysis 
method (Primer ID vs. raw sequences) and platform (454 vs. Illumina).  
Next, the 454 platform was used to sequence Primer ID tagged, amplified HIV-1 
DNA spanning HIV-1 RT codons 34-138 and 139-245 from 184 therapy-naïve patients to 
estimate the prevalence of RT inhibitor resistance (Aim 2A). Prevalence estimates 
obtained using 454 deep sequencing and Primer ID were compared to those obtained by 
bulk sequencing. For a subset of patients with evidence of increased sequence sampling 
depth using the 454 platform (N=19), samples were also submitted for paired-end 
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sequencing of HIV-1 RT codons 34-74 and 111-138 using the Illumina MiSeq platform. 
For these 19 patients, results from the analysis of Illumina MiSeq sequences were 
compared to results obtained using the 454 platform within the same HIV-1 RT coding 
region (Aim 2B).  
Finally, the effect of pre-existing RT inhibitor resistance on time-to-first virologic 
failure was estimated among 184 patients using both deep and bulk sequencing 
measured pre-existing resistance (Aim 3). To define pre-existing resistance, the number 
of active antiretrovirals within each patient’s initial RT inhibitor regimen was determined 
using the Stanford HIV Drug Resistance Database (HIVdb) [171] to interpret Primer ID 
consensus sequences and sequences obtained using bulk sequence analyses (See 
Appendix 2.3 for Stanford HIVdb scores.). Effect-measure estimates were obtained for 
deep sequencing alone, for bulk sequencing alone, and for the combined effect of 
resistance detected using both technologies to determine the added value of more 
sensitive sequencing technology. 
3.2     STUDY POPULATION 
Patients included in this study (N=184) were selected from patients enrolled in 
the University of North Carolina Center for AIDS Research HIV Clinical Cohort Study 
(UCHCC), an ongoing clinical cohort study founded in January 2000 that enrolls adults 
aged 18 years or older that are receiving HIV care at the University of North Carolina 
(UNC) Infectious Disease (ID) Clinic [339]. Patients enrolled in the UCHCC are 
representative of the HIV epidemic in the Southeastern United States, where HIV 
disproportionately affects minorities, the mode of transmission is primarily sexual, and 
most patients enter care during the chronic phase of HIV infection [340-342]. Through 
2011, 59% of all patients enrolled in the UCHCC (N=3,141 total) were African American, 
30% were female; 28% reported men who have sex with men (MSM) as a primary HIV 
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risk category, while only 11% reported injection drug use (IDU) [343]. Among 853 
UCHCC patients initiating HIV care at the UNC ID Clinic between 1999-2009, the 
median CD4+ T cell count at entry was 286 cells/µL (inter-quartile range (IQR): 63-482) 
[342].  Compared to the rest of the UCHCC cohort, this sample of 184 patients included 
in this study were less likely to be female (23%) or African American (53%), and more 
likely to be MSM (44%). These 184 patients were, however, enrolled in the cohort during 
the chronic stage of HIV infection, with a median CD4+ T cell count of 307 cells/µL (IQR: 
123-444) at entry to care. 
Only a subset of UCHCC patients was eligible for this study, based on a set of 
criteria related to the availability of a clinical sample for resistance testing and the timing 
and content of the initial antiretroviral regimen. First, UCHCC patients consented to the 
use of their specimens, which were collected as part of routine clinical care. Second, 
patients initiated therapy after December 31, 1999 to alleviate potential survivor bias 
from including patients who initiated therapy prior to the establishment of the cohort. 
Third, patients initiated therapy with a HAART regimen composed exclusively of RT 
inhibitors, including either ≥3 nucleoside(tide) reverse transcriptase inhibitors (NRTI), or 
≥2 NRTI and 1 non-NRTI (NNRTI). This criterion was imposed since sequencing was 
restricted to the coding region of HIV-1 RT associated with RT inhibitor resistance. 
Finally, patients had ≥1 pre-therapy HIV-1 RNA level recorded in the database, 
indicating a potential available sample for sequencing. A total of 331 UCHCC patients 
met the above criteria as of August 17, 2012, and of these, 184 had an archived, pre-
therapy plasma sample available for sequencing. A flow diagram of the study population 





Figure 3.1. Flow diagram of the study population. RT inhibitor regimens consisted of ≥3 
nucleoside(tide) reverse transcriptase inhibitors (NRTI) or ≥2 NRTI plus 1 non-NRTI 
(NNRTI). PI=protease inhibitor; RT=reverse transcriptase.  
 
3.3     THE UNIVERSITY OF NORTH CAROLINA CENTER FOR AIDS RESEARCH 
This study relied on data collected on behalf of the University of North Carolina at 
Chapel Hill Center for AIDS Research (UNC CFAR). UNC CFAR is a collaborative 
institution among investigators at the UNC School of Medicine, Family Health 
International, and Research Triangle Institute [344]. UNC CFAR facilitates clinical care of 
persons living with HIV disease in the Southeastern United States, provides support for 




The UNC CFAR oversees and maintains the UCHCC, which was established in 
2000 by the CFAR Clinical Core, but includes patient records dating back to the early 
years of the UNC ID Clinic. UCHCC maintains both an electronic database containing 
patient data and a repository of patient samples collected during routine care. The 
UCHCC database consists of patient data from standardized, biannual chart 
abstractions and from a hospital-wide electronic database that is updated in real time. 
UCHCC data is stored on a protected warehouse server with controlled access. Fewer 
than 2% refuse to participate in the UCHCC, and analyses indicate that patients who 
refuse are demographically and clinically similar to patients who agree to be in the 
UCHCC. 
3.4     DATA SOURCES 
Medical charts for patients enrolled in the UCHCC are routinely abstracted into 
the database at enrollment and at six month intervals. Copies of medical charts and web 
based clinic notes are used to complete paper chart abstraction forms, which are then 
entered into the electronic database using a standardized electronic data entry form. 
Chart abstraction forms are the source of the following information: patient name; unique 
identifier for UCHCC (patient key); HIV diagnosis history; entry to HIV care; clinic visit 
dates; HIV risk factors; allergies; results of screening tests (chest X-rays, PAP smears, 
mammograms); immunizations; hospitalizations; illnesses; medication history, including 
antiretroviral regimens and other medications; and HIV-related lab results not obtained 
at UNC. Paper forms are secured in a locked cabinet until they are completely entered 
into the UCHCC database, after which they are destroyed. The electronic UCHCC 
database is password protected and maintained on a secure warehouse server.  
As previously stated, the UCHCC database also contains data that is 
electronically transferred from UNC Hospital’s electronic database. This institutional 
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database is updated in real time and includes demographic information and laboratory 
results from tests performed through UNC Hospitals (e.g. HIV-1 RNA level and CD4 cell 
count). Both this electronically-transferred data and the manually abstracted data that 
are housed in the UCHCC were the source of clinical data for the 184 patients included 
in this study. Specific variables and specimens used are listed in Table 3.1. 
Table 3.1. Variables and specimens from the University of North Carolina Center 
for AIDS Research HIV Clinical Cohort Study  
Variable/clinical sample Source 
patient key* chart review 
first/last name* UNC Hospitals 
medical record number* UNC Hospitals 
date of entry to HIV care chart review 
consent questionnaire answers/date of enrollment chart review 
clinic visit dates chart review 
date of death chart review 
resistance test results/test dates† chart review 
HIV-1 RNA levels/test dates UNC Hospitals 
CD4+ T cell counts/test dates UNC Hospitals 
antiretrovirals used/start and stop dates chart review 
date of birth UNC Hospitals 
gender UNC Hospitals 
race/Latino ethnicity UNC Hospitals 
HIV risk category chart review 
≥140 μL plasma/draw date‡ repository 
*Medical record numbers, names, and patient key were linked to locate archived plasma 
samples. †Bulk sequencing results were provided at the amino acid level. ‡All plasma 
samples were collected prior to the initiation of antiretroviral therapy. If possible, the 
sample drawn closest to the last pre-therapy bulk sequencing result was used.  
 
3.5     HIV-RELATED LABORATORY PROCEDURES 
 
 
3.5.1     BLOOD SPECIMEN COLLECTION AND PREPARATION 
For UCHCC patients, venous blood is drawn as part of routine care and stored in 
the repository following informed consent. Specimens retrospectively tested for 
resistance in this study were collected from participants prior to initiating HAART 
(N=184) (Figure 3.1). On average, 2 samples consisting of 2-4 mL of blood each are 
drawn per patient prior to initiating antiretroviral therapy (IQR: 1-4), but for these 184 
patients, the median number of blood draws was 3 (IQR: 2-6). Blood samples are 
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centrifuged within 24 hours of collection to separate plasma from whole blood. Plasma is 
then used for testing or stored by the UNC CFAR Retrovirology or Immunology Core.  
Upon receipt of plasma, UNC CFAR personnel update a master specimen log 
with barcode information, and they create a tracking sheet for each specimen. Tracking 
sheets and specimen vials contain the patient’s name, UNC Hospital system medical 
record number, barcode, the sample’s collection date, batch number, and protocol 
number. Tracking sheets are updated with each freeze/thaw per sample as repeated 
cycles threaten the integrity and purity of clinical specimens. To prevent multiple cycles, 
stored plasma is usually aliquoted into smaller volumes (1 mL).  
For this study, a minimum of 140 µL plasma from each of 184 patients was used 
for resistance testing. For samples with fewer than 4.5 log10 HIV-1 RNA copies/mL, 1 mL 
of plasma was centrifuged (20,000 x g) for 2.5 hours at 4°C to concentrate the virus; this 
cut-off was chosen based on early tests of PCR primers (data not shown). After the 
centrifugation step, the supernatant was removed and stored at -80°C, and remaining 
virus-containing pellets were resuspended in 140 µL of phosphate-buffered saline (PBS) 
for RNA extraction. 
3.5.2     HIV-1 RNA EXTRACTION 
Total RNA was extracted from plasma samples to isolate RNA from impurities 
and nucleases that may degrade RNA. A total of 140 μL of plasma or PBS suspension 
was necessary to produce 60 μL of total RNA using the QIAGEN extraction protocol 
(QIAGEN, Hilden, Germany); however, high HIV-1 RNA viral loads were ideal (>4.5 log10 
copies/mL) for better sampling of the viral population. Given the instability of RNA [332, 
345] and the nature of researching rare HIV sequence variants, plasma samples and 
RNA were handled in an area where the potential for contamination and RNA 
degradation was minimized. A separate clean room free of amplified/cloned DNA, 
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enclosed safety cabinets with laminar air flow to prevent contamination, and 
ribonuclease (RNase) free surfaces and consumable items were employed to protect the 
integrity of patient samples. 
From each thawed plasma sample or PBS suspension, 140 µL was removed and 
combined with 5.6 µg of carrier RNA (to prevent template loss and aid RNA precipitation) 
and lysis buffer to: (1) denature RNases naturally present in plasma; (2) disrupt HIV-1 
envelope and capsid for RNA isolation; and (3) facilitate RNA capture. Following lysis, 
RNA was precipitated in ethanol, and applied to a silica membrane to bind nucleic acids. 
Bound RNA was washed with ethanol and high salt solutions, dried to remove excess 
ethanol, and dissolved (eluted) from the membrane using 60 µL of RNase-free water. 
Purified RNA preparations were stored at -80°C in a locked freezer. 
3.5.3     HIV-1 CDNA SYNTHESIS 
Next, HIV-1 RNA must be reverse transcribed into complimentary DNA (cDNA) 
using reverse transcriptase, since most downstream analyses rely on a DNA template. 
First, purified total RNA and dNTP were combined with an oligonucleotide primer such 
as a oligo(dT) which binds the HIV-1 RNA poly(A) tail, or a random typically 6-nucleotide 
sequence which could potentially bind any site within the genome, or HIV-specific 
nucleotide sequence that targets a specific sequence. This solution was heated and 
rapidly cooled to 2-4°C to disrupt the secondary structure of RNA and allow the primer to 
anneal to the RNA template. Next, an RT enzyme, RNase inhibitors, and reaction buffer 
were added, and the reaction was heated to allow cDNA extension. Following extension, 
the reverse transcriptase was inactivated, and RNase H was added to degrade 
remaining RNA bound to cDNA. cDNA may was then stored at -20°C. 
cDNA synthesis was performed in two separate reactions for each sample (184 
samples x 2 = 368 reactions), one per cDNA primer (Appendix 3.1). Each 60 µL cDNA 
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reaction contained 20 µL total RNA, 600 Units of SuperScript III (Life Technologies), 1st 
Strand Synthesis Buffer (Life Technologies), 0.25 mM dNTP mix, 100 mM dithiothreitol, 
120 Units of RNase OUT (Life Technologies), and 0.25 µM primer specific to either HIV-
1 HXB2 nucleotides 2965-2992 or 3258-3284 (Appendix 3.1) [346]. In addition to HIV-
specific sequence, cDNA primers featured a random 8-nucleotide Primer ID sequence 
(CGNNNNNNNNTC), a 4-nucleotide sample barcode sequence (BBBB), and a non-HIV-
specific PCR primer sequence (GCCTTGCCAGCACGCTCACAGCTGGCA). cDNA 
primers were removed following synthesis to prevent the excess from serving as primers 
for multiple sequences during downstream amplification, thus defeating the purpose of 
Primer ID. cDNA reactions were purified using the PureLink PCR Purification Kit (Life 
Technologies, Carlsbad, CA) with four wash steps to ensure their complete removal [26]. 
This kit includes a high cut-off DNA binding buffer that contains isopropanol, allowing 
separation of higher molecular weight cDNA from shorter cDNA primer sequences. 
3.5.4     HIV-1 DNA AMPLIFICATION 
Non-quantitative PCR was used to amplify HIV-1 cDNA spanning HIV-1 pol 
(HXB2 nucleotides 2620-2992 and 2992-3284). For the 1st round of PCR, 500 copies of 
cDNA, estimated using HIV-1 RNA level of the sample, were input into a 50 µL PCR 
reaction (one reaction/HIV-1 fragment) containing 0.5 µM of each round 1 PCR primer 
listed in Appendix 3.1. In addition, each reaction contained 0.2 mM of dNTP mix, 1.25 
Units of Phusion® High Fidelity Hot Start II DNA polymerase (Thermo Scientific, 
Waltham, MA), and Phusion® High Fidelity PCR Buffer with 1.5 mM MgCl2 (Thermo 
Scientific). cDNA were amplified using the following parameters: (1) 30 seconds at 98°C; 
(2) 30 cycles of 10 seconds at 98°C, 30 seconds at 67°C (HXB2 nucleotides 2620-2992) 
or 63°C (HXB2 nucleotides 2992-3284), 72°C for 30 seconds; and (3) final extension for 
10 minutes at 72°C. Next, 1-2 µL of the 1st PCR reaction was added to 25 µL containing 
identical reagents, but with 2nd round PCR primers listed in Appendix 3.1. Reactions 
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were amplified over 30 cycles using previous parameters, except that for the first 10 
amplification cycles, annealing temperatures were lowered to 57°C and 53°C, 
respectively. 
Given the large number of clinical samples and total reactions, cross-
contamination between patient samples was a significant concern. Multiple efforts were 
made to reduce the possibility of cross-contamination, including using biosafety 
cabinets, aliquoting reagents for single use, using disposable consumables, and limiting 
the number of samples processed per day. A negative control was included in the first 
and second rounds of PCR amplification to monitor contamination. For the 1st round of 
PCR, water was added instead of the cDNA template (no template control), and 2 µL of 
this amplified product was added to the 2nd round PCR reaction to check for low level 
contamination. In addition, separate water-only, no template controls were set up during 
the 2nd round of amplification to help determine the source of contamination. 
Following amplification, 10% (2.5 µL) of each sample or control was removed for 
agarose gel electrophoresis to visualize the amplified DNA band. The upstream HIV-1 
RT amplicon was expected produce a 410 bp band including 373 bp of HIV-1 sequence 
(HXB2 nucleotides 2620-2992) and 37 bp of non-HIV-1 primer sequence, while the 
downstream amplicon was expected to produce a 357 bp band, including 320 bp of HIV-
1 sequence (HXB2 nucleotides 2992-3284) and 37 bp of non-HIV-1 primer sequence. 
For each sample, band intensity for each amplicon was compared to a DNA mass 
standard to determine its concentration (Carestream Molecular Imaging Software SE, 
Rochester, NY). Samples were then pooled in equimolar amounts for UDS based on the 
determined concentration.  
Pools of amplicons from multiple samples were digested with PvuII (recognition 
sequence CAG▼CTG) to cleave a portion of the non-HIV-1 PCR primer sequence from 
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each amplicon, thus increasing the read length of HIV-1 sequence. It is possible that 
some amplicons would have the PvuII recognition site within the Primer ID sequence 
and therefore be excluded from downstream analyses after cleavage; however, this 
would only occur in 3 different Primer ID patterns: NCAGCTGN, NNCAGCTG, and 
CAGCTGNN. Thus, 42+42+42=48 out of a total 48=65,538 possible Primer ID would 
contain a PvuII cut site (0.073%). Following digestion, pools of amplicons were 
separated by agarose gel electrophoresis and gel purified to remove any short 
sequences (QIAquick Gel Purification kit, QIAGEN). Amplicons submitted for standard 
bulk sequencing analysis were not pooled, but rather 2nd round PCR products were 
individually purified before sequencing (QIAamp PCR Purification kit, QIAGEN). Both 
purified individual amplicons and amplicon pools were stored at -20°C. 
3.5.5     BULK HIV-1 DNA SEQUENCING 
Most patients (N=180/184, 98%) had a standard genotypic resistance result for at 
least one sample drawn prior to initiating therapy. For the majority of patients 
(N=140/180, 78%), genotypic resistance testing was performed using HIV GenoSure™ 
or GenoSure™ Plus assays (LabCorp, Research Triangle Park, NC), which produce a 
summary report of amino acid changes over HIV-1 RT codons 20-399 (in addition to 
protease and integrase). For 103 (74%) of these patients, resistance genotypes were 
preformed retrospectively as part of a collaboration with Virco laboratories (Mechelen, 
Belgium). For the other 37 (26%) patients, resistance tests were performed as part of 
routine care to guide initial therapy selection.  
For patients without commercial genotypic results (N=44), in-house bulk 
sequencing of both strands of each HIV-1 RT amplicon was attempted using purified 2nd 
round PCR products (with barcode and Primer ID) and 10 pmoles each of the inner PCR 
primers (Appendix 3.1). For 40 patients (91%), an in-house bulk sequence was obtained 
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for at least one of the two amplicons; for 8 of 40 patients, the downstream RT amplicon 
was not successfully sequenced.  
DNA amplicons were sequenced by the UNC-CH Genome Analysis Facility on 
an Applied Biosystems (ABI) 3730x1 DNA Analyzer (Life Technologies) using the ABI 
PRISM™ BigDye™ version 1.1 Terminator Cycle Sequencing Ready Reaction Kit with 
AmpliTaq® DNA polymerase FS (Life Technologies). Sequence chromatograms of both 
strands of each HIV-1 RT amplicon were inspected for quality, trimmed, and assembled 
using Sequencher version 4.8 (Gene Codes Corporation, Ann Arbor, MI). To check for 
evidence of cross-contamination between patient samples, sequences were aligned 
using a ClustalW2 server [347]. Alignments were input into MEGA version 5.2 to 
construct Neighbor-Joining phylogenetic trees using 1,000 bootstrap replicates [348]. 
The Kimura 2-parameter method was used to estimate evolutionary distances between 
sequences [349]. Nucleotide sequences were translated into amino acid sequences and 
antiretroviral resistance was interpreted using the Stanford HIV Drug Resistance 
database (Stanford HIVdb) [171].  
3.5.6     ULTRA DEEP HIV-1 DNA SEQUENCING 
Ultra deep sequencing (UDS) of amplicons from clinical samples was performed 
using two different proprietary platforms, Roche’s 454 GS FLX (Roche Diagnostics, 
Basel, Switzerland) and Illumina’s MiSeq (150 bp paired-end, Illumina, San Diego, CA), 
which were discussed in previous sections. For UDS using the 454 platform, a pool of 
amplicons from 184 patients spanning both RT fragments was submitted for sequencing 
on an entire plate (106 sequences expected). For Illumina MiSeq, amplicons from 19 
patients were sequenced using the 150 bp paired-end sequencing protocol to sequence 
HXB2 nucleotides 2648-2770 and 2878-2964 (107 sequences expected). These patients 
were selected because they had the greatest number of Primer ID consensus 
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sequences generated from 454 deep sequencing data, which is evidence of greater 
sampling depth of the viral population. 
3.5.7     HIV-1 RNA LEVEL AND CD4+ T CELL COUNT 
HIV-1 RNA level was measured using a quantitative RT-PCR system developed 
by Roche Diagnostics Systems (Basel, Switzerland). The Roche Amplicor HIV-1 Monitor 
assay relies on the following steps to quantify the amount of HIV-1 RNA in patient 
plasma: (1) plasma separation and HIV-1 RNA extraction; (2) reverse transcription of 
HIV-1 RNA into cDNA using biotinylated primers for a labeling reaction in steps 4 and 5; 
(3) PCR amplification of the cDNA; (4) hybridization of the PCR amplicons to 
immobilized HIV-specific probes; and (5) laser detection of the fluorescence from 
biotinyl-labeled primers. The Roche Amplicor HIV-1 Monitor assay can be performed 
using the standard or ultrasensitive procedures: the standard procedure can quantify 
HIV-1 RNA over a range from 400-750,000 copies/mL; the ultrasensitive procedure can 
quantify HIV-1 RNA over a range of 50-75,000 copies/mL. 
CD4+ T cell counts were measured in-house using single-platform technology 
and flow cytometry. This technology is capable of measuring CD4+ T cell concentrations 
as low as 10 cells/μL of plasma. Normally, CD4+ T cell counts range from 500 to 1500 
cells/μL, but many advanced HIV patients have CD4+ T cell counts below 200 cells/μL. 
3.5.8     PLASMID CONTROL SEQUENCE 
To characterize errors associated with both Illumina and Roche UDS platforms, 
all of HIV-1 reverse transcriptase (HXB2 2550-3515) from a patient HIV-1 subtype C 
isolate was cloned into a plasmid vector, pcDNA3.1 (Life Technologies) and used as a 
known sequence control. The sequence of the plasmid insert was confirmed by in-house 
bulk sequencing. Once confirmed by bulk sequencing, the plasmid was linearized by 
BamHI digestion, purified using the Minelute PCR Purification kit (QIAGEN), and 
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quantified by UV spectrophotometry. Control DNA was then serially diluted to solutions 
containing 3,000, 10,000, 30,000, and 100,000 copies. Double stranded plasmid DNA 
were denatured, cooled, and tagged with Primer ID and barcode (one per dilution) using 
Platinum Taq DNA polymerase (Life Technologies). Excess cDNA primers were 
removed [26], and HIV-1 HXB2 nucleotides 2620-2992 were amplified from each dilution 
using the same conditions as patient samples. Amplicons were pooled across copy 
number dilutions in equimolar concentration, and pools were sequenced over HIV-1 RT 
codons 34-139 using the 454 Junior (HXB2 nucleotides 2648-2964, Roche) and Illumina 
MiSeq sequencing platforms (HXB2 nucleotides 2648-2840 and 2782-2964).  
3.5.9     DEEP SEQUENCING DATA PIPELINE 
Deep sequencing data was processed using a custom pipeline of filters, 
implemented slightly differently depending on the sequencing platform. Given the 
enormous amount of data output by Illumina MiSeq, a sample of 1,000,000 sequences 
was input into the filtering pipeline. For both platforms, sequence read lengths were 
examined and reads <300 nucleotides were discarded. Next, sequences were compared 
to HXB2 pol to determine orientation and location. The barcode and Primer ID of these 
sequences was checked, and sequences with invalid barcodes or Primer ID were 
discarded. Remaining sequences were partitioned by barcode (sample) and then Primer 
ID (viral template). For sequences read by the 454 platform, sequences with a Primer ID 
occurring fewer than 3 times within a sample were discarded; for the Illumina MiSeq 
platform, sequences with a Primer ID occurring less than 5 times were discarded. A 
larger threshold was chosen for sequencing data from the Illumina platform since a 
larger number of sequences were available. Consensus sequences were then created 
from multiple sequences with identical Primer ID. These nucleotide sequences were 
then translated into amino acid sequences and resistance to particular antiretrovirals 
was predicted using the Stanford HIVdb [171]. Excluding the HIV-specific primer 
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sequences used in PCR amplification, UDS sequences spanned HXB2 nucleotides 
2648-2964 and 2993-3257 (454 FLX sequencing platform only). 
Primer ID must be correctly sequenced to accurately estimate the viral population 
within the individual patient. Since each Primer ID sequence is 8 nucleotides, and since 
errors begin to occur with greater frequency after 3 or more identical consecutive 
nucleotides, homopolymer-associated miscalls within the Primer ID sequence were a 
concern. Miscalls within the Primer ID sequence could artificially inflate the number of 
templates within a sample when consensus sequences are generated from unique 
Primer ID. If a homopolymeric Primer ID appears a vast number of times within a sample 
(resampled), some small portion of Primer ID may consistently be misread and separate 
consensus sequences may be created from these unique Primer ID. To check for this 
type of error, Primer ID clusters were examined within patient barcodes with evidence of 
resampled Primer ID (>500 occurrences of the same Primer ID) using multiple sequence 
alignment. If Primer ID was 1 or 2 nucleotides different from larger clusters (resampled 
Primer ID), these consensus sequences were discarded.  
3.6     STATISTICAL ANALYSES 
All statistical analyses were performed using SAS version 9.3 (SAS Corporation, 
Cary, NC) and Stata version 10 (StataCorp, College Station, TX).  
3.6.1     SPECIFIC AIM 1 
Using a known HIV-1 reverse transcriptase sequence, define a baseline error rate for the 
454 and MiSeq ultra deep sequencing platforms. For each platform, compare results 
estimated using Primer ID consensus sequences to those estimated using raw 
sequences. 
Known HIV-1 Reverse Transcriptase Sequence: The plasmid control for this 
study was created by co-contributor Shuntai Zhou, using an HIV-1 subtype C sequence 
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isolated from a patient sample. The entire length of HIV-1 reverse transcriptase was 
cloned into a pcDNA3.1 plasmid DNA vector. Plasmid DNA was quantified and serially 
diluted into fixed volumes containing 3,000, 10,000, 30,000, or 100,000 copies of the 
HIV-1 sequence insert. Each copy number dilution was input into four independent, 
single round DNA synthesis reactions, where DNA templates were tagged with a 
barcode and random 8-nucleotide Primer ID. Excess cDNA primers were removed and 
samples were independently amplified by semi-nested PCR. Amplified DNA was pooled 
across dilutions (barcodes) in equal amounts and submitted for deep sequencing using 
the Illumina MiSeq and Roche 454 Junior platforms.  
Homopolymeric Regions: One of the main problems with 454 technologies is 
the tendency to read too few or too many nucleotides after ≥5 of them occur 
consecutively within a sequence [24, 350]. This is because one nucleotide is added to 
the sequencing reaction at one time, and the signal generated is proportional to the 
number of identical nucleotides incorporated in a row; however, the variability in the 
relationship between the size of signal peak and the number of identical nucleotides in a 
row rapidly increases as the length of the homopolymer increases, resulting in erroneous 
nucleotide calls. Homopolymeric regions are abundant within the interrogated region of 
HIV-1 reverse transcriptase (≈20-25% of the sequence), and homopolymer-associated 
errors were expected to be common among HIV-1 sequences read by this platform.  
In this analysis, homopolymeric regions were defined as 4 or more identical 
nucleotides in a row plus the two flanking nucleotides. By this definition, 75 (24%) of 317 
nucleotides spanning HXB2 2648-2964 were expected to be susceptible to 
homopolymeric error for the HIV-1 subtype C control sequence. Since error estimates 
from control experiments were extrapolated to subtype B patient samples, 
homopolymer-associated positions were defined separately for patient samples. The 
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2004 subtype B consensus sequence, available from the Los Alamos HIV sequence 
database, was used to identify homopolymeric positions for clinical patient samples 
since the true sequences are unknown. Within the 2004 HIV-1 subtype B consensus 
sequence, 61 (19%) of 317 positions were near or within homopolymeric regions within 
the sequence spanning HXB2 2648-2964, while 45 (17%) of 265 positions spanning 
HXB2 2993-3257 were expected to be within homopolymeric influence. 
Analysis: The main objective of Aim 1 was to define a baseline error rate for the 
Primer ID method using a known sequence to provide context for resistance estimates 
within clinical samples, where the viral population is unknown. For each sequencing 
platform, raw sequences or Primer ID consensus sequences were compared to the 
sequence of the cloned HIV-1 sequence insert at each nucleotide position. This was 
done by aligning each raw or Primer ID consensus sequence to the known sequence, 
determining if the call was correct, and totaling the number of erroneous nucleotide calls 
for all sequences for each nucleotide position. The percent of erroneous calls 
(errors/total nucleotides sequenced x 100) at each nucleotide position sequenced was 
plotted for both raw and Primer ID consensus sequences. Erroneous calls were further 
categorized as: (1) substitutions, where a nucleotide other than the known nucleotide 
was called; (2) insertions, where an extra nucleotide was called in that position; (3) 
deletions, where the nucleotide was represented as a gap in that position; or (4) other 
errors, such as an ambiguous base call.  
For error rates, erroneous nucleotide calls were summed across all 317 
interrogated nucleotide positions spanning HXB2 nucleotides 2648-2964, both for all 
copy number dilutions and separately for each copy number dilution (barcode). The total 
number of errors was divided by the total number of nucleotides read and multiplied by 
10,000 to determine the error rate per 10,000 nucleotides. Error rates were calculated 
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for strata defined by sequencing platform (454 Junior or MiSeq), analysis method (raw or 
Primer ID consensus sequences), and by sequence location (homopolymeric or 
heteropolymeric regions). Standard errors and 95% confidence intervals (CI) for error 
rates were calculated using the Poisson distribution. Clustered sandwich estimators 
were used to calculate standard errors and 95% CI for error rates calculated across all 
copy number dilutions [351]. 
Sampling Minority Variants: The ability to detect minority variants depends on 
the number of unique Primer ID consensus sequences within a sample (Figure 3.2). 
Assuming an error rate of 4/10,000 nucleotides and a 400 nucleotide sequence, 59 
Primer ID consensus sequences are necessary to detect a variant present in 5% of the 
population with 95%power in a hypothesis test with a 5% type I error probability. At 95% 
power, only 29 Primer ID consensus sequences would be needed to detect a variant 
present in 10% of the sample, while 298 Primer ID consensus sequences would be 




Figure 3.2. Sampling depth and power to detect minority HIV-1 sequence variants. Assume 
4 errors per 10,000 nucleotides, a 400 nucleotide sequence, and α=0.05. 
 
3.6.2     SPECIFIC AIM 2A/B 
(A) Using the 454 FLX platform to sequence HIV-1 RT codons 34-138 and 149-236, 
estimate the prevalence and relative abundance of RT inhibitor resistance among 184 
therapy-naïve patients with concurrent bulk sequencing results. (B) Compare estimates 
obtained using the 454 platform to estimates obtained using bulk sequencing. 
Study Population: The study population for Aim 2A and 2B consisted of all 
participants enrolled in the UCHCC that met the inclusion criteria outlined below (Figure 
3.1). All HIV-infected persons at least 18 years of age and providing written, informed 
consent for inclusion in the UCHCC were eligible if: (1) they initiated combination 
antiretroviral therapy after December 31, 1999; (2) with either ≥3 NRTI or ≥2 
NRTI+NNRTI; (3) they had ≥1 HIV-1 RNA level measurement recorded in the database 
prior to therapy initiation; and (4) they had available frozen plasma prior to therapy 
 76 
 
initiation. 331 patients met criteria (1) through (3), while 184 of these patients had 
available pre-therapy samples (4). 
To examine exchangeability between populations with and without available 
samples with respect to pre-existing drug resistance, distributions of key variables were 
compared:  
(1) Age at therapy initiation 
(2) Gender 
(3) Race: black, white, or other race. 
(4) HIV risk category: separate binary variables men who have sex with 
men (MSM), injection drug use (IDU), and heterosexual contact. 
(5) Year of therapy initiation: categorized as 1999-2001, 2002-2004, 2005-
2007, and >2007.  
(6) Last pre-therapy CD4+ T cell count: continuous or categorized using 
the CDC laboratory definition of AIDS (in cells/µL) [32]: <200; and ≥200.  
(7) Last pre-therapy HIV-1 RNA level:  log10-tranformed and treated as 
continuous.  
Distributions of continuous variables were first checked within all eligible patients 
(N=331) by inspecting boxplots and histograms, and non-normally distributed variables 
were transformed as necessary. Next, continuous and categorical variables were 
examined within patients with an available sample (N=184) and those without an 
available sample (N=147) and their differences compared.  
Aim 2A Analysis: The main objective of Aim 2A was to estimate the amount of 
pre-existing resistance within a population of mostly chronically-infected, therapy-naïve 
patients using highly-sensitive UDS to measure resistance mutations. Resistance 
mutations were defined using the 2009 list of surveillance drug resistance mutations 
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(SDRM) (Appendix 2.2) since detection of these mutations in patients before starting 
therapy is more likely to represent transmission of drug resistance rather than naturally 
occurring polymorphisms [188, 189]. However, given high error rates associated with 
homopolymeric positions, mutations at HIV-1 RT codons 65, 67, 74, 100, 101, 103, 115, 
116, and 219 were excluded from overall estimates of resistance prevalence. 
Deep Sequencing Data: Two amplicons per patient were submitted for 
sequencing using the Roche 454 FLX deep sequencing platform: one amplicon spanned 
HXB2 nucleotides 2620-2992, and one spanned HXB2 nucleotides 2965-3284. 
However, the HIV-1 specific primer sequence was excluded from analyses since these 
primer sequences are theoretically identical across all sequences and not biologically 
informative. Therefore, the sequence regions used to estimate resistance in this 
population spanned HXB2 nucleotides 2648-2964 and 2993-3257, which cover HIV-1 
RT codons 34-138 and 149-236, inclusive.  
Not all patient amplicons were successfully sequenced using the 454 platform. 
For 7 (4%) and 3 (2%) subjects, only HIV-1 RT fragment 1 (RT codons 34-138) or 2 (RT 
codons 199-236) sequences were available, while for 2 (1%) patients, no sequences 
were obtained. For those missing 454 sequence information, it was assumed that they 
had no resistance within the missing RT region. Therefore, prevalence estimates used 
the full 184 patients as the denominator. Population prevalence was estimated overall 
(any RT inhibitor resistance), and by antiretroviral class (NRTI and NNRTI resistance). 
For population prevalence estimates, standard errors and 95% CI were calculated using 
the binomial distribution. 
 Deep sequencing resistance data for each patient consisted of the following: (1) 
sample draw date; (2) sample HIV-1 RNA level; (3) number of Primer ID consensus 
sequences for each HIV-1 region sequenced; (4) presence or absence of each SDRM 
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mutation among all their Primer ID consensus sequences; (5) number of Primer ID 
consensus sequences with each SDRM mutation; and (6) proportion of Primer ID 
consensus sequences with each SDRM mutation (relative abundance). In addition, 
class-wide and overall resistance variables were estimated per patient as follows: (1) 
presence or absence of any RT inhibitor, NRTI, and NNRTI resistance mutation; (2) the 
total number of unique RT inhibitor, NRTI, and NNRTI resistance mutations detected; (3) 
for each amplicon sequenced and for both amplicons together, the minimum and 
maximum total occurrences of any RT inhibitor, NRTI, and NNRTI resistance mutation 
among Primer ID consensus sequences; and (4) for each amplicon sequenced and for 
both amplicons together, the minimum and maximum proportion of Primer ID consensus 
sequences with any RT inhibitor, NRTI, and NNRTI resistance mutation.  
In light of error rates observed in the control experiments from Aim 1, a stricter 
definition of deep sequencing detected resistance was implemented for a sensitivity 
analysis. For this analysis, all single occurrences of resistance mutations were excluded 
as errors. That is, within each patient sample, a resistance mutation had to occur on at 
least two Primer ID consensus sequences to be counted as genuine. This approach was 
probably overly conservative, however. For the upstream reverse transcriptase 
fragment, given 12,971 consensus sequences generated across 181 patients and 
assuming that errors follow the Poisson distribution, a total of 493 singly occurring 
mutations were expected; 1,887 were observed (observed/expected: 3.8). For the 
downstream fragment, 379 singly occurring mutations were expected given 10,122 
consensus sequences across 177 patients, while 1,828 were observed 
(observed/expected: 4.8).  
Analysis Aim 2B:  Deep sequencing and standard bulk sequencing analysis 
resistance results were compared. Since standard bulk sequencing cannot reliably 
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detect minority variants that comprise less than 20% of the total mixture [146], all SDRM 
detected by bulk sequencing were expected to be detected using the 454 deep 
sequencing platform. Comparisons between ultra deep and bulk sequencing detected 
resistance were repeated for each definition of ultra deep sequencing detected 
resistance.  
Bulk Sequencing Data: Bulk sequencing resistance data for each patient 
consisted of the following: (1) date of sample draw; (2) sample HIV-1 RNA level; (3) an 
indicator variable for whether or not bulk sequencing was done in-house; (4) laboratory 
where sequencing was performed; (5) presence or absence of each SDRM mutation; (6) 
presence or absence of any RT inhibitor, NRTI, and NNRTI mutations; and (7) number 
of unique RT inhibitor, NRTI, and NNRTI mutations.  
Agreement between bulk sequence analysis and deep sequencing was assessed 
for each SDRM and for each antiretroviral class by calculating Kappa statistics (-1 to 1). 
Median relative abundance of SDRM was compared by whether or not the mutation was 
detected using standard bulk sequencing. 
Statistical Precision: Using the logit transformation of proportions and their 
standard errors to calculate confidence intervals, precision around prevalence estimates 
increases with lower prevalence and increasing sample size (Figure 3.3). The logit 
transformation was used to avoid illogical confidence intervals that fall outside the 0 and 
1 range. Assuming a sample size of 184 patients, prevalence estimates as low as 2% 




Figure 3.3. Prevalence and 95% confidence intervals by sample size, assuming 2%, 4%, 
10%, or 20% of the study population has resistance. Confidence intervals were calculated 
using the logit transformation. 
 
 
3.6.3     SPECIFIC AIM 2C 
(C) Among a subset of 19 patients with the greatest depth of sampling of viral templates, 
compare mutations detected within HIV-1 RT codons 34-73 and 111-138 between the 
Illumina MiSeq and Roche 454 platforms. 
Study Population: Initially, 22 patients were chosen from the full population of 
184 patients for sequencing using the Illumina MiSeq platform, which is not susceptible 
to homopolymer-associated error. This subset was chosen since they had the greatest 
number of Primer ID consensus sequences generated using the 454 platform, and their 
barcode sequences were at least two nucleotides different from each other, making it 
less likely sequences would be misclassified. However, adequate amplified DNA from 
the previous 454 deep sequencing experiment was available for only 19 patients, who 
had a median 203 Primer ID consensus sequences (IQR: 168-243) generated from a 
median 3,378 raw 454 sequences (IQR: 2,494-3,796). Amplified DNA spanning HXB2 
nucleotides 2620-2992 from the second round of PCR was pooled in equal amounts 
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across 19 patients, gel purified, and submitted for deep sequencing using the 150 bp 
paired-end sequencing protocol on the Illumina MiSeq sequencing platform. Using this 
protocol, sequences spanning HXB2 nucleotides 2648-2840 and 2782-2964 were 
available for comparison. 
Analysis: The objective of Aim 2C was to compare any detected mutations 
between two different ultra deep sequencing methods: Illumina MiSeq and Roche 454 
FLX platforms. While Illumina is not susceptible to homopolymer-associated miscalls, it 
has a shorter read length limitation, and it is associated with its own set of platform 
specific errors, discussed in Section 2.9.3. The majority of singly occurring mutations 
within the 454 Primer ID consensus sequences were expected to fall within 
homopolymeric regions. In contrast, for Illumina MiSeq, the quality of raw sequences 
was expected to decline over the sequencing run, so more single occurrences of 
mutations were expected towards the end of each paired-end read. In this case, more 
single occurrences of mutations would be expected towards RT codon 73 (downstream) 
for one paired end, while for the other paired end, more single occurrences would be 
expected towards RT codon 111 (upstream). 
Deep Sequencing Data: The upstream HIV-1 reverse transcriptase amplicon for 
each of 19 patients (spanning HXB2 nucleotides 2620-2992) was submitted for 
sequencing using the Illumina MiSeq deep sequencing platform with the 150 bp paired-
end sequencing protocol. Thus, the biologically relevant sequence did not completely 
cover the entire amplicon (317 bp). Therefore, the sequence regions used for 
comparison to 454 deep sequencing spanned HXB2 nucleotides 2648-2770 and 2878-
2964, which covered HIV-1 RT codons 34-73 and 111-138, inclusive. 
Deep sequencing data for each patient consisted of the following: (1) sample 
draw date; (2) sample HIV-1 RNA level; (3) number of Primer ID consensus sequences 
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for each platform; (4) presence or absence of each mutation among Primer ID 
consensus sequences for each platform; (5) number of Primer ID consensus sequences 
with each mutation for each platform; and (6) proportion of Primer ID consensus 
sequences with each mutation (relative abundance) for each platform. Sequences were 
first examined at the amino acid level, and when differences between platforms were 
found, at the nucleotide level. 
For each patient, the number of Primer ID consensus sequences generated was 
compared by sequencing platform. Even though the Illumina MiSeq capacity is much 
greater than the 454 sequencing platform (10-fold increase in raw sequences), a 
comparable number of Primer ID consensus sequences was expected per patient since 
the same PCR amplicons were sequenced. After comparing these values, amino acid 
mutations were compared across platforms both by individual patient, and overall across 
all patients. Mutations were categorized as detected by MiSeq alone, by 454 FLX alone, 
and by both platforms. Median relative abundances of mutations detected solely by 
Illumina MiSeq, solely by 454 FLX, and by both sequencing platforms were compared. 
For each mutation detected, the nucleotide sequence was examined to determine its 
distance from a homopolymeric tract. Also, their location along HXB2 was plotted by the 




3.6.4     SPECIFIC AIM 3 
Among study participants with RT inhibitor resistance measured using both bulk and 
deep sequencing, estimate the effect of pre-therapy resistance to one or more 
antiretrovirals within their first regimen on time-to-first virologic failure (VF). 
Study Population: The effect of pre-therapy resistance on treatment response 
(Aim 3) was estimated among a subset of Aim 2A/B’s population that had at least one 
HIV-1 RNA level measurement after beginning HAART. Of 184 patients with pre-therapy 
samples available for resistance testing (Aim 2A/B), 153 had at least one HIV-1 RNA 
level measurement following HAART initiation.  
Statistical Model: Virologic response to HAART is indicated by a single 
biomarker that is repeatedly measured both prior to and after HAART initiation: HIV-1 
RNA level in the plasma, which is expected to decline to below detection (<50 HIV-1 
RNA copies/mL) with successful antiretroviral treatment. Treatment failure is not defined 
by guidelines using the slope of HIV-1 RNA level decay within a defined time period; 
instead individuals experience treatment failure when plasma HIV-1 RNA levels rise 
above or remain above 200 copies/mL 2-8 weeks following initial treatment or regimen 
switch [6]. The timing of HIV-1 RNA replication suppression is important, however, since 
individuals who more rapidly reach these endpoints experience better outcomes in terms 
of decreased evolution of drug resistance [167], enhanced immune reconstitution [84], 
and decreased mortality [175]. Therefore, the definition of VF used here included an 
HIV-1 RNA slope change from baseline so that patients who failed to achieve at least a 
0.5 log10 drop in HIV-1 RNA copies/mL from baseline within the first 6 months of therapy 
were also considered to have experienced VF, rather than just patients who experienced 
a HIV-1 RNA level above detection (in this case >400 co/mL) after 6 months of therapy. 
Since the outcome (VF) is not only the occurrence of virologic response but also the 
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timing of response, represented by event time T, a Cox proportional hazards model of 






   
where λ0(t) is the unspecified baseline hazard function for first VF for individuals 
without evidence of baseline resistance to their initial regimen and with all covariates in 
vector L(t) set to 0. β2 is a vector of unknown coefficients for time-fixed (measured at 
baseline, t=0) and time-varying covariates L(t), while β1 represents the unknown 
coefficient for the main exposure (pre-existing resistance to their initial regimen). Cox’s 
partial likelihood method for estimating the conditional hazard of event T at time t may 
be extended so that the effects of variables may vary over time (relaxing the proportional 
hazard assumption) and so that individuals may enter and leave the risk set during the 
study period. However, since partial likelihood methods depend on the ordering of 
events, rather than the timing of events, ties in event times can be problematic. For our 
purposes, we relied on the exact methods for partial likelihood estimation of unknown 
beta coefficients proposed by Kalbfleisch and Prentice in 1980 [353], which assume that 
there are no real tied event times and that the true ordering of events is unknown 
because of imprecise measurement of time. If exact computations became too time-
consuming, approximations proposed by Efron were used [354], which are usually closer 
to exact estimations than other approximate methods [355].    
Exposure Variables: To construct clinically relevant exposure variables for pre-
therapy resistance, patients’ pre-existing resistance mutations were interpreted in the 
context of the combination of RT inhibitors they received over follow-up rather than 
examining the effect of any pre-existing resistance regardless of therapy received. To 
interpret individual patient genotypes, we relied on the Stanford HIV Drug Resistance 
Database (HIVdb) algorithm shown in Appendix 2.3 [171], which is also available online 
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at http: //hivdb.stanford.edu/. For bulk sequencing results, each patient’s amino acid 
sequence was uploaded to the Stanford HIVdb, which returned a susceptibility score for 
each of the following RT inhibitors: 3TC, FTC, ABC, AZT, d4T, ddI, TDF, EFV, ETR, 
NVP, and RPV. These scores were discrete values in intervals of 5, ranging from 0-5 
(susceptible), 10 (potential low-level resistance), 15-40 (intermediate resistance), and 45 
and above (high-level resistance). Individual antiretroviral scores were compared to each 
patient’s initial regimen, and patients receiving ≥1 antiretroviral (ARV) with a HIVdb 
score over 10 (≥15) were considered to have received a partially active initial regimen. 
For UDS genotypes, the above procedure was applied to patient Primer ID consensus 
sequences; however, Primer ID amino acid consensus sequences were interpreted 
within the context of homopolymer-associated errors. 
Susceptibility to initial regimen was categorized for each patient as follows: (1) <3 
active ARV vs. ≥3 active ARV versus using resistance detected either bulk sequencing 
or UDS; (2) by relative abundance (minority or dominant vs. ≥3 active ARV) using 
resistance detected using UDS; and (3) by absolute copy number of resistant 
sequences, calculated using the proportion of resistant consensus sequences and 
sample viral load. For patients with multiple RT inhibitor resistance mutations, the 
highest relative abundance among these was used to calculate the number of resistant 
copies. Finally, resistance was categorized by sequencing detection method (<3 active 
ARV by UDS only, by <3 active ARV bulk sequencing and UDS vs. ≥3 active ARV). This 
last variable was constructed to provide some insight into the added value of UDS 
compared to the standard method of resistance measurement. Each variable was 




Homopolymeric Regions: Again, deep sequencing resistance genotypes were 
expected to be susceptible to homopolymer-associated errors, given that deep 
sequencing was performed using 454 FLX platform. To account for homopolymer-
associated errors, homopolymeric sequencing regions were defined as sequences made 
up of 3 or more identical nucleotides in a row plus the two flanking nucleotides, which is 
more conservative than the definition given for Aim 1. Applying this definition to the 2004 
HIV-1 Subtype B consensus sequence, 140 (44%) of 317 and 94 (35%) of 265 
nucleotide positions were within homopolymeric influence within the upstream and 
downstream sequences. From the HIVdb drug resistance mutations listed in Appendix 
2.3, amino acid positions at HIV-1 RT codons 40, 41, 44, 65, 66, 67, 69, 70 71, 74, 77, 
98, 100, 101, 103, 115, 116, 118, 151, 188, 215, 219, and 227 were considered 
susceptible to homopolymeric error. Mutations on these homopolymer-susceptible 
codons had to occur on at least 2 Primer ID consensus sequences within a patient 
sample to be considered genuine. In a sensitivity analysis, this more conservative 
requirement was extended to all resistance positions. 
Outcome Variable: Patients were followed from the date of HAART initiation 
(origin) until the earliest HIV-1 RNA measurement at or before the first of the following: 
(1) switch to a regimen containing a non-RT inhibitor ARV; (2) discontinuation of HAART 
for 2 weeks or more (4 weeks in a sensitivity analysis); (3) the end of the follow-up 
period, August 17, 2012; or (4) virologic failure (VF), where VF was defined as failure to 
achieve at least 0.5 log10 HIV-1 RNA copies/mL decrease from baseline within the first 6 
months of HAART, or at 6 months or later, an HIV-1 RNA level of 400 copies/mL. The 
threshold of 400 copies/mL was chosen since this value was the highest limit of 
detection within the database. 
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Confounders: Confounders of the association between pre-therapy resistance 
and time-to-first virologic failure were first identified using a directed acyclic graph 
(DAG), shown in Figure 3.4. The exposure of interest is pre-therapy resistance to one or 
more antiretrovirals within the initial HAART regimen, represented by X(0) in the DAG. 
X(0) was technically measured using the sample most proximal but before HAART 
initiation, however, since the origin of time is HAART initiation and not the time of 
exposure measurement, the effect of X(0) was allowed to vary with S(t) to account for 
this lag. The outcome, λT(t), is the hazard of virologic failure, while T is the random 
variable representing individuals’ failure/censoring times. All repeated measures, Ln(t), 
and unmeasured time-varying adherence and treatment indication, U(t), where t indexes 
the timing of each measurement, lie on the causal path from X(0) to λT(t). Therefore, 
effect-measure estimates were not conditioned on these variables. However, variables 
included in sets Z (race/ethnicity, gender, and HIV risk group, and age at HAART 
initiation), and the time from resistance measurement until HAART initiation, S(t), lie on 
non-causal, unblocked backdoor paths from X(0) to λT(t), and are therefore should be 
adjusted for in the analysis. Adequate control may be achieved by only adjusting for 
variables in set Z, since the only pathway between S(t) and the outcome would be 




Figure 3.4. Directed acyclic graph of the causal association between pre-therapy 
resistance and time-to-virologic failure. Confounding through indication includes 
treatment decisions made by care providers. 
Confounder variables were included in the model as follows:  
(1) Age (Z): age at therapy initition was modeled using restricted cubic 
splines with knots at the quartiles of the entire population distribution, 
allowing the effect of age to vary in a non-linear fashion. 
(2) Gender (Z): female versus male.  
(3) Race (Z): white versus non-white race. 
(4) MSM (Z): MSM versus non-MSM. IDU was not included since only 15 
patients fit into this category and none were exposed. 
(5) Lag Time [S(t)]: Days between the draw date of the sample used for 
UDS and therapy initiation was modeled as a simple continuous variable.  
For each confounding variable and for each resistance exposure variable, a 
cumulative incidence curve was created to examine the relationship between the 
confounder and cumulative incidence of virologic failure [356]. Curves were compared 
between categories of confounding variables using the log-rank test. For age and time 
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between UDS sample draw and HAART initiation, categories defined using quartile cut-
points were used to examine cumulative incidence curves. 
Proportional Hazards Assumption: Proportional hazards models, unadjusted 
and adjusted and stratified by months from UDS sample draw to therapy initiation, were 
fit for each resistance variable. Hazard ratios (HR) and 95% confidence intervals (CI) 
compared the hazard rate of VF among patients with resistance to their initial regimen, 
measured at the time of therapy initiation, to those initiating with all active antiretrovirals. 
The proportional hazards assumption was evaluated by inspection of log[-log(survival)] 
curves for confounder variables and for each exposure variable. If graphs of the survival 
function versus the log of survival time revealed non-parallel lines for a variable, an 
interaction with time since HAART initiation was included in the model. Using this 
criterion, the effects of MSM and race were allowed to vary over time since HAART 
initiation. 
Non-Informative Censoring: For sensitivity analyses to quantify the influence of 
potentially informative censoring, the regression analysis was repeated under two 
extreme operating assumptions [357]: (1) Censored observations were assumed to 
experience VF immediately after censoring. (2) Individuals who were censored had 
event times greater than any individuals with observed event times. For the first analysis, 
all patients were assumed to have experienced VF on the day after they were censored. 
For the second assumption, the event time for censored observations was changed to 
the maximum event time plus one day, August 18, 2012. Analyses, both adjusted and 
unadjusted, were repeated for each assumption and effect-measure estimates were 
compared between sets of three models to examine the influence of these assumptions 
on effect estimates. 
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Statistical Power: Assuming 10% of the 184 patients received less than fully 
active HAART, 25% of the patients without any resistance experience virologic failure 
within one-year, and 30% of patients are censored during follow-up, this study would 
have 80% power to detect an HR of 2.1 (α=0.05, two-sided log-rank test). HR estimates 
are from models containing the only the main exposure, or for models where there is no 
correlation between additional confounding variables and the main exposure. Power 
curves were generated assuming a range of individuals experience the event (Figure 
3.5). Here, statistical power declines as the proportion who experience the event 
declines as well as with the HR for the main effect.  
 
Figure 3.5. Statistical power to detect various hazard ratios, assuming 30% non-
informative censoring, virologic failure occurs among 25% of unexposed individuals 
within one year of HAART, and 10%, 20% or 30% of the study population has evidence of 
pre-existing drug resistance, two-sided test, α=0.05. Power curves are estimated for 




3.7     LIMITATIONS 
The limitations of the proposed study affect each of the aims, and may be divided 
broadly by their relationship to validity and precision. Validity-related limitations include 
restricted generalizability, information bias, unmeasured confounding, and selection 
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bias. Precision-related limitations are associated with the fixed sample sizes, both in 
terms of the sampled patient population and the sampling depth achieved for minority 
viral variants. These limitations are outlined below:  
Generalizability: The results of our analysis may not be generalized to 
populations outside the Southeastern US, especially to areas where resistance testing is 
not routinely offered to all therapy-naïve individuals as they enter care. However, the 
results could be extrapolated with caution to other populations where the HIV epidemic 
includes more rural residents, among minority populations and driven by sexual 
transmission, and where the majority of individuals are diagnosed with HIV later in the 
course of infection. In addition, this analysis is restricted to RT inhibitor resistance, which 
limits generalizability to these two classes of antiretrovirals only. Since these 
antiretrovirals continue to make up the majority of first line regimens worldwide, this 
limitation is not particularly restrictive at this time. 
Information bias: Information bias was primarily related to exposure 
measurement by UDS in terms of accounting for additional sources of sequence error 
and achieving adequate sampling of the viral population. On one level, 454 deep 
pyrosequencing is superior to standard bulk sequencing given increased sensitivity for 
minority variants, quantification of variants in the viral population, and the possibility of 
linkage analysis; however, resistance data must be interpreted carefully to properly 
account for any additional errors introduced by this platform that may increase false 
positives (i.e., reduce specificity) and that may increase false negatives (i.e., reduce 
sensitivity). To limit the impact of this first limitation, the Primer ID method was used to 
more accurately estimate the viral population, rather than the population that best 
amplified, and resistance among the clinical population was interpreted within the 
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context of error rates from control experiments by imposing stricter definitions to account 
for errors associated with homopolymeric sequence regions. 
With respect to sampling depth, Primer ID enumerates the viral population within 
the infected patient, but the ability to detect minority variants is sharply limited by the 
number of viral templates sampled. To address this problem, several laboratory 
procedures were adjusted to maximize the number of templates sampled per patient. 
For example, virus was concentrated prior to RNA extraction if sample viral load was 
<4.5 log10 HIV-1 RNA copies/mL. However, preliminary experiments reveal that the 
number of viral genomes that are actually sampled is a small fraction of the total number 
that are available, assuming accurate viral load measurement.   
Unmeasured Confounding: There are at least two sources of unmeasured 
confounding in this study that may not be adequately controlled with measured 
confounders in our analysis for Aim 2: (1) adherence to HAART; (2) confounding by 
indication, whereby treatments are selected based on provider-patient decisions 
(disease severity, physician experience, underlying health of patient, etc.). On the DAG 
in Figure 3.4, the path from these unmeasured confounders adherence and indication 
are blocked by adjustment for measured confounders in the set Z, including age at 
HAART initiation, gender, race/ethnicity, and HIV risk factors. While we have no 
surrogate information about unmeasured adherence, we are able to examine the effect 
of one specific type of confounding by indication. Some patients in this dataset may have 
been offered alternative HAART regimens based on pre-therapy bulk sequencing 
(N=37). None of the 37 patients had reduced susceptibility to any of their prescribed 
regimens as predicted using bulk sequence analysis, but a few did have predominant 
resistance mutations that were detected by standard sequence analysis. This 
phenomenon itself may introduce bias if patients with drug resistance at baseline also 
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tended to have minority drug resistant variants that would not be detected by standard 
bulk sequence analysis. 
Selection Bias: Selection bias may be an important source of error for analyses 
involving clinical samples, since almost half of samples from eligible patients were not 
available for resistance testing. Patients with available samples tended to have a longer 
amount of follow-up time from entry to care and HAART initiation, and they had more 
samples drawn prior to HAART. This may lead to selection bias due to 
underrepresentation of fast progressors, which would artificially lengthen virologic failure 
times. In addition, the lack of fast progressors could inflate the estimate the prevalence 
of pre-therapy resistance, since individuals with infected with resistant virus may 
experience some initial benefit in terms of higher CD4 cell count [304], which could bias 
the hazard ratio estimates upward. However, if fast progressors were more likely to carry 
resistant virus, particularly multi-drug resistant virus, the effect-measure estimates for 
Aim 2 could be biased downward.  
Statistical Precision and Power: The precision of our measures of disease 
frequency and effect-measure estimates are limited by the fixed sample size for each 
study population, in terms of the population of patients. To address the problem with 
patient sample size, only retrospectively obtained samples were tested for UDS, and 
many of these were not available. A concerted effort was made to obtain the maximum 
number of clinical samples; however, the size of this population is relatively large 




CHAPTER 4     PRIMER ID CORRECTS NEXT-GENERATION SEQUENCING 
PLATFORMS AND STILL REVEALS PRE-EXISTING DRUG RESISTANCE 
MUTATIONS IN THE HIV-1 REVERSE TRANSCRIPTASE CODING DOMAIN 
 
4.1     INTRODUCTION 
Combination antiretroviral therapy continues to improve patient outcomes as better 
treatment options are developed [1, 358, 359]. Advances may be offset among participants 
failing multiple regimens by development of resistance and cross-resistance [116, 144], 
which also may be transmitted to susceptible partners [360, 361]. Since transmitted drug 
resistance may compromise patient response to first-line combination therapy [303, 362, 
363], genotypic resistance testing is routinely recommended before therapy initiation [6]. 
The utility of pre-therapy testing may be limited by minority HIV-1 variants, present in <20% 
of the viral population, that are not reliably detected by standard sequencing [146], and that 
may jeopardize virologic response [346, 364-367].  
The prevalence of minority pre-therapy drug resistance varies, with estimates based 
on highly-sensitive research assays often double those reported using standard sequence 
analysis [336, 346, 365-368]. Some variation may be related to methods for measuring low 
abundance resistance. For example, allele-specific PCR detects mutations that make up 
≥0.01% of the viral population [366]; however, prevalence estimates are based on a few, 
pre-determined mutations, and estimates of resistance in an individual may be biased by 
differential amplification. Alternatively, single genome sequencing allows interrogation of 
entire viral genomes diluted to a single viral sequence, bypassing some amplification errors, 
but this labor-intensive method generally achieves low sensitivity due to limited sampling 
depth [146]. In contrast, ultra deep sequencing involves massively-parallel sequencing of 
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amplified viral sequences, producing upwards of 106 sequences and reaching apparent 
sampling depths of 1% or less [22]; however this method frequently generates errors during 
amplification and sequencing, making it difficult to distinguish true minority variants from 
sequencing errors [24]. In addition, resequencing of a smaller number of viral genomes after 
PCR amplification (PCR resampling) gives over-estimates of the true sampling depth. 
To address errors associated with deep sequencing, others have established 
threshold cut-offs based on estimated error rates from known sequences [23]. Cut-offs do 
not account for errors that may be introduced during the PCR step, such as biased 
amplification and nucleotide misincorporation [19, 20], nor do they address PCR resampling. 
Here, an alternative strategy engineered into the cDNA synthesis step (Primer ID) was used  
to circumvent the need for statistically-defined cut-offs [26] allowing: (1) definition of a 
background error rate for two deep sequencing platforms; (2) estimation of the prevalence of 
pre-existing reverse transcriptase inhibitor (RTI) resistance among chronically-infected 
patients; and (3) comparison of prevalence estimates from standard methods to those 
obtained by deep sequencing. 
4.2     METHODS 
 
4.2.1     STUDY POPULATION 
Study participants were previously enrolled in the University of North Carolina Center 
for AIDS Research HIV Clinical Cohort Study (UCHCC)  [339]. UCHCC is an ongoing, 
clinical cohort enrolling HIV-infected adults receiving care at UNC. UCHCC maintains an 
electronic database of patient information and houses a repository of plasma samples 
obtained during routine care. Patients were eligible for this study if they: (1) provided 
informed consent for inclusion in the UCHCC; (2) initiated therapy after December 31, 1999; 
(3) with two or more nucleoside/tide reverse transcriptase inhibitors (NRTI) plus one non-
nucleoside reverse transcriptase inhibitor (NNRTI), or three or more NRTI; (4) had at least 
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one reported pre-therapy HIV-1 RNA level; and (5) had an archived pre-therapy plasma 
sample available for resistance testing. This study was reviewed and approved by the 
University of North Carolina Institutional Review Board. 
4.2.2     HIV-1 SEQUENCING  
For most participants (141/184), bulk sequencing analyses were obtained using 
commercial HIV-1 GenoSure (Plus) assays (LabCorp, Research Triangle Park, NC). If no 
bulk sequence analysis was available (43/184), we attempted in-house sequencing of HIV-1 
reverse transcriptase (RT) codons 34-245 using the ABI Prism BigDye Version 1.1 Terminal 
Cycle Sequencing (Life Technologies, Carlsbad, CA). To check for evidence of cross-
contamination, sequences were aligned by ClustalW version 2 [347] and inspected by 
constructing Neighbor-Joining phylogenetic trees evaluated with 1,000 bootstrap replicates 
[348]. 
Sample amplicon libraries were generated using previously described methods [26]. 
Samples with <4.5 log10 HIV-1 RNA copies/mL were centrifuged to concentrate the virus 
particles prior to RNA extraction (QIAamp viral RNA extraction kit, QIAGEN, Hilden, 
Germany). One-third of the RNA was used in separate cDNA synthesis reactions targeting 
two regions of HIV-1 RT, HXB2 nucleotides 2648-2964 and 2965-3257 (RT codons 34-139 
and 139-245) [346], using the primers listed in Appendix 3.1. The cDNA primers included a 
barcode to allow pooling of samples during the deep sequencing step, and a randomized 
sequence tag of 8 nucleotides (Primer ID) to allow identification of each individual template 
in the subsequent sequence analysis (Figure 4.1A). Purified cDNA [26] was used for semi-
nested PCR (Figure 4.1B) using Phusion Hot Start II High Fidelity DNA polymerase (Thermo 
Fisher Scientific, Waltham, MA); annealing temperatures were 67°C and 63°C for RT 
fragments 1 and 2, respectively (Appendix 3.1). Input cDNA was estimated based on the 




Figure 4.1. Primer ID to estimate the HIV-1 population. (A) During cDNA synthesis, a 
unique Primer ID sequence is incorporated into each viral genome along with a 
sample-specific barcode. (B) During PCR, differential amplification may occur so that 
the probability of amplification is not equally distributed across viral genomes. (C) 
Primer ID is applied to correct errors that accumulated over a deep sequencing run. 
Within each sample, a single majority-rules consensus sequence is generated from 3 
or more sequences with the same Primer ID (red, green, yellow). Collectively, 
consensus sequences reflect the number of viral genomes rather than what best 
amplified. Method (2) is more conservative than (1) since single occurrences of 
resistance mutations on Primer ID consensus sequences are also excluded as error. 
Amplified DNA was pooled in equimolar concentration, cleaved with PvuII to 
remove part of the PCR primer, and gel purified (QIAquick gel purification kit, 
QIAGEN). Pools were submitted for sequencing on the 454 GS FLX sequencing 
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platform with XLR80 Titanium reagents (Roche, Indianapolis, IN). To compare 454 
and MiSeq nucleotide calls, 19 amplicons were also sequenced using the 150 bp 
paired-end sequencing protocol (HIV-1 RT codons 34-74 and 111-139, HXB2 
nucleotides 2648-2770 and 2878-2964) on the Illumina MiSeq sequencing platform 
(San Diego, CA).    
4.2.3     PLASMID CONTROLS 
The entirety of HIV-1 RT (HXB2 nucleotides 2550-3515), derived from a 
clinical sample, was cloned into vector pcDNA3.1 (Life Technologies). Plasmids were 
linearized with BamHI, purified using the Minelute PCR purification kit (QIAGEN), 
quantified by UV spectrophotometry using a Nanodrop 1000 (Thermo Fisher 
Scientific), and serially diluted to 3,000, 10,000, 30,000, and 300,000 copies. 
Plasmid DNA dilutions were denatured at 95°C for 5 minutes, cooled, and tagged 
with distinct cDNA primers during a single round of DNA synthesis with Platinum Taq 
(Life Technologies). Excess cDNA primers were removed [26], samples were 
amplified by nested PCR using a protocol identical to samples with primers listed in 
Appendix 3.1, pooled in equimolar concentration, and gel purified (QIAGEN). Pools 
were sequenced over HIV-1 RT codons 34-139 using the Roche 454 Junior (HXB2 
nucleotides 2648-2964) and Illumina MiSeq sequencing platforms (HXB2 nucleotides 
2648-2868 and 2782-2964). 
4.2.4     SEQUENCE ANALYSIS 
Deep sequencing data was processed using a custom pipeline of computer 
programs [26]. Briefly, sequence length distributions were inspected, short reads 
were discarded, and the remaining sequences were compared to HXB2 pol for 
orientation and location. Sequences with an invalid Primer ID or barcode were 
discarded, and filtered sequences were partitioned first by barcode (sample) and 
then Primer ID (viral template). Sequences with a Primer ID that occurred less than 
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three times within a sample were discarded (fewer than five times for MiSeq), and 
consensus sequences were generated from sequences with the same Primer ID. A 
larger number of identical Primer ID reads was used to build the consensus 
sequence for data from the MiSeq platform because of the larger number of reads 
available and with the goal of obtaining a more reliable consensus sequence. There 
was no evidence that fortuitous consensus sequences were created as the result of 
sequencing errors in the Primer ID. 
Drug resistance was defined using an updated list of surveillance drug 
resistance mutations to exclude polymorphisms that may not contribute to resistance 
phenotype (Appendix 2.2) [189]. Deep sequencing detected surveillance drug 
resistance mutations were quantified using two conditions (Figure 4.1C): (1) 
barcode- and Primer ID-defined consensus sequences; and (2) barcode- and Primer 
ID-defined consensus sequences, but only including resistance mutations that 
occurred more than one time within a sample (i.e. associated with two or more 
different Primer ID consensus sequences). Relative abundance of individual 
resistance mutations per sample was calculated by dividing the number of 
sequences with resistance by the total number of consensus sequences obtained for 
the sample.  
Deep sequencing detected resistance mutations were considered in the 
context of homopolymeric regions, which are error hotspots for 454 sequencing 
platforms [24, 369]. We defined homopolymeric regions as four or more consecutive, 
identical nucleotides plus the two flanking nucleotides. We used the 2004 HIV-1 
subtype B consensus sequence to define homopolymer-associated positions for 
clinical subject samples (available from the Los Alamos HIV Database at http: 
//www.hiv.lanl.gov), and we defined homopolymeric regions directly for the subtype C 
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plasmid control. In the subtype C control sequence, 75 homopolymer-associated 
positions were identified within the sequence spanning HXB2 2648-2964. In the 
2004 subtype B consensus sequence, 61 and 45 homopolymer-associated positions 
were identified within the analogous upstream sequence and the downstream 
sequence spanning HXB2 2993-3257. Since mutations on HIV-1 RT codons 65, 67, 
74, 100, 101, 103, 115, 116, and 219 were within homopolymeric influence, they 
were excluded from prevalence estimates. 
4.2.5     STATISTICAL ANALYSIS 
Standard errors and 95% confidence intervals (CI) for plasmid control error 
rates (errors per 10,000 nucleotides) were calculated across all samples using 
clustered sandwich estimators [351] and the Poisson distribution. Standard errors 
and 95% CI for proportions were estimated using the binomial distribution. 
Sequencing depth, or the number of sequences required to observe x% viral variant 
with 95% confidence, was estimated using a power analysis (Figure 3.2). 
Distributions of categorical variables were compared using Pearson’s χ2 test, median 
values of continuously distributed variables were compared using the Kruskal-Wallis 
test. Statistical analyses were conducted in SAS version 9.3 (SAS Institute, Cary, 
NC). 
4.3     RESULTS 
 
4.3.1     QUANTIFYING DEEP SEQUENCING ERROR 
The goal of this study was to examine low level resistance to RT inhibitors 
encoded within the RT coding domain. Control amplicons were designed to include 
several important resistance positions: RT codons 34-139 or HXB2 nucleotides 
2648-2964. First, we established a residual error rate for both the 454 and MiSeq 
platforms using plasmid controls to evaluate our ability to interpret rare variants using 
either the raw sequences or sequences corrected by Primer ID, which was used as 
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the primer in the first round of DNA synthesis. We used Taq DNA polymerase rather 
than RT in the first round of synthesis because of low template utilization by RT 
when starting with a DNA template; also, we used a DNA template rather than an 
RNA template to avoid misincorporation during the synthesis of RNA in vitro. A total 
of 112,108 reads of the 317 nucleotide amplicon obtained using the 454 platform 
were collapsed into 2,893 Primer ID consensus sequences. The overall error rate 
using raw sequences was 71/10,000 nucleotides (95% CI: 70-72), which was 
reduced to 2.6/10,000 nucleotides (95% CI: 2.2-3.2) using the Primer ID/consensus 
sequence approach (Appendix 4.1). Over 75 homopolymeric positions, 6.0 (95%CI: 
4.8-7.4) miscalls were observed every 10,000 nucleotides using Primer ID; excluding 
homopolymeric regions reduced error to 1.6/10,000 (95% CI: 1.3-2.0) nucleotides. 
Errors were substitutions (76%), deletions (22%), or insertions (1.7%). Error 
frequency is compared for each position queried in Figure 4.2A. 
We were especially interested in the potential impact of homopolymeric error 
in the region of the K65 codon, the position of an important resistance mutation for 
tenofovir. In most subtype B isolates the lysine codon at this position is AAA and part 
of a longer homopolymeric region. However, some subtype B and most subtype C 
isolates have the AAG codon embedded in this longer homopolymer, and 
misplacement of the G can create the appearance of the AGA codon at this position 
which would be interpreted as a resistance mutation (arginine). In the control 
plasmid, which had a K65 AAG codon, only 59% of raw sequences had the correct 
sequence and 38% of the sequences were “ATA AAA A-G AAA GAC.” This was 
caused by the under-call of an A in the homopolymeric region in front of the AAG 
codon, thus shifting the G one position to the left and creating an AGA codon. Since 
it is not possible to know which A of the homopolymeric tract was undercounted one 
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cannot interpret the presence of the AGA codon. A more difficult situation would be 
when there is an under-call in the upstream portion of the homopolymeric tract and 
an over-call in the downstream portion, which would shift the G and leave the 
reading frame intact, thus obscuring the effect of the homopolymeric errors and 
creating an erroneous call for a resistance mutation. This was a very rare event that 
occurred in 12/112,108 raw reads. 
Alternatively, deep sequencing with the MiSeq platform is not susceptible to 
homopolymeric miscalls because it does not rely on the linearity of the relationship 
between the number of consecutive identical nucleotides and signal peak. Using the 
MiSeq sequencing platform, 123,822 raw reads were sampled from 678,702 total 
paired-end reads of the 317 nucleotide control amplicon that passed Illumina quality 
filters. From these, 2,710 Primer ID consensus sequences were generated. Using 
the MiSeq platform to sequence the same set of controls yielded an error rate of 
1.2/10,000 bases (95% CI: 0.59-2.4) compared to 24/10,000 bases (95% CI: 18-32) 
using raw sequence data (Appendix 4.1). All errors were substitutions, and no 
difference was observed within homopolymeric regions (1.1 errors/10,000 
nucleotides, 95% CI: 0.51-2.5). However, higher error rates were observed in the 
downstream than in the upstream paired-end sequence (rate ratio: 2.9, 95% CI: 1.7-
5.0). Within the downstream sequence, errors increased over the run 2.6 times per 
100 nucleotides sequenced (95% CI: 1.3-5.0). Positional errors associated with the 





Figure 4.2. Percent incorrect nucleotide calls for each queried position of control sequence. 
(A) and (B) Positional errors for sequences read by the 454 Junior deep sequencing platform, 
with (B) enlarged to visualize very low error frequency of Primer ID corrected sequencing. 
Homopolymeric tracts are highlighted by dark gray bars. (C) Positional errors for sequences 
read using the Illumina MiSeq deep sequencing platform. The read length of each paired end 
is highlighted by dark gray bars. Error frequency was calculated for each platform across all 
dilutions submitted for deep sequencing. 
 
4.3.2     PREVALENCE OF PRE-THERAPY DRUG RESISTANCE 
Of 331 otherwise eligible participants in the UCHCC, 184 (56%) had an 
archived pre-therapy sample. Most were chronically infected, with median 254 (inter-
quartile range (IQR): 95-398) CD4+ T cells/µL and 4.8 (IQR: 4.2-5.3) log10 HIV-1 
RNA copies/mL prior to therapy (Table 4.1). The sequence analysis for these 184 
participants was based on the identification of resistance mutations to any reverse 
transcriptase inhibitor (RTI), or specifically to a nucleoside/tide RT inhibitor (NRTI) or 
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a non-nucleoside RT inhibitor (NNRTI), with the resistance mutations defined by the 
2009 list of surveillance drug resistance mutations [189]. We excluded homopolymer-
associated positions from these prevalence estimates to allow for later comparison to 
the 454 platform. Based on sequencing of a bulk PCR product, 2.7% of participants 
(5/184, 95% CI: 0.89-6.2%) had an RTI resistance-associated mutation. NRTI-
associated resistance was most common being present in 2.2% of participants 
(4/184, 95% CI: 0.60-5.5%), while 1.1% of participants (2/184, 95% CI: 0.13-3.4%) 
had an NNRTI resistance-associated mutation. The RTI resistance mutations 





Table 4.1. Baseline characteristics of clinical participants. 
 All eligible Sample available 
Characteristic N=331 N=184 
Gender, n (%)     
 Female 77 (23%) 42 (23%) 
 Male 254 (77%) 142 (77%) 
Race, n (%)     
 Black 181 (55%) 98 (53%) 
 White 92 (28%) 51 (28%) 
 Other 58 (17%) 35 (19%) 
Age, median (IQR)
*
 38 (31-46) 38 (31-47) 
HIV risk group     
 MSM, n (%) 144 (44%) 80 (43%) 
 IDU, n (%) 29 (8.8%) 15 (8.1%) 
 Heterosexual, n (%) 196 (59%) 110 (60%) 
Year of 1
st
 therapy, n (%)     
 1999-2001 104 (31) 38 (21%) 
 2002-2004 99 (30%) 64 (35%) 
 2005-2007 83 (25%) 54 (29%) 
 >2007 45 (14%) 28 (15%) 
1
st
 regimen, n (%)     
 NRTI only 45 (14%) 22 (12%) 
 NVP 22 (6.7%) 9 (4.9%) 
 EFV 264 (80%) 153 (83%) 
HIV-1 RNA log10 copies/mL, median 
(IQR) 4.8 (4.3-5.4) 4.8 (4.2-5.3) 
CD4+T cells/µL, median (IQR) 205 (54-357) 254 (95-398) 
IQR=interquartile range; MSM=men who have sex with men; IDU=injection drug use; 
NRTI=nucleoside reverse transcriptase inhibitor; NVP=nevirapine; EFV=efavirenz. *Age 
is calculated using the date of antiretroviral therapy initiation. 
 Across 184 participants, >106 raw sequences were generated using the 454 
sequencing platform, 73% (746,809) of which were >300 nucleotides long. If we 
relied on raw sequence data, nearly all participants had evidence of an RT inhibitor 
resistance mutation (148/184, 80%), but 75% of these mutations occurred among 
<1% of sequences within a population (Table 4.2). Excluding these very low 
abundance mutations in the analysis of the raw reads, 21% of participants (38/184, 
95% CI: 15-27%) had any RT inhibitor resistance mutations, including 18% (34/184, 
95% CI: 13-25%) and 7.1% (13/184, 95% CI: 3.8-12%) with an NRTI or NNRTI 
resistance mutation. However, these estimates overlook the effects of allelic bias 
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during PCR amplification, PCR resampling, and potential hotspots for error 
incorporation. 
Table 4.2. Resistance mutations within clinical participant samples estimated 
using raw or Primer ID sequences. 
 454 FLX sequences
*
 














    
 NRTI     
  M41L 62 (85%) 7 (0%) 
  T69D 16 (81%) 3 (0%) 
  K70R 14 (100%) 1 (100%) 
  V75A 17 (94%) 0 (0%) 
  F77L 50 (90%) 6 (33%) 
  M184I 20 (100%) 1 (100%) 
  L210W 25 (92%) 3 (0%) 
  T215Y 12 (92%) 1 (0%) 
  T215F 5 (80%) 0 (0%) 
  T215I 40 (100%) 1 (100%) 
  T215S 0 (0%) 2 (50%) 
  T215D 7 (100%) 1 (0%) 
 NNRTI     
  V106A 10 (90%) 0 (0%) 
  Y181C 18 (89%) 1 (0%) 
  Y188C 12 (100%) 1 (100%) 
  G190A 27 (96%) 5 (40%) 
  G190S 14 (86%) 1 (0%) 
  G190E 23 (91%) 2 (50%) 
Homopolymer-associated
†
    
 NRTI     
  K65R 62 (98%) 0 (0%) 
  D67N 150 (44%) 20 (0%) 
  D67G 49 (100%) 1 (100%) 
  D67E 55 (100%) 1 (0%) 
  L74V 38 (87%) 4 (25%) 
  L74I 55 (98%) 3 (67%) 
  K219Q 109 (85%) 9 (11%) 
  K219E 18 (100%) 1 (100%) 
  K219N 18 (100%) 1 (100%) 
  K219R 24 (96%) 0 (0%) 
 NNRTI     
  L100I 43 (95%) 0 (0%) 
  K101E 63 (76%) 7 (57%) 
  K103N 100 (91%) 2 (0%) 
  K103S 15 (100%) 1 (0%) 
NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-NRTI. *Primer ID 
used to generate consensus sequences from ≥3 raw sequences sharing a 
Primer ID. †Positions near homopolymeric runs, ≥4 consecutive identical 
nucleotides plus 2 flanking nucleotides. ‡Minority variants detected among 




We next used the Primer IDs to form consensus sequences from the reads 
that represented PCR resampling. From a median 1,475 (IQR: 598-2,471) raw 
sequences per subject, a median 41 (IQR: 18-76) consensus sequences were 
constructed per subject corresponding to an average sequencing depth for reliable 
detection of about 7% (IQR: 4-17%). The large reduction in useable reads from the 
raw reads to the consensus sequences is a function of removing PCR resampling 
with Primer ID tagging to reveal the actual number of templates sampled. We 
observed that only 5-15% of the RNA templates added to the cDNA reactions 
resulted in consensus sequences, indicating either inefficient cDNA priming and/or 
extension, or inefficient inclusion of cDNA products into the PCR. 
In our first analysis using Primer ID, a resistance mutation was considered if it 
appeared in any consensus sequence created using Primer ID, even if it appeared in 
a single consensus sequence (Figure 4.1C, method 1). A total of 14% (26/184, 95% 
CI: 9.4-20%) of participants had RTI resistance-associated mutations among Primer 
ID consensus sequences using the 454 platform, including 11% (20/184, 95% CI: 
6.8-16%) of participants with NRTI resistance, and 4.9% (9/184, 95% CI: 2.3-9.1%) 
of participants with NNRTI resistance. All of the RTI resistance mutations observed 
by bulk sequencing were also observed in the Primer ID consensus sequences 
(Figure 4.3B). Conversely, using Primer ID consensus sequences rather than raw 
sequences resulted in a 33% reduction in the number of participants where a 
resistance mutation was observed (21% versus 14%), even after using a 






Figure 4.3. Participants with pre-existing RT inhibitor resistance mutations. (A) RT inhibitor 
resistance genotype for 5 participants with mutations detected using standard sequence 
analysis. (B)  RT inhibitor resistance genotype for 26 participants with resistance detected 
using the 454 FLX deep sequencing platform, corrected using Primer ID. Mutations associated 
with a single Primer ID consensus sequence within a subject sample are shown in 
parentheses. RT codons and mutations associated with NNRTI resistance are highlighted in 
bold italic type, while RT codons and mutations associated with NRTI resistance are shown in 
standard type. Only RT codons outside of homopolymeric influence were included in this 
analysis. Lack of resistance for a particular RT codon is indicated by a dash. 
The frequency of single mutations of any type in the data set of Primer ID 
consensus sequences was four as high as expected given the error rate determined 
using the plasmid sequences. Thus, in most cases the call of a resistance mutation 
based on a single observation was likely accurate. However, in a second, more 
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conservative analysis, only those resistance mutations that appeared in at least two 
consensus sequences were counted (Figure 4.1C, method 2). When only multiple 
(i.e. 2 or more) within-subject observations of a specific resistance mutation were 
included, the prevalence of RTI resistance among these 184 participants was 6.0% 
(11/184, 95% CI: 3.0-10%), representing 6 additional participants over the 5 who 
were also identified using bulk sequence analysis (Figure 4.3B). 
The preceding analysis did not include the homopolymeric regions, and we 
carried out a separate analysis to see what influence they would have on calls of 
drug resistance mutations. We found that only 4 (2%) out of 184 participants 
sequenced using 454 had a predominant “AAG” (a wild type lys codon) at RT codon 
65, and 11 (6%) participants had an “AAG” at RT codon 65 as a minority variant with 
abundance ranging from 1% to 24%. No evidence of K65R was found. If other 
homopolymeric positions were included, an additional 24 participants would have 
been classified as RTI resistant using the 454 data with consensus sequences, 
raising the overall prevalence to 27% (50/184). Some resistance calls at 
homopolymeric positions were also seen by bulk sequence analysis (in three 
participants) and were unlikely due to homopolymeric error given their high 
abundance. In contrast, homopolymer-associated resistance mutations detected 
solely by deep sequencing ranged in frequency from 0.35%-12.5% and most 
appeared once within a sample. Assuming these single occurrences were miscalls 
due to homopolymeric error, only six additional participants would be classified as 
having pre-existing RTI resistance (based on the mutation being on more than one 
consensus sequence). Thus, if homopolymer-associated positions were included, 




4.3.3     RELATIVE ABUNDANCE OF RESISTANCE MUTATIONS WITHIN VIRAL POPULATIONS 
The use of Primer ID allows an assessment of the number of viral genomes 
that were actually sampled from a subject, thus allowing an assessment of both 
sequencing depth and the relative abundance of detected mutations from a specific 
clinical sample. There were 6 participants who had resistance mutations that were 
detected in multiple Primer ID consensus sequences but not detected by bulk 
sequencing. The median abundance of these mutations within the viral population in 
each person was 1.8% (IQR: 1.2-2.8%). There were an additional 15 participants 
who had a resistance mutation present in one Primer ID consensus sequence and 
the median abundance of these mutations was 1.7% (IQR: 0.67-1.1%). However, the 
estimate of abundance is significantly limited given the low number of observations 
of each mutation, and the ability to detect variants at even less abundance is limited 
by low template utilization, as revealed using the Primer ID. This phenomenon is 
highlighted in Figure 4.4, where the majority of low abundance resistance was 
detected on a single Primer ID consensus sequence within a subject sample.  
 
Figure 4.4. Prevalence and frequency of pre-existing RT inhibitor resistance among 
participants. The left-hand panel excludes homopolymeric tracts (≥4 consecutive, 
identical nucleotides plus 2 flanking nucleotides). Resistance was defined using the 




Using Primer ID, few participants with RTI resistance had evidence of 
multiple resistance mutations. Of 21 participants with minority drug resistance, only 2 
(10%) had more than one drug resistance mutation, each occurring on separate 
Primer ID consensus sequences at very low frequency. Of 5 participants with a 
majority drug resistant population, only 1 (20%) had multiple resistance mutations. 
This subject had extensive drug resistance that was also revealed by bulk sequence 
analysis: Y181C, G190S, and L210W appeared with T215Y, T215S, or T215D 
among 79% (26/29), 10% (3/29), or 10% (3/29) of consensus sequences, 
respectively, while M41L was linked to homopolymer-associated L74V and K101E in 
94% (29/31) of consensus sequences. Together, this suggests that this subject was 
initially infected with a variant carrying M41L, L74V, K101E, Y181C, G190S, L210W, 
and T215Y mutations, with the virus slowly reverting at codons 74 and 215. 
4.3.4     COMPARISON OF DEEP SEQUENCING PLATFORMS IN A CLINICAL SETTING 
Sequences spanning HIV-1 RT codons 34-74 and 111-139 (HXB2 
nucleotides 2648-2770 and 2878-2964) were determined for 19 of 184 participants 
using the Illumina MiSeq platform. Based on previous analyses of the data from the 
454 FLX sequencing platform, we selected participants who had the most consensus 
sequences constructed from ≥3 raw sequences sharing the same Primer ID (median 
203 [IQR: 168-247] consensus sequences), indicating that these samples had the 
highest level of genomes incorporated into the cDNA/PCR step. Using the MiSeq 
platform, a median 273 (IQR: 192-583) consensus sequences were constructed from 
≥5 raw sequences sharing a Primer ID (median 29,743 (IQR): 24,686-33,086 raw 
sequences). For 17 of the 19 participants, the number of consensus sequences 
generated using the MiSeq platform was comparable to those obtained using the 454 
FLX platform despite a nearly 10-fold increase in raw sequences. For the remaining 
2 participants, the number of consensus sequences increased 6- or 12-fold. While 
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every effort was made to sequence the same amplicons submitted for 454 
sequencing, RNA extraction was repeated for these 2 participants since their cDNA 
and amplicons were previously exhausted. In these 2 cases, high viral titers (6.6-7.9 
log10 HIV-1 RNA copies/mL) and dilution error could explain the discrepancy in 
apparent higher template utilization. 
 A total of 108 amino acid changes were observed in the RT coding 
region using both sequencing platforms, with 74 mutations detected using the 454 
platform and 82 using the MiSeq platform. About half (48/108) were detected by both 
sequencing platforms, 25% (26/108) were detected by the 454 platform alone, and 
33% (34/108) were detected solely by the Illumina MiSeq platform. Nearly 72% 
(43/60) of mutations detected by a single sequencing platform occurred on a single 
Primer ID consensus sequence, suggesting these mutations were either the result of 
method error or of stochastic sampling of rare variants. All 34 variants detected 
solely by the Illumina MiSeq platform were within the downstream paired end 
sequence, which was revealed as an error hotspot by the control experiments 
(Figure 4.2C). Conversely, 38% (10/26) of variants detected by the 454 platform 
alone were associated with homopolymeric regions, but most of the variants outside 
of homopolymeric regions occurred once (10/16, 62%) and could be due to a low 
number of templates. 
4.4     DISCUSSION 
Deep sequencing methods are subject to bias introduced by PCR 
amplification, and those methods that allow consecutive nucleotide additions in a 
homopolymeric run are also vulnerable to erroneous calls in or near these runs [369]. 
Here, an alternative deep sequencing method that tags a single viral template with a 
unique Primer ID prior to PCR [26] was used to estimate the prevalence of pre-
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existing RTI resistance within a clinical population initiating care for HIV-1. Among 
184 participants, up to 14% had evidence of RTI resistance, compared to 2.7% 
detection by sequencing of a bulk PCR product. An even more conservative use of 
the deep sequencing data based on making calls only if the mutation was associated 
with at least two consensus sequences gave an RTI resistance mutation detection 
rate of 6.0%, still more than a 2-fold increase over that seen by sequencing of a bulk 
PCR product, and these estimates did not include an analysis of homopolymeric 
regions that are susceptible to especially high error rates using the 454 sequencing 
platform.   
Prevalence estimates must be critically interpreted since the value can be 
inflated due to several intrinsic errors in the sequencing methodology, not all of which 
can be corrected by Primer ID. The 454 platform control experiments demonstrated 
nearly 4-fold higher error rates within homopolymeric regions compared to 
heteropolymeric regions despite the use of 3 or more raw sequences with the same 
Primer ID to create a consensus sequence. Intractable homopolymeric errors argue 
against using sequencing platforms that are subject to these errors to estimate the 
prevalence of minority variants, especially those associated with homopolymeric 
regions such as variants with K103N and K65R [346, 366, 370]. The Illumina MiSeq 
platform, which does not rely on the incorporation of multiple nucleotides at a 
homopolymeric stretch, eliminated homopolymer-associated errors in control 
experiments. However, this system has its own set of limitations including the 
accumulation of errors over the sequencing run [326], which was consistent with our 
own control experiments, and poor discrimination of highly similar sequences [371]. 
When Illumina was used to sequence samples from a subset of participants and 
compared to the 454 sequencing platform, concordance between the two platforms 
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was only 50% across all queried positions, suggesting either substantial sequencing 
error or stochastic sampling, particularly associated with very low abundance 
variants. There is some evidence of homopolymer-associated sequencing error, 
since nearly 40% of mutations detected only by the 454 platform were near or within 
these sites. It is also likely that many of the mutations detected by the MiSeq 
platform alone were the result of sequencing error, since all of these mutations were 
within the downstream paired-end which is associated with a 3-fold increase in error. 
However, it is not possible to rule out stochastic sampling of the viral population as 
the source of the discrepancy in most cases given the limited template usage 
revealed by the use of Primer ID. 
Our analysis of clinical subject samples was clearly limited by the number of 
templates we sampled, and if sufficient numbers of templates had been available 
(i.e. enough to give 1,000 or more consensus sequences) we could have queried 
down to the 0.1% to 0.5% range, below which residual method error still confounds 
the analysis. While limited template utilization was a problem in our analysis of these 
samples, it was the use of Primer ID that revealed the extent of template utilization 
and allowed us to estimate the quality of sampling. Alternatively, if we had relied on 
the raw reads with an arbitrary cut-off (1%), we would have not only overestimated 
the prevalence of RT inhibitor resistance, but we would have also erroneously 
concluded that our sampling depth was much higher for these samples given the 
number of raw reads that passed quality filters (median >2,000), and our estimates 
of the frequency of resistance mutations in the viral population would have been 
skewed upwards by nearly 20% compared to Primer ID.  
Even after correction with Primer ID, including all resistance mutations in 
estimates, i.e. even those that appear in only one Primer ID consensus sequence, 
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may fail to correct for errors that are introduced during cDNA synthesis, that occur in 
the earliest cycles of PCR amplification, or that are homopolymer-associated. 
Unfortunately, downstream data filtering with Primer ID cannot account for the first 
two of these biases, but control experiments did demonstrate a substantial reduction 
in errors within homopolymeric regions. Sequencing errors within the Primer ID itself 
cannot be ruled out, either, and these errors may be even more likely if the Primer ID 
itself contains a homopolymeric sequence. In the worst-case scenario, a viral 
genome is linked to a homopolymeric Primer ID and subsequently oversampled, 
such as might occur when the number of input templates is low, and thus the number 
of reads of each Primer ID is high. Since the original Primer ID itself contains a 
homopolymeric sequence, it is more likely to be misread repeatedly and in the same 
way by the 454 sequencing platform. In this manner, more than one Primer ID may 
be linked to the same viral genome, and these would be counted as separate viral 
genomes when collapsed into separate consensus sequences. Most such Primer IDs 
are unlikely to be abundant enough to be included in consensus sequence 
assembly. We assessed this type of error by building a tree of the Primer ID 
sequences themselves. We found no evidence of this type of oversampling in this 
dataset, although this type of monitoring is likely to be an important feature of using 
Primer ID. Finally, Primer ID may also fail when there are ties in nucleotide calls at a 
given position (ambiguity) among resampled raw sequences, thus making it 
impossible to infer the “real” viral sequence. This scenario is more likely to occur 
when consensus sequences are constructed from a low number of resampled raw 
sequences. Among 184 subject samples, each Primer ID consensus sequence was 
constructed from a median 12 (IQR: 6-24) resampled raw sequences, and therefore, 
this scenario cannot be excluded. 
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Despite its limitations, Primer ID offers an opportunity to make inferences 
about changes within the viral population when multiple resistance mutations are 
present, assuming that each unique Primer ID represents an individual viral genome. 
Only three participants had evidence of multiple resistance mutations on non-
homopolymer-associated codons, one of whom was identified by bulk sequence 
analysis. Two participants had multiple, low frequency NRTI resistance mutations on 
separate Primer ID consensus sequences, which could indicate past NRTI exposure 
followed by the reappearance of wild type from the participants’ reservoirs. The 
remaining subject had multiple, linked resistance mutations (M41L+L74V+K101E 
and Y181C+G190S+T215Y/D/S) that predominated the Primer ID consensus 
sequences with evidence of reversion at codons 74 and 215. Previous studies have 
shown that K101E+G190S reduce fitness compared to wild type virus in the absence 
of antiretroviral therapy, but that the addition of M41L+T215Y or L74V in particular 
improves fitness without reducing NNRTI resistance [372, 373]. In this subject it 
appears that T215Y is reverting more rapidly than L74V given the higher frequency 
of sequences with T215 revertant mutations compared to L74 (21% vs. 6%), but we 
are limited in our conclusions since these regions of RT were independently 
amplified and sequenced and thus for these different amplicons cannot be linked.  
Many studies, including a recent systematic review [18], have linked minority 
pre-therapy NNRTI resistance with an increased risk of virologic failure. Despite this 
evidence, questions still remain surrounding the clinical importance of minority drug 
resistant variants, particularly with respect to defining a specific abundance threshold 
at which resistance begins to affect response to combination therapy [364]. Before 
any particular cut-off for clinical significance can be determined, the drug resistant 
viral population must first be measured as accurately as possible. The most 
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promising method with potential to move beyond the research setting, ultra deep 
sequencing, still suffers from multiple sources of error that are inherent in this 
method. In this study, these errors and PCR resampling were addressed using the 
Primer ID, which showed a 30-fold reduction in error rates over raw sequence 
analyses and which, despite limited viral template usage in clinical samples, still 
revealed additional participants with pre-therapy resistance. As important, the use of 
Primer ID reveals the number of templates that were actually sampled thus providing 
an accurate assessment of the quality of the sampling depth, an essential piece of 





CHAPTER 5     VIROLOGIC CONSEQUENSES OF PRE-EXISTING LOW 
ABUNDANCE RESISTANCE AMONG PATIENTS INITIATING WITH A 
REVERSE TRANSCRIPTASE INHIBITOR REGIMEN 
 
5.1     INTRODUCTION 
Accurate pre-therapy resistance profiles are critical to initial treatment 
selection [363]; however, standard sequencing fails to reliably sample viral variants 
<20% of the population [336]. This limitation has implications for chronically-infected 
patients with resistant virus that has faded to levels below detection, yet still remains 
clinically relevant [128]. Ultra deep sequencing (UDS) is capable of achieving 
sampling depths <1% of viral populations [23], but is limited by a PCR step that 
biases estimates upward through enzyme-mediated errors, differential amplification, 
and sequence resampling [20]. Some UDS platforms are additionally vulnerable to 
miscalls near homopolymeric nucleotide regions [24]. These artifacts must be 
distinguished from low level HIV resistance that may affect treatment [18].  
In this study, to minimize errors, each viral template was tagged by a random 
8-nucleotide sequence during cDNA synthesis, allowing identification of specific 
transcripts that were subsequently amplified. Amplified sequences sharing the same 
8-nucleotide Primer ID originate from the same genome so that concordant 
nucleotide changes from a consensus sequence are more likely to be actual 
mutations and discordant nucleotide changes are more likely to be errors. Creating 
consensus sequences from ≥3 sequences sharing the same Primer ID allows for 
fewer miscalls and estimation of input templates [26]. In patients receiving highly 
active antiretroviral therapy (HAART), this method was used to estimate the 
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proportion who received less than 3 fully-active antiretrovirals (ARV) and to examine 
the association between suboptimal HAART and virologic failure (VF).   
5.2     METHODS 
Patients enrolled in the University of North Carolina Center for AIDS 
Research HIV Clinical Cohort Study (UCHCC) were included if they: (1) provided 
written, informed consent for enrollment in the cohort study and use of their 
specimens for research purposes; (2) initiated HAART after December 31, 1999; (3) 
with either ≥2 nucleoside(tide) reverse transcriptase inhibitors (NRTI) plus an non-
NRTI or ≥3 NRTI; and (4) had at least one recorded pre-therapy HIV-1 RNA level; 
and (5) had an archived sample available for sequencing. UCHCC is an ongoing 
clinical cohort study enrolling adults seeking HIV care at UNC. UCHCC maintains an 
electronic database of patient information and repository of patient plasma samples 
[339]. This study was approved by the UNC Institutional Review Board. 
HIV-1 RNA was extracted from 140 µL of plasma, and concentrated if HIV-1 
RNA was <4.5 log10 copies/mL. One-third of the RNA was added to two cDNA 
reactions [26] using HIV-1 reverse transcriptase (RT) specific primers: (1) 5’-
GCCTTGCCAGCACGCTCACAGCTGGCA-NNNN-CGNNNNNNNNTC-
ACATTGTACTGATATCTAATYCCTGGTG-3’ complimentary to HXB2 nucleotides 
2965-2992 (fragment 1) [346]; and (2) 5’-GCCTTGCCAGCACGCTCACAGCTGGCA-
NNNN-CGNNNNNNNNTC-CACTATAGGCTGTACTGTCCATTTATC-3’ 
complimentary to HXB2 nucleotides 3258-3284 (fragment 2) [346]. Primers featured 
a patient barcode (NNNN) [22], a random template specific Primer ID 
(CGNNNNNNNNTC) [26], and a PCR primer with a PvuII cut site (Figure 5.1A).  
DNA was amplified using primers: (1) 5’-
GGCCATTGACAGAAGAAAAAATAAAAGC-3’, sense, fragment 1 [346]; (2) 5’-
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CACCAGGRATTAGATATCAGTACAATGT-3’, sense, fragment 2 [346]; (3) 5’-
GCCTTGCCAGCACGCTCACAG-3’, antisense, round 1; and (4) 5’-
CCAGCACGCTCACAGCTGGCA-3’, antisense, round 2. PCR conditions included 
30 cycles with 67°C (fragment 1) or 63°C (fragment 2) annealing temperatures 
(Phusion High Fidelity Hot Start II, Thermo Scientific, Waltham, MA). Amplicons were 
pooled in equimolar concentration and PvuII digested. Pools were gel purified, 
quantified, and submitted for 454 GS FLX sequencing (Roche, Indianapolis, IN). 
UDS sequences <300 nucleotides and those with ambiguous patient specific 
barcodes or Primer ID were discarded. Remaining sequences were partitioned by 
patient barcode. Sequences with template specific Primer ID that occurred <3 times 
were discarded as discrepancies between sequences could not be adjudicated, and 
majority-rules consensus sequences were constructed from remaining sequences 
sharing the same Primer ID. These were input into the Stanford HIV Drug Resistance 
Database (HIVdb) for interpretation [171]. To increase confidence of calls near 
homopolymeric regions, mutations on HIV-1 RT codons 40, 41, 44, 62, 65, 66, 67, 
69, 70, 71, 74, 77, 98, 100, 101, 103, 115, 116, 118, 151, 188, 215, 219, 221, and 
227 were considered genuine if they were associated with more than one Primer ID 
within a patient sample (Figure 1A). In sensitivity analyses, these criteria were 
extended to HIV-1 RT codons outside of homopolymeric regions. The number of 
active antiretroviral (ARV) in the initial regimen was calculated, with HIVdb scores 
≥15 considered resistant.  
Bulk sequences were obtained using HIV GenoSure (LabCorp, Research 
Triangle Park, NC) or by in-house bulk sequencing using 2nd round PCR primers. 
The majority of bulk sequencing was performed retrospectively. All patients with 
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prospective results available (N=37/184, 20%) were prescribed fully-active HAART 
as predicted by HIVdb interpretation of bulk sequences [171]. 
 Patients were followed from therapy initiation until the HIV-1 RNA level 
before the earliest of the following: (1) switch to non-reverse transcriptase inhibitor 
(non-RTI) HAART; (2) discontinuation of HAART for >2 weeks; or (3) August 17, 
2012. Patients experienced VF if they did not achieve 0.5 log10 HIV-1 RNA 
copies/mL decrease from baseline in the first 6 months of therapy, or after 6 months, 
if they had an HIV-1 RNA level >400 copies/mL.  
The combined association of NNRTI or NRTI resistance to all RTI regimens 
received with time-to-VF was examined. Drug resistance mutations were categorized 
as follows: (1) overall (<3 active ARV vs. ≥3 active ARV); (2) by relative abundance 
(minority or dominant vs. ≥3 active ARV); and (3) by absolute copy number of RTI 
resistant sequences, calculated using the proportion of resistant consensus 
sequences and sample viral load. Finally, the receipt of <3 active ARV was 
categorized by sequencing detection method (by UDS only, or by both bulk 
sequencing and UDS vs. ≥3 active ARV).  
Causal diagram analysis was used to identify adjustment variables, which 
consisted of gender, race (white vs. non-white), men who have sex with men (MSM), 
and age at therapy initiation (modeled using restricted cubic splines with knots at the 
quartiles of the population distribution). To account for lag between resistance 
measurement and the beginning of therapy, a continuous variable for months from 
sample draw to therapy initiation was created and included as an interaction term 
with resistance.  
Cumulative incidence curves for time-to-VF were stratified by key variables 
and compared using log-rank tests. Proportional hazards models, unadjusted and 
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adjusted and stratified by months from UDS sample draw to therapy initiation, were 
fit for each resistance variable. Hazard ratios (HR) and 95% confidence intervals (CI) 
compared the hazard (instantaneous rate) of VF among patients with resistance to 
their initial regimen, measured at the time of therapy initiation, to those initiating with 
all active ARV. The proportional hazards assumption was evaluated by inspection of 
log[-log(survival)] curves.  
5.3     RESULTS 
As of January 2010, 768 (37%, N=768/2076) UCHCC patients initiated 
therapy after 2000, 367 started with an RTI regimen, and 331 had ≥1 reported pre-
therapy HIV-1 RNA level. Of these, 184 (56%) patients had available pre-therapy 
samples. Median age at first therapy was 38 years (inter-quartile range (IQR): 31-
47). Patients were mostly male (77%), one-half African American (53%), and 43% 
and 8% of patients were MSM or had a history of injection drug use (IDU). Patients 
had median baseline 254 CD4+ T cells/µL (IQR: 95-398) and 4.8 log10 HIV-1 RNA 
copies/mL (IQR: 4.2-5.3).  
Most patients initially received efavirenz (EFV) (N=153, 83%), 9 received 
nevirapine (5%), and 22 (12%) received exclusively NRTI. Of NNRTI initiating 
patients, 78 (48%) were coadministered emtricitabine and tenofovir, and 58 (36%) 
received lamivudine (3TC) and zidovudine (AZT). Of NRTI initiating patients, 20 
(91%) were given abacavir, 3TC, and AZT. Patients received RTI regimens for a 
median 13 months (IQR: 3.3-39). Nearly 38% (N=70) of patients had not 
experienced VF and remained on RTI regimens at the close of follow-up; 23% 
(N=43) and 14% (N=26) of patients were censored because they discontinued 
therapy for >2 weeks or switched to a non-RTI. 
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UDS and bulk sequencing data were obtained for 182 and 180 patients; 
combined, 181 had both. Overall, 10% (N=19/181, 95% CI: 6-15%) of patients 
received a regimen with fewer than three active RTI, including 3 patients identified by 
both technologies. These 3 patients received regimens containing 3TC, AZT, and 
EFV and had evidence of the following mutations: M41L, L74V, K101E, Y181C, 
G190S, L210W, and T215Y/D/S; K103N/S and G190A; and M41L alone. An 
additional 9% (N=16/181; 95%CI: 5-14%) of patients had resistance detected by 
UDS alone, about half of which was NNRTI-associated (N=9/16). The most common 
mutations detected were G190A/S/E/V (N=6) M41L (N=3), and D67N (N=3). The 
characteristics of patients who received ≥3 active vs. <3 active ARV are compared in 
Table 5.1. 
Table 5.1. Baseline characteristics of patient population by number of active 
drugs. 
 <3 active RTI* ≥3 active RTI* 
 N=19 N=162 
Women, n (%) 3 (16%) 38 (23%) 
Age at 1st regimen, median (IQR) 41 (32-47) 38 (31-47) 
African American, n (%) 10 (53%) 86 (53%) 
MSM, n (%) 9 (47%) 70 (43%) 
IDU, n (%) 1 (5.3%) 14 (8.6%) 
1st regimen, n (%)     
 NRTI only 3 (16%) 19 (12%) 
 EFV based 14 (74%) 137 (85%) 
 NVP based 2 (10%) 6 (3.7%) 
Retrospective genotype, n (%) 17 (89%) 127 (78%) 
Deep sequencing to 1st regimen, n (%)     
 Same day 13 (68%) 99 (61%) 
 1-90 days 6 (32%) 42 (26%) 
 90+ days 9 (0.0%) 21 (13%) 
log10 HIV-1 RNA co/mL, median (IQR) 5.0 4.6-5.6 4.8 (4.1-5.2) 
CD4+ T cells/µL, median (IQR) 150 (33-306) 257 (108-402) 
Months follow-up, median (IQR) 18 (7.3-50) 12 (1.9-38) 
RTI=reverse transcriptase inhibitor; IQR=inter-quartile range; MSM=men who have sex 
with men; IDU=injection drug use; NRTI=nucleoside reverse transcriptase inhibitor; 
EFV=efavirenz; NVP=nevirapine *Mutations on HIV-1 reverse transcriptase codons 40, 
41, 44, 62, 65, 66, 67, 69, 70, 71, 74, 77, 98, 100, 101, 103, 115, 116, 118, 151, 188, 215, 
219, 221, or 227 were considered genuine only if they occurred >1 time within a patient 
sample. The number of active RTI per regimen was predicted using the Stanford HIV 
drug resistance database to interpret mutations detected by bulk PCR sequence 
analysis and/or ultra deep sequencing [171]. 
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Nearly one-fourth of patients (N=45) experienced VF within a median 60 
months (IQR: 17->142). Patients receiving sub-optimal regimens trended toward 
shorter time-to-VF than patients receiving 3 or more active RTI (HR: 1.8, 95% CI: 
0.87-3.7, p=0.1) (Figure 5.1B). Shorter failure times were driven largely by bulk 
sequencing predicted resistance; 2 of 3 patients, both of whom received inactive 
EFV, failed within 7.6 months (Figure 5.1C). Patients taking fewer than 3 active RTI 
predicted by UDS alone experienced VF at rates slightly higher than but not 
statistically different from those without resistance (HR: 1.6, 95% CI: 0.71-3.6, 
p=0.3), but the power to detect a difference was limited by the small number of 





Figure 5.1. Activity of early therapy predicted using Primer ID corrected deep 
sequencing genotype and time-to-virologic failure. Panel A illustrates the Primer ID 
correction method [26]. Individual HIV-1 RNA within a patient sample are tagged during 
cDNA synthesis with a randomized Primer ID sequence, a patient barcode and a PCR 
primer sequence. Sequences linked to unique Primer ID (dots, diagonal lines, hash) 
may be differentially amplified during PCR. Consensus sequences are constructed 
from >3 raw sequences sharing the same Primer ID within a sample and interpreted 
using the Stanford drug resistance database [171]. The association between receiving 
fewer than three active reverse transcriptase inhibitors over follow-up and time-to-
virologic failure is shown in panels B and C. ARV=antiretroviral; UDS=ultra deep 
sequencing; bulk=bulk PCR sequencing. 
The adjusted analysis produced similar results (Table 5.2). Shorter time to VF 
was associated with more abundant resistant variants, with mutations present among 
≥20% of the total viral population having a larger effect on time-to-VF (HR: 2.2, 95% 
CI: 0.77-6.5, p=0.1). Failure times were shorter for patients with as few as 2,000 
copies/mL of resistant virus. Using stricter interpretations of UDS data drove 
estimates further toward the null (Appendix 5.1). 
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Table 5.2. Adjusted hazard ratios for time-to-virologic failure and receiving 
suboptimal therapy. 
    Adjusted estimates 
Resistance to early therapy* n VF p-m HR† 95% CI 95%CLR 
Predicted resistance       
 <3 inactive RTI, Bulk or UDS 19 9 97 1.9 0.90-4.1 4.5 
 ≥3 active RTI 162 35 619 1.0   
 
Predicted resistance       
 <3 inactive RTI, Bulk & UDS 3 2 14 2.9 0.65-13 19 
 <3 inactive RTI, UDS Only 16 7 83 1.7 0.75-4.0 5.4 
 ≥3 active RTI 162 35 619 1.0   
 
% Viral population, UDS       
 ≥20% resistant 8 4 29 2.2 0.77-6.5 8.4 
 <20% resistant 11 5 68 1.7 0.64-4.5 6.9 
 None 163 36 635 1.0   
 
Copies resistant virus, UDS       
 ≥2,000 co/mL 14 6 56 1.6 0.65-3.8 5.9 
 <2,000 co/mL 168 39 676 1.0   
 
Copies resistant virus, UDS       
 ≥10,000 co/mL 9 5 38 3.5 1.0-7.1 6.9 
 <10,000 co/mL 173 40 694 1.0   
VF=virologic failure; p-m=person-months; CLR=confidence limit ratio; RTI=reverse 
transcriptase inhibitor; UDS=ultra deep sequencing; MSM, men who have sex with 
men. *Mutations near homopolymeric sequence regions were considered genuine if 
they occurred >1 time within a sample. RTI activity was predicted using the Stanford 
HIV drug resistance database [171]. †HR and 95% CI were adjusted for the following: 
(1) time-varying MSM and race; (2) gender; and (3) age at therapy initiation modeled as 








5.4     DISCUSSION 
Nearly 10% of patients received partially-active HAART, and 84% of these 
were not captured by standard sequencing. Although bulk sequencing was 
performed retrospectively for most patients, the number receiving suboptimal therapy 
was lower than in other cohorts with prospective testing [362]. By bulk sequencing 
analysis, <2% of study patients received suboptimal HAART, while 6% of patients 
from another cohort with clinically-available tests received suboptimal RTI 
combinations [362]. Additional resistance observed with UDS is consistent other 
groups that used more sensitive assays and reported an increase in NRTI resistance 
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from 3 to 13% of patients [374] or NNRTI resistance from 6% to 13% of patients 
[346]. 
In our analysis, the intra-patient distribution of pre-existing resistance was 
highly skewed towards the upper (≥20%) and lower (<5%) ends. Thus, a specific cut-
off at which minority variants affect VF could not be determined. Others suggest the 
effect of RTI resistance on time-to-VF may be more a function of copies of resistant 
virus rather than percent abundance alone [18, 364]. In this study, the magnitude of 
the estimated effect of copy number exceeded the estimated effect of variants 
defined by a percent cut-off at the highest copy numbers. This result is not 
surprising, since patients with a relatively high proportion of resistant virus often had 
lower viral loads and may have achieved sustained viral suppression more easily.  
To produce clinically relevant estimates, baseline resistance was defined in 
the context of the antiretroviral activity of each HAART regimen received over the 
course of follow-up [171], which is predictive of VF [363]. Consistent with previous 
bulk sequencing studies [362, 363], pre-therapy resistance was associated with a 
near 100% increase of the hazard of VF. Estimates were heavily influenced by 
NNRTI resistance detected by bulk sequencing, rather than additional resistance 
identified by UDS. Patients identified solely by UDS, nearly half of whom were 
resistant to their prescribed NRTI, experienced slightly elevated rates of VF 
compared to those receiving a fully active regimen, in agreement with other 
estimates for NRTI minority variants and VF [18]. It is possible that patients harboring 
minority resistance have accelerated failure times, but this study was unable to 
discriminate between groups with NRTI and NNRTI resistance, especially given the 
rigorous definition of drug resistance. 
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This is the first study to scale up the Primer ID based method to a large 
population of patients who went on to receive HAART. Primer ID allows a more 
accurate estimation of the viral population with UDS data [26] and may allow more 
refined estimation of the effects of minority drug resistant variants on virologic 
response given greater sampling depth and moderation of sequencing error. 
Predicting virologic response will likely improve by precise enumeration of minority 
variants actually present in the viral population pre-treatment. In order for these 
highly sensitive assays to complement clinical decision-making, it is important to 
distinguish resistance from error and to consider how resistance interacts with other 




CHAPTER 6     CONCLUSION 
 
6.1     SUMMARY OF RESULTS 
A clear picture of antiretroviral resistance within the HIV-infected patient is 
clouded by factors that both are native to the virus, with its enormous capacity for 
evolution, and technology that is currently available for its measurement, which is 
tasked with distinguishing sequencing errors that, while rare, may occur more 
frequently than some mutations. Ultra deep sequencing (UDS) promises far better 
sampling of the viral population than standard sequencing, but UDS protocols are 
highly complex with multiple opportunities for error introduction. In particular, UDS 
still relies on a PCR amplification step to enrich rare HIV-1 sequences for an 
adequate sequencing signal; this step notoriously misrepresents the viral population 
through differential amplification of HIV-1 genomes [19]. Thus, when millions of HIV-
1 sequences are returned for analysis, they are not necessarily providing a clear 
picture of the HIV-1 population within the individual, but rather a picture of what HIV-
1 sequences were most efficiently amplified during PCR. Without accurately 
sampling and measuring the HIV-1 population within the individual, critical questions 
about the threshold at which minority drug resistant HIV-1 begins to affect treatment 
outcomes cannot be addressed. 
One method of addressing UDS error is through the use of Primer ID. This 
stretch of randomized nucleotides is incorporated into the HIV-1 genome before PCR 
amplification so that each viral genome is tagged with a unique Primer ID sequence. 
Primer ID are amplified along with the HIV-1 sequence, and multiple occurrences of 
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the same Primer ID sequence within a sample are used to create a single consensus 
sequence that not only better reflects the true nucleotide sequence of that particular 
viral genome, but also its distribution within the sampled viral population. Others 
have used UDS to measure minority drug resistant HIV-1, and they have attempted 
to determine a threshold at which these variants begin to affect treatment outcome 
[18]. However, this study shows that Primer ID may be successfully applied to this 
problem, increasing the potential to tease out clinically meaningful thresholds that 
are not confounded by UDS error.  
In this study, we first observed in control experiments that Primer ID virtually 
eliminated stochastic sequencing errors while revealing systematic errors associated 
with certain sequence regions. In known sequences spanning HIV-1 RT codons 34-
139, the overall error rate using the 454 platform was reduced from 70/10,000 
nucleotides (95% CI: 70-72) to 2.6/10,000 nucleotides (95% CI: 2.2-3.2) when raw 
sequences were corrected using the Primer ID. Homopolymeric sequence tracts are 
known to be particularly difficult to read for 454 sequencing platforms [24], and 
Primer ID dramatically reduced, but did not completely eliminate errors associated 
with these regions. Using raw sequences, we observed 216 errors/10,000 
nucleotides (95% CI: 213-220) near homopolymeric sequences that were 4 or more 
nucleotides in length, but Primer ID reduced this rate to 6.0/10,000 nucleotides (95% 
CI: 4.8-7.4) within these problematic areas. In contrast, the Illumina sequencing 
platform is not susceptible to homopolymeric errors, but it is associated with errors 
toward the end of a sequencing run (ie., towards the end of the sequence read) and 
within the downstream paired-end sequence [326]. Using the Illumina MiSeq 
platform, the overall error rate for both pair-end sequences was reduced from 
24/10,000 nucleotides (95% CI: 18-32) using raw sequences to 1.2/10,000 
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nucleotides (95% CI: 0.59-2.4) using Primer ID correction. However, while in raw 
sequences errors appeared more randomly distributed between the paired-ends, 
Primer ID revealed that residual errors were concentrated within the downstream 
paired-end. 
We next used Primer ID corrected 454 deep sequencing of HIV-1 RT codons 
34-245 to measure the amount of pre-existing RT inhibitor resistance in a population 
of 184 therapy naïve patients seeking HIV care in North Carolina. Although we relied 
on the most current list of surveillance drug resistance mutations to estimate the 
prevalence of transmitted drug resistance [189], we excluded those mutations near 
homopolymer-associated positions from our overall estimates in light of residual 
errors revealed by control experiments even after Primer ID correction. We also 
produced another set of prevalence estimates under the stricter assumption that a 
drug resistance mutation was genuine only if it occurred more than once within a 
patient sample (ie. on at least two Primer ID consensus sequences). Under the less 
strict interpretation, we found that nearly 14% (95% CI: 9.4-20%) of patients had one 
or more RT inhibitor mutations, including 11% (95% CI: 6.8-16%) with NRTI 
resistance and 4.9% (95% CI: 2.3-9.1%) with NNRTI resistance. Under the more 
conservative definition, 6.0% (95% CI: 3.0-10%) of patients had any RT inhibitor 
resistance; the prevalence of NRTI and NNRTI resistance was 6.0% (95% CI: 3.0-
10%) and 1.6% (95% CI: 0.34-4.7%), respectively. The latter was probably overly 
conservative since, given the error rate estimated from controls, we observed nearly 
a 3-fold excess of singly occurring mutations than what we would expect by chance 
alone. However, even the strictest interpretation of Primer ID consensus sequences 
revealed an increase in resistance prevalence over standard sequencing, since only 
2.7% (95% CI: 0.89-6.2%) of patients had evidence of RT inhibitor resistance by bulk 
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sequence analysis, including 2.2% (95% CI: 0.60-5.5%) and 1.1% of patients (95% 
CI: 0.13-3.4%) with NRTI or NNRTI resistance, respectively. 
Resistance mutations that were detected by both standard bulk sequencing 
and UDS dominated the viral population, and all were present in far greater than 
20% of Primer ID consensus sequences. In contrast, resistance mutations detected 
solely by UDS were in very low abundance (<1% to <5%), and these most often 
occurred on a single Primer ID within a patient sample. Our goal was to input 500 
HIV-1 RNA templates into the sequencing reaction, but the median number of Primer 
ID consensus sequences per patient was 41 (IQR: 18-76) created from a median 12 
raw sequences (IQR: 6-24) each, suggesting very limited sampling depth and low 
template utilization. We would not have observed this limitation if we had relied on 
raw sequences alone, since patients had a median 1,475 raw sequences (IQR: 598-
2,471), but since we restricted our analysis to mutations outside of homopolymeric 
influence, it is likely that even single occurrences of resistance mutations were 
authentic.  
When we compared all amino acid changes in a subset of 19 patients 
between results from Illumina MiSeq and 454, we found similar numbers of Primer ID 
consensus sequences for 11 of these patients despite a 9-fold increase in the 
number of raw sequences, while 8 had up to 9-fold more Primer ID consensus 
sequences using the Illumina platform. We could not explain this difference between 
platforms for all patients even though Illumina MiSeq outputs vastly more raw 
sequences compared to 454 platforms; however, 4 of 8 of these patients did have 
viral loads exceeding the limit of detection (>750,000 HIV-1 RNA co/mL), so the 
number 454 Primer ID consensus sequences could have been limited by platform 
throughput rather than template usage. When we compared all amino acid changes 
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between platform, we found that only 50% (N=48/108) were detected by both UDS 
platforms. Most of these (72% of 48) were detected on a single Primer ID consensus 
sequence. Further, up to 73% (N=19/26) of mutations detected by the 454 platform 
alone were near homopolymeric sequences, while all 33 mutations detected by the 
Illumina platform alone were within the downstream paired-end associated with the 
highest error rates in the control. Together, this suggests that many of these single 
occurrences are due to sequencing errors, rather than stochastic sampling of rare 
sequence variants. 
These 184 patients were initially selected for this study since they were 
therapy naïve at the time their plasma sample was obtained, and because they 
eventually initiated HAART with a regimen containing only RT inhibitors. Our goal 
was to estimate the effect of undetected minority drug resistance on time-to-virologic 
failure, to determine if UDS had any added value over standard bulk sequence 
analysis with respect to treatment outcomes, and to enumerate a clinically relevant 
threshold for intra-patient resistant HIV-1 variants. To address these questions, we 
used a genotypic scoring method available through the Stanford HIV Drug 
Resistance Database to interpret drug resistance mutations detected by UDS and/or 
bulk sequence analysis [171]. Using the Stanford database scores, we estimated the 
number of active antiretrovirals within each RT inhibitor regimen based on the 
spectrum of resistance mutations observed within each patient sample, with <3 
active antiretrovirals considered resistant. Using this scoring algorithm, only about 
10% of patients received fewer than three active RT inhibitors at any given time over 
the course of follow-up. We found that these patients tended to experience virologic 
failure faster than patients that received fully-active HAART; however, results were 
not statistically significant (adjusted HR: 1.9, 95% CI: 0.90-4.1). Only 3 patients were 
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taking suboptimal HAART according to their bulk sequencing and UDS results, and 2 
of 3 patients failed within the first 8 months of HAART. Patients receiving suboptimal 
HAART revealed by UDS alone also tended to experience virologic failure more 
quickly than patients without any resistance, but we were limited by the small number 
of patients in the exposed category (adjusted HR: 1.7, 95% CI: 0.75-4.0). We were 
also limited by the depth of sampling with respect to HIV-1 within individual patients. 
Since the resistance mutations we observed were either very high (>60%) or very 
low (<5%) abundance, we did not arrive at a clinical threshold for minority variants 
and virologic failure. We did, however, observe that very high copies of drug resistant 
virus (>10,000 co/mL) was associated with a decrease in time-to-virologic failure 
(adjusted HR: 3.5, 95% CI: 1.0-7.1). 
6.2     IMPLICATIONS 
In known control sequences, the large discrepancy in errors that we observed 
between analyses relying on raw sequences and Primer ID corrected consensus 
sequences highlighted the limitations of UDS technologies in their current form. 
Primer ID revealed that the number of HIV-1 RNA templates that we actually 
sampled is far lower than what we would have believed had we used raw sequence 
data alone. Thus, UDS is probably not able to reliably achieve the sampling depths 
that are often reported by others that rely on such data. These studies may filter 
errors from raw sequences based on control experiments and statistically defined 
cutoffs, but these methods do not account for differential amplification or PCR 
resampling. Measurement bias at all steps of UDS must be addressed before the 
effect of minority drug resistance on patient outcomes can be assessed. 
However, it is also clear that Primer ID does not completely eliminate all 
errors, especially those that are associated with particular sequencing platforms. 
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This residual error is based on the composition of the nucleotide sequence itself, 
which is unknown for clinical samples, and its interaction with the specific UDS 
technology (ie., homopolymeric sequence regions). Residual, systematic errors 
associated with specific UDS platforms may skew estimates in unpredictable ways in 
large pools of unknown HIV-1 sequences. Further, for Primer ID corrected estimates 
to be accurate, we must make a number of assumptions. For example, excess 
Primer ID must be completely removed from each sample prior to amplification to 
prevent Primer ID sequences from being associated with multiple HIV-1 templates. If 
such a phenomenon were to occur, the viral population’s sequence diversity could be 
deflated when consensus sequences are generated. Also, the Primer ID must be 
correctly sequenced so that a single Primer ID is not misread as multiple, unique 
Primer ID, thus inflating estimates of the size of the viral population. 
When we used the Primer ID to more accurately measure RT inhibitor 
resistance in our population of 184 patients, we further showed how limited our ability 
is for detection of minority drug resistant variants using UDS. Untreated patients had 
relatively high viral loads compared to patients on therapy, which theoretically would 
allow the highest level of resolution of the HIV-1 population. Yet, we still only 
achieved the ability to reliably sample variants that were present among ≥7% of 
sequences on average. This is still superior to standard bulk sequence analysis 
(≥20%), and we identified a number of additional patients who were placed on 
suboptimal therapy that would not have been captured by standard sequencing 
methods. We did observe an increased risk of virologic failure among patients with 
minority variants that appeared to increase with copies of resistant virus or relative 
abundance, and these estimates were probably underestimates given their lack of 
statistical significance. However, to what degree these estimates would change 
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given a larger patient population or deeper sampling of the viral population is 
unknown. 
6.3     FUTURE DIRECTIONS 
Since this study’s inception, the Primer ID has continued to improve. For 
example, the pre-assigned barcode sequence that differentiates patient samples is 
now represented twice within the cDNA primer, preventing incorrectly sequenced 
patient barcodes from either being discarded as non-matching, or worse, included 
with other similar patient barcode sequences as part of another sample. The Primer 
ID itself has been increased in length from 8 nucleotides to 11 nucleotides, which 
could facilitate increased sampling depth given the increase in available Primer ID 
sequence combinations from >65,000 to >4,000,000.  
However, it is imperative that this method continue to be rigorously validated 
before it is expanded into additional epidemiologic or clinical use. Because Primer ID 
addresses sequencing errors from the PCR step forward, it is still unknown if the 
HIV-1 RNA is actually the same sequence. Known, HIV-1 RNA sequences that 
originate from viral culture and that replicate with complete fidelity must be generated 
to estimate the amount of error introduced during the cDNA synthesis step. Within 
the PCR step, we are still limited in terms of interpreting resistance mutations that 
are linked to the same HIV-1 genome because of the potential for PCR 
recombination. A mixture of control sequences with recombination markers include 
within every UDS run may allow us to at least determine the extent of this 
phenomenon. Finally, additional experiments are needed to determine the limit of our 
capacity to detect rare HIV-1 sequence variants given a set number of available 
templates. This is crucial to interpreting rare HIV-1 sequence variants in the context 
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of lower patient viral loads, such as might be expected for patients experiencing 
virologic failure. 
Upon addressing these technical issues, Primer ID can and should be 
expanded to a larger number of patients, both prior to therapy and at treatment 
failure, to better estimate the point at which minority drug resistant variants begin to 
negatively affect patients receiving corresponding drugs. Clinically relevant 
thresholds are likely different not only between antiretroviral classes, but also for 
different individual resistance mutations and their combinations. This variability 
presents a major challenge to attempts at fleshing out meaningful estimates that 
clinical care providers can use to guide treatment selection. The Primer ID should 
also be expanded to other regions of the HIV-1 genome outside of RT that are drug 
targets. The very first study using Primer ID interrogated HIV-1 protease [26], but 
HIV-1 integrase and envelop could provide important information for clinicians 
considering regimens containing classes of drugs that target these enzymes. 
Although UDS is still far from supplanting current sequencing technology, Primer ID 
brings us a step closer to the level of accuracy needed for critical decision making.
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APPENDIX 2.1     MUTATIONS ASSOCIATED WITH REVERSE 
TRANSCRIPTASE INHIBITOR RESISTANCE, INTERANTIONAL AIDS 







FTC ABC AZT d4T ddI TDF +T69ins +Q151M TAM 
M41L   X X   X  X 
A62V       X X  
K65R X X  X X X    
D67N   X X     X 
K70R   X X   X  X 
K70E      X    
L74V  X   X     
V75I        X  
F77L        X  
Y115F  X        
F116Y        X  
M184V X X        
M184I X         
L210W   X X   X  X 
T215Y/F   X X   X  X 
T219Q/E   X X   X  X 
 
NNRTI 
EFV ETR NVP RPV 
V90I  X   
A98G  X   
L100I X X X  
K101E  X  X 
K101P X X X X 
K101H  X   
K103N/S X  X  
V106A   X  
V106M X X X  
V106I  X   
V108I X  X  
E138A/G/K/Q  X  X 
E138R    X 
V179D/F/T  X   
V179L    X 
Y181C/I X X X X 
Y181V  X  X 
Y188C/H   X  
Y188L X  X X 
G190S X X   
G190A X X X  
H221Y    X 
P225H X    





 EFV ETR NVP RPV 
M230I    X 
M230L X X X X 
RT=reverse transcriptase; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-
NRTI; 3TC=lamivudine; FTC=emtricitabine; ABC=abacavir; AZT=zidovudine; 
d4T=stavudine; ddI=didanosine; TDF=tenofovir; ins=insertion; TAM=thymidine analogue 
mutation; EFV=efavirenz; ETR=etravirine; NVP=nevirapine; RPV=rilpivirine. *Amino acid 
changes are given in the following format: wild type amino acid, HIV-1 RT codon, mutant 




APPENDIX 2.2     SURVEILLANCE DRUG RESISTANCE MUTATIONS FOR 




3TC/FTC ABC AZT d4T ddI TDF 
M41L   X X   
K65R X X  X X X 
D67N/G/E   X X   
T69ins/D X X X X X X 
K70R   X X   
K70E      X 
L74V/I  X   X  
V75M/T/A/S    X X  
F77L       
Y115F  X     
F116Y       
Q151M X X X X X X 
M184V X X     
M184I X      
L210W   X X   
T215Y/F   X X   
T215I/S/C/D/E/V*       
T219Q/E/N/R   X X   
 
NNRTI 
EFV ETR NVP RPV 
L100I X X X  
K101E  X  X 
K101P X X X X 
K103N/S X  X  
V106A   X  
V106M X X X  
V179F  X   
Y181C/I X X X X 
Y181V  X  X 
Y188C/H   X  
Y188L X  X X 
G190S X X   
G190A X X X  
G190E X X X X 
H221Y    X 
P225H X    
M230L X X X X 
NRTI=nucleoside(tide) reverse transcriptase inhibitor; NNRTI=non-NRTI; 3TC=lamivudine; 
FTC=emtricitabine; ABC=abacavir; AZT=zidovudine; d4T=stavudine; ddI=didanosine; 
TDF=tenofovir; ins=insertion; EFV=efavirenz; ETR=etravirine; NVP=nevirapine; 




APPENDIX 2.3     STANFORD HIV DRUG RESISTANCE DATABASE 
ANTIRETROVIRAL SUSCEPTIBILITY SCORES FOR HIV-1 REVERSE 
TRANSCRIPTASE MUTATIONS [171] 
Amino acid change† 
NRTI Score* 
3TC/FTC ABC AZT d4T ddI TDF 
E40F 0 5 5 5 5 5 
M41L 5 5 15 15 5 5 
E44A/D 5 5 5 5 5 5 
A62V 5 5 5 5 5 5 
K65R 30 45 -10 30 45 45 
K65N 15 15 9 15 15 15 
K66ins 30 45 45 45 45 45 
K66del 15 15 15 15 15 15 
D67N/G/E 0 5 15 15 5 5 
D67S/T/H 0 5 10 10 5 5 
D67ins 30 45 45 45 45 45 
D67del 15 15 15 15 15 15 
S68ins 30 45 45 45 45 45 
S68del 15 15 15 15 15 15 
T69D 0 0 0 10 30 0 
T69N 0 0 5 5 10 0 
T69G 0 10 10 10 10 10 
T69ins 30 45 45 45 45 45 
T69del 15 15 15 15 15 15 
K70R 0 0 30 15 0 10 
K70E/G 10 15 -10 0 15 25 
K70T/S/N/Q 10 10 0 10 10 10 
K70ins 30 45 45 45 45 45 
K70del 15 15 15 15 15 15 
W71ins 30 45 45 45 45 45 
W71del 15 15 15 15 15 15 
L74I 0 20 0 0 60 0 
L74V 0 30 -10 0 60 0 
V75A 0 0 0 15 15 0 
V75I 5 0 0 10 10 0 
V75M/T 0 0 0 60 30 0 
V75S 0 0 0 20 10 0 
F77L 5 10 10 10 10 5 
Y115F 0 45 0 0 0 15 
F116Y 5 10 10 10 10 5 
V118I 0 5 5 5 5 5 
Q151L 10 30 30 30 30 10 
Q151M 15 60 60 60 60 15 





Amino acid change† 
NRTI Score* 
3TC/FTC ABC AZT d4T ddI TDF 
L210W 5 5 15 15 5 5 
T215I/S/C/D/E/V/S 0 10 20 20 10 5 
T215N/A/L 0 5 20 20 5 5 
T215Y/F 5 15 45 45 15 15 
T219Q/E/N/R/W/D/H 0 5 10 10 5 5 
Combinations‡       
 M41L+L210W 0 10 10 10 10 10 
 M41L+T215Y/F 0 10 10 10 10 10 
 M41L+T215X§ 0 5 5 5 5 5 
 K65R+Y115F 0 0 0 0 0 10 
 K65R+Q151M 0 0 0 0 0 10 
 L74V/I+M184I/V 0 20 0 0 0 0 
 L210W+T215Y/F 0 10 10 10 10 10 
 L210W+T215X§ 0 5 5 5 5 5 
 
NNRTI Score* 
EFV ETR NVP RPV 
V90I 0 5 0 5 
A98G 5 5 15 5 
L100I 30 15 30 15 
K101E 15 10 30 10 
K101P 30 30 60 60 
K101H 10 10 15 10 
K103N/H 60 0 60 0 
K103S 30 0 60 0 
L103T 15 0 60 0 
V106A 30 0 60 0 
V106M 60 0 60 0 
V108I 5 0 10 0 
E138A 5 5 5 5 
E138K 10 10 10 30 
E138Q/G/R 5 10 5 15 
V179D 10 10 10 10 
V179E 10 5 10 5 
V179T 0 5 0 5 
V179F 5 15 10 15 
Y181C 30 30 60 30 
Y181I/V 30 60 60 60 
Y188S 15 15 30 15 
Y188C/H 15 0 60 0 
Y188L 60 10 60 60 
G190A 40 10 60 10 
G190S/C/V/T 60 10 60 10 
G190E/Q 60 15 60 15 
H221Y 5 5 5 5 





Amino acid change† 
NNRTI Score* 
EFV ETR NVP RPV 
Combinations‡     
 K103R+V179D 5 0 20 0 
 V106A+F227L 15 0 0 0 
 V106I+V179D 5 0 5 0 
 V179F+Y181C/I/V 0 15 0 15 
 Y181C/I/V+G190X§ 0 15 0 15 
NRTI=nucleoside(tide) reverse transcriptase inhibitor; NNRTI=non-NRTI; 3TC=lamivudine; 
FTC=emtricitabine; ABC=abacavir; AZT=zidovudine; d4T=stavudine; ddI=didanosine; 
TDF=tenofovir; ins=insertion; EFV=efavirenz; ETR=etravirine; NVP=nevirapine; 
RPV=rilpivirine. *To determine susceptibility to an individual antiretroviral, scores are 
added for each resistance mutation. A higher score corresponds to increased resistance 
to that antiretroviral. †Amino acid changes from are given in the following format: wild 
type amino acid, codon, resistant amino acid. ‡When combinations of given mutations are 
present, susceptibility scores for some antiretrovirals are increased over the score for the 
individual mutations. §For L215X, X is I/S/C/D/E/V/S/N/A/L; for G190X, X is A/S/E/Q/C/V/T. 
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APPENDIX 3.1     PRIMERS FOR CDNA SYNTHESIS AND DNA AMPLIFICATION 
    
Application Direction HXB2* Sequence (5’3’) 
       
Patient samples   
      cDNA† antisense 2965-2992 GCCTTGCCAGCACGCTCACAGCTGGCA-
BBBB-CGNNNNNNNNTC-
ACATTGTACTGATATCTAATYCCTGGTG 
      cDNA† antisense 3258-3284 GCCTTGCCAGCACGCTCACAGCTGGCA-
BBBB-CGNNNNNNNNTC-
CACTATAGGCTGTACTGTCCATTTATC 
      PCR 1/2  sense 2620-2647 GGCCATTGACAGAAGAAAAAATAAAAGC 
      PCR 1/2  sense 2965-2992 CACCAGGRATTAGATATCAGTACAATGT 
      PCR 1  antisense  GCCTTGCCAGCACGCTCACAG 
      PCR 2  antisense  CCAGCACGCTCACAGCTGGCA 
   
Plasmid samples   
      PCR 1 sense 2571-2598 GTACCAGTAAAATTAAAGCCAGGAATGG 
      PCR 1 antisense  GCCTTGCCAGCACGCTCAGGC 
      PCR 2 sense 2992-3284 CACCAGGGATTAGATATCAATATAATGT 
      PCR 2 antisense  CCAGCACGCTCAGGCCTTGCA 
     
*HIV-1-specific sequence targeting each region were derived from primers used in Simen 
et al. [346]. †Primers used for cDNA sequence contained a PvuII recognition site (bold), a  
four-nucleotide sample barcode linked to each individual patient (B), a random 8-







APPENDIX 4.1     ERROR RATES ESTIMATED FROM DEEP SEQUENCING CONTROLS 
 
Raw sequence analysis Primer ID consensus sequence analysis 
Sequences Errors Nt* Rate† (95% CI) Sequences Errors Nt* Rate† (95% CI) 
454 Junior           
 3,000 29,055 65,765 9,210,435 71 (71-72) 80 10 25,360 3.9 (1.9-7.3) 
 10,000 26,561 60,289 8,419,837 72 (71-72) 186 25 58,962 4.2 (2.7-6.3) 
 30,000 25,808 57,310 8,181,136 70 (69-71) 664 47 210,488 2.2 (1.6-3.0) 
 100,000 30,684 68,960 9,726,828 71 (70-71) 1,863 146 590,571 2.5 (2.1-2.9) 
 Total‡ 112,108 252,324 35,538,236 71 (70-72) 2,893 228 885,381 2.6 (2.2-3.2) 
MiSeq           
 3,000, F 33,305 20,489 7,360,405 28 (27-28) 79 10 17,459 5.7 (2.7-11) 
 3,000, R 33,305 5,491 6,094,815 9.0 (8.8-9.3) 79 18 14,457 12 (7.4-20) 
 10,000, F 32,186 22,711 7,113,106 32 (32-32) 168 2 37,128 0.54 (0.0065-1.9) 
 10,000, R 32,186 4,274 5,890,038 7.3 (7.0-7.5) 168 9 30,744 2.9 (1.3-5.6) 
 30,000, F 28,318 23,162 6,258,278 37 (37-37) 656 6 144,976 0.41 (0.15-0.90) 
 30,000, R 28,318 3,635 5,182,194 7.0 (6.8-7.2) 656 30 120,048 2.5 (1.7-3.6) 
 100,000, F 30,013 103,490 6,632,873 56 (55-57) 1,807 8 399,347 0.20 (0.0086-0.40) 
 100,000, R 30,013 17,493 5,492,379 7.5 (7.2-7.7) 1,807 47 330,681 1.4 (1.0-1.9) 
 Total‡ 123,822 120,983 50,024,088 24 (18-32) 2,710 130 1,094,840 1.2 (0.59-2.4) 
*For the 454 Junior platform, the read length was 317 nucleotides (nt) spanning HIV-1 reverse transcriptase (RT) codons 34-139 
(HXB2 nt 2648-2964). For the MiSeq platform, read lengths were 221 nt spanning HIV-1 RT codons 34-97 in the forward (F) 
direction (HXB2 nt 2648-2840), and 183 nt spanning codons 78-139 in the reverse (R) direction (HXB2 nt 2782-2964). †Rates are 
expressed as errors per 10,000 nt. ‡Standard errors for total error rates were calculated across all input DNA copy number 





APPENDIX 5.1     ADJUSTED HAZARD RATIOS USING STRICTER 
INTERPRETATION OF DEEP SEQUENCING DATA  
Resistance to early therapy* 
Adjusted estimates 
n VF p-m HR† 95% CI CLR P-value 
Predicted resistance        
 
<3 inactive RTI, Bulk or 
UDS 11 4 35 1.2 0.43-3.5 8.1 0.7 
 ≥3 active RTI 170 40 681     
Predicted resistance        
 
<3 inactive RTI, Bulk & 
UDS 3 2 14 2.7 0.61-12 19 0.4 
 <3 inactive RTI, UDS only 8 2 21 0.77 0.18-3.3 18  
 ≥3 active RTI 170 40 681 1.0    
% Viral population, UDS        
 ≥20% resistant 6 3 22 2.1 0.63-7.4 12 0.4 
 <20% resistant 5 1 13 0.51 0.067-3.9 58  
 None 171 41 697 1.0    
Copies resistant virus, UDS        
 ≥2,000 co/mL 9 3 22 1.2 0.35-3.8 11 0.8 
 <2,000 co/mL 173 42 710 1.0    
Copies resistant virus, UDS        
 ≥10,000 co/mL 6 3 22 2.2 0.63.-7.4 12 0.2 
 <10,000 co/mL 176 42 710 1.0    
VF=virologic failure; p-m=person-months; CLR=confidence interval ratio; RTI=reverse 
transcriptase inhibitor; UDS=ultra deep sequencing; MSM=men who have sex with men. 
*For deep sequencing, resistance mutations were considered genuine if they occurred >1 
time within a patient sample. The number of active RTI per regimen was predicted using 
the Stanford HIV drug resistance database to interpret to interpret resistance mutations 
detected by bulk PCR sequence analysis and/or UDS [171]. †HR and 95% CI were adjusted 
for the following: (1) time-varying MSM and white race; (2) gender; and (3) age at therapy 













1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis 
of HIV-1-infected patients starting highly active antiretroviral therapy: a 
collaborative analysis of prospective studies. Lancet 2002,360:119-129. 
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et 
al. Decline in the AIDS and death rates in the EuroSIDA study: an observational 
study. Lancet 2003,362:22-29. 
3. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et 
al. Antiretroviral drug resistance testing in adults infected with human 
immunodeficiency virus type 1: 2003 recommendations of an International AIDS 
Society-USA Panel. Clin Infect Dis 2003,37:113-128. 
4. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. 
Time trends in primary HIV-1 drug resistance among recently infected persons. 
JAMA 2002,288:181-188. 
5. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. 
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J 
Med 2002,347:385-394. 
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the 
Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. 
Department of Health and Human Services 2013:1-267. Available at: 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed: 
March 2013. 
7. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative 
performance of high-density oligonucleotide sequencing and dideoxynucleotide 
sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 
1998,14:869-876. 
8. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, et al. Changes in 
human immunodeficiency virus type 1 populations after treatment interruption in 
patients failing antiretroviral therapy. J Virol 2001,75:6410-6417. 
9. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of 
HIV-1 drug resistance mutations after stopping therapy. AIDS 1999,13:F123-127. 
 148 
 
10. Cane PA. Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect 
Dis 2005,18:537-542. 
11. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in 
primary resistance to HIV drugs in the United Kingdom: multicentre observational 
study. BMJ 2005,331:1368. 
12. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al. 
French national sentinel survey of antiretroviral drug resistance in patients with 
HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 
2001-2002. J Acquir Immune Defic Syndr 2005,38:545-552. 
13. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. 
Persistence of primary drug resistance among recently HIV-1 infected adults. 
AIDS 2004,18:1683-1689. 
14. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, et al. Persistence of 
multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 
2004,18:1653-1660. 
15. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, 
et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 
years after sexual transmission. Antivir Ther 2004,9:415-421. 
16. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, et al. HIV-1 
resistant strains acquired at the time of primary infection massively fuel the 
cellular reservoir and persist for lengthy periods of time. AIDS 2006,20:159-170. 
17. Fox J, Dustan S, McClure M, Weber J, Fidler S. Transmitted drug-resistant HIV-1 
in primary HIV-1 infection; incidence, evolution and impact on response to 
antiretroviral therapy. HIV Med 2006,7:477-483. 
18. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. 
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based 
antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 
2011,305:1327-1335. 
19. Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, et al. HIV 
quasispecies and resampling. Science 1996,273:415-416. 
20. Kanagawa T. Bias and artifacts in multitemplate polymerase chain reactions 
(PCR). J Biosci Bioeng 2003,96:317-323. 
 149 
 
21. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, 
pathogenesis, and therapy. Science 1995,267:483-489. 
22. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, et al. DNA bar 
coding and pyrosequencing to identify rare HIV drug resistance mutations. 
Nucleic Acids Res 2007,35:e91. 
23. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of 
mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug 
resistance. Genome Res 2007,17:1195-1201. 
24. Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, Martin JF. Accuracy and 
quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 
2011,12:245. 
25. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, et al. Detection 
of minority resistance during early HIV-1 infection: natural variation and spurious 
detection rather than transmission and evolution of multiple viral variants. J Virol 
2011,85:8359-8367. 
26. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling 
and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl 
Acad Sci U S A 2011,108:20166-20171. 
27. Centers for Disease Control and Prevention. Pneumocystis pneumonia--Los 
Angeles. MMWR 1981,30:250-252. 
28. UNAIDS. Report on the Global AIDS Epidemic, 2012. In: Available at: 
http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/. Geneva, 
Switzerland: World Health Oraganization; 2012. pp. 1-212. 
29. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2011. In. Atlanta: U.S. Department of Health and Human Services; 2013. pp. 1-
84. 
30. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et 
al. Declining morbidity and mortality among patients with advanced human 
immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J 
Med 1998,338:853-860. 
31. Centers for Disease Control and Prevention. AIDS Cases, Deaths, and Persons 





32. Centers for Disease Control and Prevention. 1993 revised classification system 
for HIV infection and expanded surveillance case definition for AIDS among 
adolescents and adults. MMWR Recomm Rep 1992,41:1-19. 
33. Centers for Disease Control and Prevention. Twenty-five years of HIV/AIDS--
United States, 1981-2006. MMWR 2006,55:585-589. 
34. Merriam-Webster Inc. Merriam-Webster's collegiate dictionary. 11th ed. 
Springfield, Mass.: Merriam-Webster, Inc.; 2003. 
35. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2001. In. Atlanta: U.S. Department of Health and Human Services; 2002. pp. 1-
50. 
36. Centers for Disease Control and Prevention. Update: AIDS--United States, 2000. 
MMWR 2002,51:592-595. 
37. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2002. In. Atlanta: U.S. Department of Health and Human Services; 2003. pp. 1-
46. 
38. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2003. In. Atlanta: U.S. Department of Health and Human Services; 2004. pp. 1-
46. 
39. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2004. In. Atlanta: U.S. Department of Health and Human Services; 2005. pp. 1-
46. 
40. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2005. In. Atlanta: U.S. Department of Health and Human Services; 2006. pp. 1-
54. 
41. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 




42. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2007. In. Atlanta: U.S. Department of Health and Human Services; 2008. pp. 1-
63. 
43. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2008. In. Atlanta: U.S. Department of Health and Human Services; 2009. pp. 1-
79. 
44. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2009. In. Atlanta: U.S. Department of Health and Human Services; 2010. pp. 1-
79. 
45. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 
2010. In. Atlanta: U.S. Department of Health and Human Services; 2011. pp. 1-
79. 
46. Krawczyk CS, Funkhouser E, Kilby JM, Vermund SH. Delayed access to HIV 
diagnosis and care: Special concerns for the Southern United States. AIDS Care 
2006,18 Suppl 1:S35-44. 
47. Centers for Disease Control and Prevention. AIDS Public Information Data Set. 
In: U.S. Dept. of Health and Human Services; 2002. 
48. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et 
al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired 
immune deficiency syndrome (AIDS). Science 1983,220:868-871. 
49. Fields BN, Knipe DM, Howley PM. Fields' Virology. 5th ed. Philadelphia: Wolters 
Kluwer Health/Lippincott Williams & Wilkins; 2007. 
50. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The 
replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group 
M, HIV-1 group O, and HIV-2 isolates. J Virol 2005,79:8979-8990. 
51. Centers for Disease Control and Prevention. Human Immunodeficiency Virus 
Type 2. In; 1998. 
52. Freed EO. HIV-1 replication. Somat Cell Mol Genet 2001,26:13-33. 
 152 
 
53. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al. 
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-
mediated suppression. Nat Med 1997,3:1259-1265. 
54. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, et al. 
Cellular latency in human immunodeficiency virus-infected individuals with high 
CD4 levels can be detected by the presence of promoter-proximal transcripts. 
Proc Natl Acad Sci U S A 1994,91:3862-3866. 
55. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms 
of HIV infection. Ann Intern Med 1996,124:654-663. 
56. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of 
human immunodeficiency virus infection. N Engl J Med 1993,328:327-335. 
57. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. 
Natural history of human immunodeficiency virus type 1 viremia after 
seroconversion and proximal to AIDS in a large cohort of homosexual men. 
Multicenter AIDS Cohort Study. J Infect Dis 2000,181:872-880. 
58. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. 
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen 
and blood during acute and chronic infection. AIDS 2007,21:1723-1730. 
59. Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, et al. HIV in 
body fluids during primary HIV infection: implications for pathogenesis, treatment 
and public health. AIDS 2001,15:837-845. 
60. Royce RA, Sena A, Cates W, Jr., Cohen MS. Sexual transmission of HIV. N Engl 
J Med 1997,336:1072-1078. 
61. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent 
antiretroviral treatment of HIV-infection results in suppression of the seminal 
shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000,14:117-121. 
62. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. 
Decline in HIV infectivity following the introduction of highly active antiretroviral 
therapy. AIDS 2004,18:81-88. 
63. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy 




64. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role 
of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 
1996,2:1240-1243. 
65. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. 
Circumcision in HIV-infected men and its effect on HIV transmission to female 
partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009,374:229-
237. 
66. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, et al. 
Influence of HLA supertypes on susceptibility and resistance to human 
immunodeficiency virus type 1 infection. J Infect Dis 2000,181:1581-1589. 
67. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy 
and practice: the contribution of other sexually transmitted diseases to sexual 
transmission of HIV infection. Sex Transm Infect 1999,75:3-17. 
68. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, Krieger J, et al. 
Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue 
reservoirs during acute and early HIV infection: implications for timing of 
antiretroviral therapy. J Infect Dis 2000,181:354-357. 
69. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. 
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in 
the gastrointestinal tract. J Exp Med 2004,200:749-759. 
70. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. 
Primary HIV-1 infection is associated with preferential depletion of CD4+ T 
lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 
2004,200:761-770. 
71. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV 
infection: what the virus spares is as important as what it destroys. Nat Med 
2006,12:289-295. 
72. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of 
acute HIV-1 infection. J Exp Med 1999,190:841-850. 
73. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic 
features of primary HIV infection. Ann Intern Med 1996,125:257-264. 
 154 
 
74. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North 
Am 2000,14:809-+. 
75. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for 
strategies to prevent infection. Nat Med 2003,9:847-852. 
76. Blattner WA, Oursler KA, Cleghorn F, Charurat M, Sill A, Bartholomew C, et al. 
Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J 
Infect Dis 2004,189:1793-1801. 
77. Sabin CA, Lundgren JD. The natural history of HIV infection. Curr Opin HIV AIDS 
2013,8:311-317. 
78. Collaborative Group on AIDS Incubation and HIV Survival. Time from HIV-1 
seroconversion to AIDS and death before widespread use of highly-active 
antiretroviral therapy: a collaborative re-analysis. Lancet 2000,355:1131-1137. 
79. Biberfeld P, Porwit-Ksiazek A, Bottiger B, Morfeldt-Mansson L, Biberfeld G. 
Immunohistopathology of lymph nodes in HTLV-III infected homosexuals with 
persistent adenopathy or AIDS. Cancer Res 1985,45:4665s-4670s. 
80. Longini IM, Jr., Clark WS, Gardner LI, Brundage JF. The dynamics of CD4+ T-
lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J 
Acquir Immune Defic Syndr 1991,4:1141-1147. 
81. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS 
survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. 
JAMA 1994,271:1083-1087. 
82. Mocroft AJ, Lundgren JD, d'Armino Monforte A, Ledergerber B, Barton SE, Vella 
S, et al. Survival of AIDS patients according to type of AIDS-defining event. The 
AIDS in Europe Study Group. Int J Epidemiol 1997,26:400-407. 
83. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. 
Clinical progression and virological failure on highly active antiretroviral therapy 
in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 
1999,353:863-868. 
84. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued 
improvement in survival among HIV-infected individuals with newer forms of 
highly active antiretroviral therapy. AIDS 2007,21:685-692. 
 155 
 
85. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. 
Highly active antiretroviral therapy decreases mortality and morbidity in patients 
with advanced HIV disease. Ann Intern Med 2001,135:17-26. 
86. U.S. Food and Drug Administration. http://www.fda.gov/oashi/AIDS/virals.html. 
In; 2008. 
87. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, 
et al. Treatment for adult HIV infection: 2006 recommendations of the 
International AIDS Society-USA panel. JAMA 2006,296:827-843. 
88. Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG, Klingman KL, et 
al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing 
regimens for initial treatment of HIV-1 infection - ACTG 5142. In: Presented at: 
XVI International AIDS Conference. Aug 13-18, 2006; Toronto, Canada. Abstract 
THLB0204. 
89. Squires KE. An introduction to nucleoside and nucleotide analogues. Antivir Ther 
2001,6 Suppl 3:1-14. 
90. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 
2005,48:1297-1313. 
91. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors 
of human immunodeficiency virus type 1. Curr Top Med Chem 2004,4:921-944. 
92. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. British 
HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with 
antiretroviral therapy (2006). HIV Med 2006,7:487-503. 
93. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early 
versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J 
Med 2010,363:257-265. 
94. Gay CL, Napravnik S, Eron JJ, Jr. Advanced immunosuppression at entry to HIV 
care in the southeastern United States and associated risk factors. AIDS 
2006,20:775-778. 
95. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay 




96. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral 
dynamics in human immunodeficiency virus type 1 infection. Nature 
1995,373:117-122. 
97. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, et 
al. Biphasic decay of latently infected CD4+ T cells in acute human 
immunodeficiency virus type 1 infection. J Infect Dis 2000,182:1636-1642. 
98. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, et al. 
Intermittent and sustained low-level HIV viral rebound in patients receiving potent 
antiretroviral therapy. AIDS 2002,16:1967-1969. 
99. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, et al. A novel 
antiviral intervention results in more accurate assessment of human 
immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J 
Virol 2003,77:5037-5038. 
100. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. 
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics 
of HIV, significantly reducing the second phase. AIDS 2007,21:2315-2321. 
101. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. 
Characterization of viral dynamics in human immunodeficiency virus type 1-
infected patients treated with combination antiretroviral therapy: relationships to 
host factors, cellular restoration, and virologic end points. J Infect Dis 
1999,179:799-807. 
102. Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, et al. 
Residual viraemia in subjects with chronic HIV infection and viral load < 50 
copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005,19:1843-
1847. 
103. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. 
Quantifying residual HIV-1 replication in patients receiving combination 
antiretroviral therapy. N Engl J Med 1999,340:1605-1613. 
104. Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, et al. Viral 
blip dynamics during highly active antiretroviral therapy. J Virol 2003,77:12165-
12172. 
105. Metzner KJ. Persistence of drug-resistant HIV-1 and possible implications for 
antiretroviral therapy. Future Virology 2006,1:377-391. 
 157 
 
106. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, et al. Prevalence and 
significance of HIV-1 drug resistance mutations among patients on antiretroviral 
therapy with detectable low-level viremia. Antimicrob Agents Chemother 
2012,56:5998-6000. 
107. Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, et al. The 
natural history and clinical significance of intermittent viraemia in patients with 
initial viral suppression to < 400 copies/ml. AIDS 2002,16:1521-1527. 
108. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence 
and predictive value of intermittent viremia with combination HIV therapy. JAMA 
2001,286:171-179. 
109. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, et al. Prevalence 
and clinical correlates of HIV viremia ('blips') in patients with previous 
suppression below the limits of quantification. AIDS 2002,16:2035-2041. 
110. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for 
modification and discontinuation of antiretrovirals: results from a single treatment 
centre. AIDS 2001,15:185-194. 
111. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender 
differences in discontinuation of antiretroviral treatment regimens. J Acquir 
Immune Defic Syndr 2009,52:336-341. 
112. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, et al. 
Short-term discontinuation of HAART regimens more common in vulnerable 
patient populations. AIDS Res Hum Retroviruses 2008,24:1347-1355. 
113. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors 
associated with a reduced CD4 lymphocyte count response to HAART despite 
full viral suppression in the EuroSIDA study. HIV Med 2003,4:255-262. 
114. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T 
cell response after virologic failure of protease inhibitor-based regimens in 
patients with human immunodeficiency virus infection. J Infect Dis 2000,181:946-
953. 
115. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent 




116. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004,350:1023-1035. 
117. Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, Hance AJ. Contribution 
of recombination to the evolution of human immunodeficiency viruses expressing 
resistance to antiretroviral treatment. J Virol 2007,81:7620-7628. 
118. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ. Extensive 
recombination among human immunodeficiency virus type 1 quasispecies makes 
an important contribution to viral diversity in individual patients. J Virol 
2006,80:2472-2482. 
119. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped 
catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. 
Science 1998,282:1669-1675. 
120. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral 
fitness. Curr Opin Infect Dis 2001,14:23-28. 
121. Quiñones-Mateu ME, Arts EJ. HIV-1 Fitness: Implications for Drug Resistance, 
Disease Progression, and Global Epidemic Evolution. In: HIV Sequence 
Compendium. Edited by Kuiken C, Foley B, Hahn B, et al. Los Alamos, NM: 
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 
2001. pp. 134-170. 
122. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, et al. 
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse 
transcriptase containing both K65R and M184V mutations. J Biol Chem 
2004,279:509-516. 
123. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation 
in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 
2003,311:202-212. 
124. Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and 
resistance during human immunodeficiency virus reverse transcription. 
Antimicrob Agents Chemother 1996,40:527-540. 
125. Paintsil E, Margolis A, Collins JA, Alexander L. The contribution of HIV fitness to 




126. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of 
thymidine analog resistance pathways in human immunodeficiency virus type 1. 
J Virol 2006,80:7020-7027. 
127. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, et al. 
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine 
therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad 
Sci U S A 2006,103:7094-7099. 
128. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al. Persistence 
of transmitted drug resistance among subjects with primary human 
immunodeficiency virus infection. J Virol 2008,82:5510-5518. 
129. Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance 
mutations and fitness: a view from the clinic and ex vivo. Virus Res 
2008,134:104-123. 
130. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, et al. HIV-1 Protease 
and reverse-transcriptase mutations: correlations with antiretroviral therapy in 
subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 
2005,192:456-465. 
131. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine 
(AZT) isolated during prolonged therapy. Science 1989,243:1731-1734. 
132. Sarafianos SG, Das K, Clark AD, Jr., Ding J, Boyer PL, Hughes SH, et al. 
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric 
hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A 
1999,96:10027-10032. 
133. White KL, Margot NA, Ly JK, Chen JM, Ray AS, Pavelko M, et al. A combination 
of decreased NRTI incorporation and decreased excision determines the 
resistance profile of HIV-1 K65R RT. AIDS 2005,19:1751-1760. 
134. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular 
mechanisms of resistance to human immunodeficiency virus type 1 with reverse 
transcriptase mutations K65R and K65R+M184V and their effects on enzyme 
function and viral replication capacity. Antimicrob Agents Chemother 
2002,46:3437-3446. 
135. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et 




136. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human 
immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. 
Antimicrob Agents Chemother 2001,45:2144-2146. 
137. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors 
of HIV-1 reverse transcriptase. Virus Res 2008,134:124-146. 
138. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse 
transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-
terminated DNA synthesis. J Virol 2000,74:3579-3585. 
139. Hsiou Y, Ding J, Das K, Clark AD, Jr., Hughes SH, Arnold E. Structure of 
unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of 
conformational changes for polymerization and inhibition mechanisms. Structure 
1996,4:853-860. 
140. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Jr., Lu X, Tantillo C, et al. Crystal 
structure of human immunodeficiency virus type 1 reverse transcriptase 
complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc 
Natl Acad Sci U S A 1993,90:6320-6324. 
141. Domaoal RA, Demeter LM. Structural and biochemical effects of human 
immunodeficiency virus mutants resistant to non-nucleoside reverse 
transcriptase inhibitors. Int J Biochem Cell Biol 2004,36:1735-1751. 
142. Hsiou Y, Ding J, Das K, Clark AD, Jr., Boyer PL, Lewi P, et al. The Lys103Asn 
mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 
2001,309:437-445. 
143. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al. Structural 
mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 
reverse transcriptase and the improved resilience of second generation non-
nucleoside inhibitors. J Mol Biol 2001,312:795-805. 
144. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et 
al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 
Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 
2008. 
145. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of 
antiretroviral-drug-resistant HIV-1 variants. Lancet 1999,354:729-733. 
 161 
 
146. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. 
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations 
in treatment-experienced patients are missed by standard genotype analysis. J 
Clin Microbiol 2005,43:406-413. 
147. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, Major JC, et al. 
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a 
longitudinal testing approach. J Infect Dis 2005,191:1325-1330. 
148. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The 
prevalence of antiretroviral drug resistance in the United States. AIDS 
2004,18:1393-1401. 
149. Cheung PK, Wynhoven B, Harrigan PR. 2004: which HIV-1 drug resistance 
mutations are common in clinical practice? AIDS Rev 2004,6:107-116. 
150. de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I, 
Zahonero N, et al. Changing rates and patterns of drug resistance mutations in 
antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 
2007,23:879-885. 
151. Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in 
a clinical database correlates with antiretroviral utilization. AIDS Res Hum 
Retroviruses 2004,20:1-9. 
152. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long 
term probability of detection of HIV-1 drug resistance after starting antiretroviral 
therapy in routine clinical practice. AIDS 2005,19:487-494. 
153. Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, et al. Temporal 
characterization of drug resistance associated mutations in HIV-1 protease and 
reverse transcriptase in patients failing antiretroviral therapy. New Microbiol 
2006,29:89-100. 
154. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple 
antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis 
of over 7000 genotypes. AIDS 2003,17:2383-2388. 
155. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ, Jr. Triple-
class antiretroviral drug resistance: risk and predictors among HIV-1-infected 
patients. AIDS 2007,21:825-834. 
 162 
 
156. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et 
al. Multiple drug class-wide resistance associated with poorer survival after 
treatment failure in a cohort of HIV-infected patients. AIDS 2005,19:1081-1089. 
157. Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, 
Brodard V, et al. Prevalence of HIV-1 drug resistance in treated patients: a 
French nationwide study. J Acquir Immune Defic Syndr 2007,46:12-18. 
158. Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, et al. 
Genotypic resistance and immunologic outcomes among HIV-1-infected women 
with viral failure. J Acquir Immune Defic Syndr 2006,41:68-74. 
159. Gallego O, de Mendoza C, Corral A, Soriano V. Prevalence of drug resistance 
genotypes causing broad cross-resistance to nucleos(t)ide analogues. AIDS 
2004,18:689-690. 
160. Camacho R, Theys K, Abecasis A, Deforche K, Carvalho AP, Cabanas J, et al. 
Rise and fall of the RT K65R incidence in the Portugese resistance database 
[Abstract 121]. Antivir Ther 2006,11:S134. 
161. de Mendoza C, Jimenez-Nacher I, Garrido C, Barreiro P, Poveda E, Corral A, et 
al. Changing patterns in HIV reverse transcriptase resistance mutations after 
availability of tenofovir. Clin Infect Dis 2008,46:1782-1785. 
162. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, et al. 
Resistance profile and cross-resistance of HIV-1 among patients failing a non-
nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 
2001,65:445-448. 
163. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, et al. 
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral 
therapy. AIDS 2004,18:1503-1511. 
164. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ, Jr. HIV-1 
drug resistance evolution among patients on potent combination antiretroviral 
therapy with detectable viremia. J Acquir Immune Defic Syndr 2005,40:34-40. 
165. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution 
of drug resistance in HIV-infected patients remaining on a virologically failing 
combination antiretroviral therapy regimen. AIDS 2007,21:721-732. 
 163 
 
166. Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, et al. Rate of viral 
evolution and risk of losing future drug options in heavily pretreated, HIV-infected 
patients who continue to receive a stable, partially suppressive treatment 
regimen. Clin Infect Dis 2006,43:1329-1336. 
167. Metzner KJ, Allers K, Rauch P, Harrer T. Rapid selection of drug-resistant HIV-1 
during the first months of suppressive ART in treatment-naive patients. AIDS 
2007,21:703-711. 
168. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et 
al. Clinical outcome of patients with HIV-1 infection according to immunologic 
and virologic response after 6 months of highly active antiretroviral therapy. Ann 
Intern Med 2000,133:401-410. 
169. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. 
The clinical relevance of non-nucleoside reverse transcriptase inhibitor 
hypersusceptibility: a prospective cohort analysis. AIDS 2002,16:F33-40. 
170. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and 
HIV-1 disease progression or death in patients undergoing resistance testing. 
AIDS 2004,18:1539-1548. 
171. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test 
interpretation. Clin Infect Dis 2006,42:1608-1618. 
172. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. 
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 
2006,14:125-130. 
173. Bracciale L, Di Giambenedetto S, Colafigli M, La Torre G, Prosperi M, 
Santangelo R, et al. Virological suppression reduces clinical progression in 
patients with multiclass-resistant HIV type 1. AIDS Res Hum Retroviruses 
2009,25:261-267. 
174. Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, et al. The 
relationship between genotypic sensitivity score and treatment outcomes in late 
stage HIV disease after supervised HAART. J Med Virol 2009,81:1323-1335. 
175. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. 
Emergence of drug resistance is associated with an increased risk of death 
among patients first starting HAART. PLoS Med 2006,3:e356. 
 164 
 
176. Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf M, Peng G, Xiang Y, et al. The 
Incidence of HIV drug resistance and its impact on progression of HIV disease 
among antiretroviral-naive participants started on three different antiretroviral 
therapy strategies. HIV Clin Trials 2007,8:357-370. 
177. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. 
Sexual transmission of an HIV-1 variant resistant to multiple reverse-
transcriptase and protease inhibitors. N Engl J Med 1998,339:307-311. 
178. Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical 
transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998,12:2281-
2288. 
179. Veenstra J, Schuurman R, Cornelissen M, van't Wout AB, Boucher CA, 
Schuitemaker H, et al. Transmission of zidovudine-resistant human 
immunodeficiency virus type 1 variants following deliberate injection of blood 
from a patient with AIDS: characteristics and natural history of the virus. Clin 
Infect Dis 1995,21:556-560. 
180. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P, et al. 
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular 
epidemiology survey. AIDS 2007,21:2223-2229. 
181. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for 
epidemiological surveillance: basic principles and potential controversies. Antivir 
Ther 2008,13 Suppl 2:59-68. 
182. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. 
Curr Opin Infect Dis 2007,20:22-32. 
183. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. 
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 
2013,21:6-14. 
184. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human 
immunodeficiency virus reverse transcriptase and protease sequence database. 
Nucleic Acids Res 2003,31:298-303. 
185. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, et al. Risk of 
failure in patients with 215 HIV-1 revertants starting their first thymidine analog-
containing highly active antiretroviral therapy. AIDS 2004,18:227-235. 
 165 
 
186. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, et al. 
Switch to unusual amino acids at codon 215 of the human immunodeficiency 
virus type 1 reverse transcriptase gene in seroconvertors infected with 
zidovudine-resistant variants. J Virol 1998,72:3520-3523. 
187. Mihailidis C, Dunn D, Pillay D, Pozniak A. Effect of isolated V118I mutation in 
reverse transcriptase on response to first-line antiretroviral therapy. AIDS 
2008,22:427-430. 
188. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 
protease and reverse transcriptase mutations for drug resistance surveillance. 
AIDS 2007,21:215-223. 
189. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. 
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 
2009 update. PLoS ONE 2009,4:e4724. 
190. Fox JM, Fidler S, Weber J. Resistance to HIV drugs in UK may be lower in some 
areas. BMJ 2006,332:179-180. 
191. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, et al. A 
population-based approach to determine the prevalence of transmitted drug-
resistant HIV among recent versus established HIV infections: results from the 
Canadian HIV strain and drug resistance surveillance program. J Acquir Immune 
Defic Syndr 2006,42:86-90. 
192. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. 
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, 
treatment-naive patients: implications for routine resistance screening before 
initiation of antiretroviral therapy. Clin Infect Dis 2005,40:468-474. 
193. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains 
limited to single classes. AIDS 2008,22:625-635. 
194. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, 
Jr., et al. The epidemiology of antiretroviral drug resistance among drug-naive 
HIV-1-infected persons in 10 US cities. J Infect Dis 2004,189:2174-2180. 
195. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral 
drug resistance in HIV-1 infection. J Antimicrob Chemother 2007,59:1047-1056. 
 166 
 
196. Toni T, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, et al. HIV-1 
antiretroviral drug resistance in recently infected patients in Abidjan, Cote 
d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 
2007,23:1155-1160. 
197. Sigaloff KC, Mandaliya K, Hamers RL, Otieno F, Jao IM, Lyagoba F, et al. Short 
communication: High prevalence of transmitted antiretroviral drug resistance 
among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum 
Retroviruses 2012,28:1033-1037. 
198. Ssemwanga D, Kapaata A, Lyagoba F, Magambo B, Nanyonjo M, Mayanja BN, 
et al. Low drug resistance levels among drug-naive individuals with recent HIV 
type 1 infection in a rural clinical cohort in southwestern Uganda. AIDS Res Hum 
Retroviruses 2012,28:1784-1787. 
199. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, Nanteza B, et al. 
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young 
individuals in Kampala. AIDS 2011,25:905-910. 
200. Nazziwa J, Njai HF, Ndembi N, Birungi J, Lyagoba F, Gershim A, et al. Short 
communication: HIV type 1 transmitted drug resistance and evidence of 
transmission clusters among recently infected antiretroviral-naive individuals from 
Ugandan fishing communities of Lake Victoria. AIDS Res Hum Retroviruses 
2013,29:788-795. 
201. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al. Transmitted 
HIV type 1 drug resistance among individuals with recent HIV infection in East 
and Southern Africa. AIDS Res Hum Retroviruses 2011,27:5-12. 
202. Zhang J, Kang D, Fu J, Sun X, Lin B, Bi Z, et al. Surveillance of transmitted HIV 
type 1 drug resistance in newly diagnosed hiv type 1-infected patients in 
Shandong Province, China. AIDS Res Hum Retroviruses 2010,26:99-103. 
203. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, 
Kittihanukul C, Kamudamas A, et al. Antiretroviral drug resistance among 
antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 
2008,9:322-325. 
204. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, et al. 
Prevalence of transmitted HIV-1 drug resistance and the role of resistance 
algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 
2003. J Acquir Immune Defic Syndr 2005,40:505-511. 
 167 
 
205. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, et al. 
Prevalence of transmitted drug resistance and impact of transmitted resistance 
on treatment success in the German HIV-1 Seroconverter Cohort. PLoS ONE 
2010,5:e12718. 
206. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, et al. Evolution of 
transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 
2010. Clin Microbiol Infect 2012,18:E299-304. 
207. Temereanca A, Ene L, Mehta S, Manolescu L, Duiculescu D, Ruta S. 
Transmitted HIV drug resistance in treatment-naive Romanian patients. J Med 
Virol 2013. 
208. Lunar MM, Zidovec Lepej S, Abecasis AB, Tomazic J, Vidmar L, Karner P, et al. 
Short communication: prevalence of HIV type 1 transmitted drug resistance in 
Slovenia: 2005-2010. AIDS Res Hum Retroviruses 2013,29:343-349. 
209. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, et al. 
Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of 
HIV type 1 non-B subtypes are increasing among persons with recent infection in 
Spain. Clin Infect Dis 2005,41:1350-1354. 
210. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort 
Study, UK Register of HIV Seroconverters. Evidence of a decline in transmitted 
HIV-1 drug resistance in the United Kingdom. AIDS 2007,21:1035-1039. 
211. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. 
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed 
HIV-1 infection. J Antimicrob Chemother 2007,59:517-524. 
212. Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, et al. Prevalence of primary 
genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly 
diagnosed treatment-naive individuals. AIDS 2007,21:237-239. 
213. Dilernia DA, Lourtau L, Gomez AM, Ebenrstejin J, Toibaro JJ, Bautista CT, et al. 
Drug-resistance surveillance among newly HIV-1 diagnosed individuals in 
Buenos Aires, Argentina. AIDS 2007,21:1355-1360. 
214. Barreto CC, Nishyia A, Araujo LV, Ferreira JE, Busch MP, Sabino EC. Trends in 
antiretroviral drug resistance and clade distributions among HIV-1--infected blood 
donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006,41:338-341. 
 168 
 
215. Varella RB, Ferreira SB, de Castro MB, Zalis MG, Tavares MD. Human 
immunodeficiency virus type 1 protease and reverse transcriptase mutation 
patterns among treatment-naive patients in different stages of infection in Rio de 
Janeiro, Brazil. J Med Virol 2007,79:1033-1039. 
216. Perez L, Kouri V, Aleman Y, Abrahantes Y, Correa C, Aragones C, et al. 
Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba. Infect 
Genet Evol 2013,16:144-150. 
217. Murillo W, Lorenzana de Rivera I, Albert J, Guardado ME, Nieto AI, Paz-Bailey 
G. Prevalence of transmitted HIV-1 drug resistance among female sex workers 
and men who have sex with men in El Salvador, Central America. J Med Virol 
2012,84:1514-1521. 
218. Viani RM, Hsia K, Hubbard P, Ruiz-Calderon J, Lozada R, Alvelais J, et al. 
Prevalence of primary HIV-1 drug resistance in pregnant women and in newly 
diagnosed adults at Tijuana General Hospital, Baja California, Mexico. Int J STD 
AIDS 2007,18:235-238. 
219. Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, et al. 
Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a 
third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 
2006,42:501-505. 
220. Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, et al. 
Factors associated with a decrease in the prevalence of drug resistance in newly 
HIV-1 infected individuals in Montreal. AIDS 2004,18:2305-2312. 
221. Liu L, May S, Richman DD, Hecht FM, Markowitz M, Daar ES, et al. Comparison 
of algorithms that interpret genotypic HIV-1 drug resistance to determine the 
prevalence of transmitted drug resistance. AIDS 2008,22:835-839. 
222. Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, et al. 
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who 
have sex with men with recent HIV-1 infection. Aids 2007,21:1165-1174. 
223. Yanik EL, Napravnik S, Hurt CB, Dennis A, Quinlivan EB, Sebastian J, et al. 
Prevalence of Transmitted Antiretroviral Drug Resistance Differs Between 




224. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, et al. Tracking the 
prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of 
experience. J Acquir Immune Defic Syndr 2006,41:439-446. 
225. Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A, et al. Transmitted 
drug resistance and phylogenetic relationships among acute and early HIV-1-
infected individuals in New York City. J Acquir Immune Defic Syndr 2012,61:1-8. 
226. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 
drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after 
rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect 
Dis 2011,11:750-759. 
227. Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, et al. 
HIV-1 drug-resistance mutations among newly diagnosed patients before 
scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 
2006,11:575-579. 
228. Muwonga J, Edidi S, Butel C, Vidal N, Monleau M, Okenge A, et al. Resistance 
to antiretroviral drugs in treated and drug-naive patients in the Democratic 
Republic of Congo. J Acquir Immune Defic Syndr 2011,57 Suppl 1:S27-33. 
229. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiura W. Molecular 
epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS 
Res Hum Retroviruses 2007,23:564-568. 
230. Hassan AS, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ, Rinke de Wit 
TF, et al. Low prevalence of transmitted HIV type 1 drug resistance among 
antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum 
Retroviruses 2013,29:129-135. 
231. Derache A, Maiga AI, Traore O, Akonde A, Cisse M, Jarrousse B, et al. Evolution 
of genetic diversity and drug resistance mutations in HIV-1 among untreated 
patients from Mali between 2005 and 2006. J Antimicrob Chemother 
2008,62:456-463. 
232. Maiga AI, Fofana DB, Maiga AC, Diallo F, Ait-Arkoub Z, Daou F, et al. 
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated 




233. Annaz HE, Recordon-Pinson P, Baba N, Sedrati O, Mrani S, Fleury H. Presence 
of drug resistance mutations among drug-naive patients in Morocco. AIDS Res 
Hum Retroviruses 2011,27:917-920. 
234. Diop-Ndiaye H, Toure-Kane C, Leye N, Ngom-Gueye NF, Montavon C, Peeters 
M, et al. Antiretroviral drug resistance mutations in antiretroviral-naive patients 
from Senegal. AIDS Res Hum Retroviruses 2010,26:1133-1138. 
235. Nwobegahay J, Selabe G, Ndjeka NO, Manhaeve C, Bessong PO. Low 
prevalence of transmitted genetic drug resistance in a cohort of HIV infected 
naive patients entering antiretroviral treatment programs at two sites in northern 
South Africa. J Med Virol 2012,84:1839-1843. 
236. Ndembi N, Lyagoba F, Nanteza B, Kushemererwa G, Serwanga J, Katongole-
Mbidde E, et al. Transmitted antiretroviral drug resistance surveillance among 
newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, 
Uganda. AIDS Res Hum Retroviruses 2008,24:889-895. 
237. Arora SK, Gupta S, Toor JS, Singla A. Drug resistance-associated genotypic 
alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North 
India. AIDS Res Hum Retroviruses 2008,24:125-130. 
238. Chaturbhuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS, et 
al. Transmitted HIV drug resistance among HIV-infected voluntary counseling 
and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum 
Retroviruses 2010,26:927-932. 
239. Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, Koppada R, Datkar 
SR, et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 
1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res 
Hum Retroviruses 2011,27:1291-1297. 
240. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et 
al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 
2011. PLoS ONE 2013,8:e61864. 
241. Grossman Z, Lorber M, Maayan S, Bar-Yacov N, Levy I, Averbuch D, et al. Drug-
resistant HIV infection among drug-naive patients in Israel. Clin Infect Dis 
2005,40:294-302. 
242. Ibe S, Hattori J, Fujisaki S, Shigemi U, Fujisaki S, Shimizu K, et al. Trend of drug-
resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: 
 171 
 
an 8-year surveillance from 1999 to 2006. AIDS Res Hum Retroviruses 
2008,24:7-14. 
243. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, et al. 
Trends in transmitted drug-resistant HIV-1 and demographic characteristics of 
newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. 
Antiviral Res 2010,88:72-79. 
244. Bang JI, Song KH, Kim SH, Cho JH, Park WB, Park SW, et al. Prevalence of 
primary antiretroviral resistance: trends in Korea. AIDS Res Hum Retroviruses 
2008,24:83-85. 
245. Tee KK, Kamarulzaman A, Ng KP. Short communication: low prevalence of 
genotypic drug resistance mutations among antiretroviral-naive HIV type 1 
patients in Malaysia. AIDS Res Hum Retroviruses 2006,22:121-124. 
246. Chang SY, Chen MY, Lee CN, Sun HY, Ko W, Chang SF, et al. Trends of 
antiretroviral drug resistance in treatment-naive patients with human 
immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 
2008,61:689-693. 
247. Apisarnthanarak A, Mundy LM. Antiretroviral drug resistance among 
antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. 
Clin Infect Dis 2008,46:1630-1631. 
248. Sungkanuparph S, Sukasem C, Kiertiburanakul S, Pasomsub E, Chantratita W. 
Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-
infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int 
AIDS Soc 2012,15:12. 
249. Manosuthi W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. HIV-
1 drug resistance-associated mutations among antiretroviral-naive Thai patients 
with chronic HIV-1 infection. J Med Virol 2013,85:194-199. 
250. Duc NB, Hien BT, Wagar N, Tram TH, Giang le T, Yang C, et al. Surveillance of 
transmitted HIV drug resistance using matched plasma and dried blood spot 
specimens from voluntary counseling and testing sites in Ho Chi Minh City, 
Vietnam, 2007-2008. Clin Infect Dis 2012,54 Suppl 4:S343-347. 
251. Dean J, Ta Thi TH, Dunford L, Carr MJ, Nguyen LT, Coughlan S, et al. 
Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a 
multicenter study. AIDS Res Hum Retroviruses 2011,27:797-801. 
 172 
 
252. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, et al. 
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell 
count response to combination antiretroviral therapy in the EuroSIDA Study. J 
Acquir Immune Defic Syndr 2008,48:324-333. 
253. Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, et al. 
Prevalence and epidemiology of HIV type 1 drug resistance among newly 
diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum 
Retroviruses 2008,24:355-362. 
254. Grgic I, Lepej SZ, Lunar MM, Poljak M, Vince A, Vrakela IB, et al. The 
prevalence of transmitted drug resistance in newly diagnosed HIV-infected 
individuals in Croatia: the role of transmission clusters of men who have sex with 
men carrying the T215S surveillance drug resistance mutation. AIDS Res Hum 
Retroviruses 2013,29:329-336. 
255. Audelin AM, Gerstoft J, Obel N, Mathiesen L, Laursen A, Pedersen C, et al. 
Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV 
Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses 
2011,27:1283-1290. 
256. Vazquez de Parga E, Rakhmanova A, Perez-Alvarez L, Vinogradova A, Delgado 
E, Thomson MM, et al. Analysis of drug resistance-associated mutations in 
treatment-naive individuals infected with different genetic forms of HIV-1 
circulating in countries of the former Soviet Union. J Med Virol 2005,77:337-344. 
257. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al. 
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob 
Chemother 2007,60:843-848. 
258. Paraskevis D, Magiorkinis E, Katsoulidou A, Hatzitheodorou E, Antoniadou A, 
Papadopoulos A, et al. Prevalence of resistance-associated mutations in newly 
diagnosed HIV-1 patients in Greece. Virus Res 2005,112:115-122. 
259. Skoura L, Metallidis S, Pilalas D, Kourelis A, Margariti A, Papadimitriou E, et al. 
High rates of transmitted drug resistance among newly-diagnosed antiretroviral 
naive HIV patients in Northern Greece, data from 2009-2011. Clin Microbiol 
Infect 2013,19:E169-172. 
260. Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, et al. 
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in 




261. Lapadula G, Izzo I, Gargiulo F, Paraninfo G, Castelnuovo F, Quiros-Roldan E, et 
al. Updated prevalence of genotypic resistance among HIV-1 positive patients 
naive to antiretroviral therapy: a single center analysis. J Med Virol 2008,80:747-
753. 
262. Balode D, Westman M, Kolupajeva T, Rozentale B, Albert J. Low prevalence of 
transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J 
Med Virol 2010,82:2013-2018. 
263. Babic DZ, Zelnikar M, Seme K, Vandamme AM, Snoeck J, Tomazic J, et al. 
Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes 
in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 
2006,118:156-163. 
264. Garcia F, Perez-Cachafeiro S, Guillot V, Alvarez M, Perez-Romero P, Perez-
Elias MJ, et al. Transmission of HIV drug resistance and non-B subtype 
distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected 
individuals (CoRIS). Antiviral Res 2011,91:150-153. 
265. Monge S, Guillot V, Alvarez M, Pena A, Viciana P, Garcia-Bujalance S, et al. 
Analysis of transmitted drug resistance in Spain in the years 2007-2010 
documents a decline in mutations to the non-nucleoside drug class. Clin 
Microbiol Infect 2012,18:E485-490. 
266. Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, Sonnerborg A, et al. Low 
prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 
infection in Sweden 2003-2010. PLoS ONE 2012,7:e33484. 
267. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The Impact of Different 
Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the 
United Kingdom. J Acquir Immune Defic Syndr 2008. 
268. Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar JA, et al. Low 
prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 
cohort. J Antimicrob Chemother 2008,62:464-468. 
269. Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, et al. Time trends in 
drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre 
observational study. BMJ 2012,345:e5253. 
270. Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JL, 
et al. Low prevalence of primary antiretroviral resistance mutations and 
 174 
 
predominance of HIV-1 clade C at polymerase gene in newly diagnosed 
individuals from south Brazil. Virus Res 2006,116:201-207. 
271. Arruda E, Simoes L, Sucupira C, Medeiros M, Diaz RS, Lima A. Short 
communication: intermediate prevalence of HIV type 1 primary antiretroviral 
resistance in Ceara State, Northeast Brazil. AIDS Res Hum Retroviruses 
2011,27:153-156. 
272. Bermudez-Aza EH, Kerr LR, Kendall C, Pinho AA, de Mello MB, Mota RS, et al. 
Antiretroviral drug resistance in a respondent-driven sample of HIV-infected men 
who have sex with men in Brazil. J Acquir Immune Defic Syndr 2011,57 Suppl 
3:S186-192. 
273. Graf T, Passaes CP, Ferreira LG, Grisard EC, Morgado MG, Bello G, et al. HIV-1 
genetic diversity and drug resistance among treatment naive patients from 
Southern Brazil: an association of HIV-1 subtypes with exposure categories. J 
Clin Virol 2011,51:186-191. 
274. Rios M, Delgado E, Perez-Alvarez L, Fernandez J, Galvez P, de Parga EV, et al. 
Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med 
Virol 2007,79:647-656. 
275. Myers JE, Taylor BS, Rojas Fermin RA, Reyes EV, Vaughan C, Jose L, et al. 
Transmitted drug resistance among antiretroviral-naive patients with established 
HIV type 1 infection in Santo Domingo, Dominican Republic and review of the 
Latin American and Caribbean literature. AIDS Res Hum Retroviruses 
2012,28:667-674. 
276. Lloyd B, O'Connell RJ, Michael NL, Aviles R, Palou E, Hernandez R, et al. 
Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning 
of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 
2008,24:529-535. 
277. Murillo W, Paz-Bailey G, Morales S, Monterroso E, Paredes M, Dobbs T, et al. 
Transmitted drug resistance and type of infection in newly diagnosed HIV-1 
individuals in Honduras. J Clin Virol 2010,49:239-244. 
278. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, Corona-Nakamura 
A, Amaya-Tapia G, Quintero-Perez N, et al. Drug-resistance mutations in 




279. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, et al. Prevalence 
of antiretroviral drug resistance and resistance-associated mutations in 
antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. 
HIV Clin Trials 2007,8:1-8. 
280. Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, et al. 
Transmitted drug resistance in the CFAR network of integrated clinical systems 
cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS ONE 
2011,6:e21189. 
281. Hightow-Weidman LB, Hurt CB, Phillips G, 2nd, Jones K, Magnus M, Giordano 
TP, et al. Transmitted HIV-1 drug resistance among young men of color who 
have sex with men: a multicenter cohort analysis. J Adolesc Health 2011,48:94-
99. 
282. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. 
Prevalence of transmitted drug resistance associated mutations and HIV-1 
subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010,24:1203-1212. 
283. Huang HY, Daar ES, Sax PE, Young B, Cook P, Benson P, et al. The prevalence 
of transmitted antiretroviral drug resistance in treatment-naive patients and 
factors influencing first-line treatment regimen selection. HIV Med 2008,9:285-
293. 
284. Klibanov OM, Dolder CR, Assefa F, Ekwonu TJ. Baseline antiretroviral resistance 
and clinical outcomes in an urban HIV clinic. AIDS Patient Care STDS 
2013,27:205-207. 
285. Huaman MA, Aguilar J, Baxa D, Golembieski A, Brar I, Markowitz N. Late 
presentation and transmitted drug resistance mutations in new HIV-1 diagnoses 
in Detroit. Int J Infect Dis 2011,15:e764-768. 
286. MacVeigh MS, Kosmetatos MK, McDonald JE, Reeder JL, Parrish DA, Young 
TP. Prevalence of drug-resistant HIV type 1 at the time of initiation of 
antiretroviral therapy in Portland, Oregon. AIDS Res Hum Retroviruses 
2013,29:337-342. 
287. Grubb JR, Singhatiraj E, Mondy K, Powderly WG, Overton ET. Patterns of 
primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected 
individuals in a midwest university clinic. AIDS 2006,20:2115-2116. 
288. Taniguchi T, Nurutdinova D, Grubb JR, Onen NF, Shacham E, Donovan M, et al. 
Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic 
 176 
 
outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum 
Retroviruses 2012,28:259-264. 
289. Boyd AC, Herzberg EM, Marshall MM, Lamparello NA, De Leon MA, Porter A, et 
al. Antiretroviral Drug Resistance Among Treatment-Naive HIV-1-Infected 
Persons in Washington, D.C. AIDS Patient Care STDS 2008. 
290. Readhead AC, Gordon DE, Wang Z, Anderson BJ, Brousseau KS, Kouznetsova 
MA, et al. Transmitted antiretroviral drug resistance in New York State, 2006-
2008: results from a new surveillance system. PLoS ONE 2012,7:e40533. 
291. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. 
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: 
implications for clinical management. J Infect Dis 2005,192:958-966. 
292. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology 
of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012,14:17-
27. 
293. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, et al. 
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. 
Antivir Ther 2008,13 Suppl 2:49-57. 
294. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global 
trends in antiretroviral resistance in treatment-naive individuals with HIV after 
rollout of antiretroviral treatment in resource-limited settings: a global 
collaborative study and meta-regression analysis. Lancet 2012,380:1250-1258. 
295. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, et al. Evidence of 
differential selection of HIV-1 variants carrying drug-resistant mutations in 
seroconverters. Antivir Ther 2006,11:329-334. 
296. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, et al. Infrequent 
transmission of HIV-1 drug-resistant variants. Antivir Ther 2004,9:375-384. 
297. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, et al. Diminished 
representation of HIV-1 variants containing select drug resistance-conferring 




298. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, et al. Evolution of 
transmitted HIV-1 with drug-resistance mutations in the absence of therapy: 
effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 2006,11:173-178. 
299. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, et al. Long-term 
persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir 
Immune Defic Syndr 2004,37:1570-1573. 
300. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A. Individual contributions of 
mutant protease and reverse transcriptase to viral infectivity, replication, and 
protein maturation of antiretroviral drug-resistant human immunodeficiency virus 
type 1. J Virol 2001,75:3291-3300. 
301. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations 
associated with human immunodeficiency virus type 1 drug resistance is 
modulated by mutational interactions. J Virol 2007,81:3037-3041. 
302. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, et al. 
Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 
2004,18:1571-1577. 
303. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, Dupke S, et al. 
Impact of transmission of drug-resistant HIV on the course of infection and the 
treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 
2007,8:511-519. 
304. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The 
impact of transmitted drug resistance on the natural history of HIV infection and 
response to first-line therapy. AIDS 2006,20:21-28. 
305. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, 
et al. Transmission of HIV-1 minority-resistant variants and response to first-line 
antiretroviral therapy. AIDS 2008,22:1417-1423. 
306. Tamalet C, Pasquier C, Yahi N, Colson P, Poizot-Martin I, Lepeu G, et al. 
Prevalence of drug resistant mutants and virological response to combination 
therapy in patients with primary HIV-1 infection. J Med Virol 2000,61:181-186. 
307. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics 




308. Shafer RW, Warford A, Winters MA, Gonzales MJ. Reproducibility of human 
immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase 
sequencing of plasma samples from heavily treated HIV-1-infected individuals. J 
Virol Methods 2000,86:143-153. 
309. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci U S A 1977,74:5463-5467. 
310. Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, et al. 
Fluorescence detection in automated DNA sequence analysis. Nature 
1986,321:674-679. 
311. Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, 
Bacheler L. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update 
based on recent pivotal clinical trial data and a revised approach to viral 
mixtures. J Virol Methods 2009,162:101-108. 
312. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. 
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy 
after treatment failure: a randomized trial. AIDS 2002,16:727-736. 
313. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 
update of the drug resistance mutations in HIV-1. Top Antivir Med 2011,19:156-
164. 
314. Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, Belousov ES, et al. 3'-
minor groove binder-DNA probes increase sequence specificity at PCR 
extension temperatures. Nucleic Acids Res 2000,28:655-661. 
315. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. 
Emergence of minor populations of human immunodeficiency virus type 1 
carrying the M184V and L90M mutations in subjects undergoing structured 
treatment interruptions. J Infect Dis 2003,188:1433-1443. 
316. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, et al. Blinded, 
multicenter comparison of methods to detect a drug-resistant mutant of human 
immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006,44:2612-
2614. 
317. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. 
Oligonucleotide ligation assay for detecting mutations in the human 
immunodeficiency virus type 1 pol gene that are associated with resistance to 
zidovudine, didanosine, and lamivudine. J Clin Microbiol 1998,36:569-572. 
 179 
 
318. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, Delwart EL. 
Sequencing-based detection of low-frequency human immunodeficiency virus 
type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking 
assay. J Virol 2004,78:7112-7123. 
319. Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R. A multiple-site-specific 
heteroduplex tracking assay as a tool for the study of viral population dynamics. 
Proc Natl Acad Sci U S A 2001,98:176-181. 
320. Schnell G, Ince WL, Swanstrom R. Identification and recovery of minor HIV-1 
variants using the heteroduplex tracking assay and biotinylated probes. Nat 
Methods (in press) 2008. 
321. Holterman L, Dubbes R, Mullins J, Haaijman J, Heeney J. A strategy for cloning 
infectious molecular clones of retroviruses from serum or plasma. J Virol 
Methods 2000,84:37-48. 
322. Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, et al. 
Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood 
mononuclear cells and viral isolates from treatment-naive and HAART patients. J 
Med Virol 2001,65:207-217. 
323. Malet I, Belnard M, Agut H, Cahour A. From RNA to quasispecies: a DNA 
polymerase with proofreading activity is highly recommended for accurate 
assessment of viral diversity. J Virol Methods 2003,109:161-170. 
324. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et 
al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. 
Nature 1995,374:569-571. 
325. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. Monitoring 
resistance to human immunodeficiency virus type 1 protease inhibitors by 
pyrosequencing. J Clin Microbiol 2001,39:464-473. 
326. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, 
et al. Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature 2008,456:53-59. 
327. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. 




328. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single 
DNA molecules into fluorescent magnetic particles for detection and enumeration 
of genetic variations. Proc Natl Acad Sci U S A 2003,100:8817-8822. 
329. Leamon JH, Lee WL, Tartaro KR, Lanza JR, Sarkis GJ, deWinter AD, et al. A 
massively parallel PicoTiterPlate based platform for discrete picoliter-scale 
polymerase chain reactions. Electrophoresis 2003,24:3769-3777. 
330. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. 
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. 
Proc Natl Acad Sci U S A 2008,105:13081-13086. 
331. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 
2010,11:31-46. 
332. Holodniy M, Mole L, Yen-Lieberman B, Margolis D, Starkey C, Carroll R, et al. 
Comparative stabilities of quantitative human immunodeficiency virus RNA in 
plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and 
standard VACUTAINER tubes. J Clin Microbiol 1995,33:1562-1566. 
333. Cepko C. Large-scale preparation and concentration of retrovirus stocks. Curr 
Protoc Mol Biol 2001,Chapter 9:Unit9 12. 
334. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from 
HIV-1. Science 1988,242:1171-1173. 
335. Fang G, Zhu G, Burger H, Keithly JS, Weiser B. Minimizing DNA recombination 
during long RT-PCR. J Virol Methods 1998,76:139-148. 
336. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, Jessen H, et al. 
Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. 
AIDS 2005,19:1819-1825. 
337. Cline J, Braman JC, Hogrefe HH. PCR fidelity of pfu DNA polymerase and other 
thermostable DNA polymerases. Nucleic Acids Res 1996,24:3546-3551. 
338. Yang YL, Wang G, Dorman K, Kaplan AH. Long polymerase chain reaction 
amplification of heterogeneous HIV type 1 templates produces recombination at 
a relatively high frequency. AIDS Res Hum Retroviruses 1996,12:303-306. 
 181 
 
339. Napravnik S, Eron JJ, Jr., McKaig RG, Heine AD, Menezes P, Quinlivan E. 
Factors associated with fewer visits for HIV primary care at a tertiary care center 
in the Southeastern U.S. AIDS Care 2006,18 Suppl 1:S45-50. 
340. Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the 
southern United States: sexual networks and social context. Sex Transm Dis 
2006,33:S39-45. 
341. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at 
the turn of the century: an epidemic in transition. Am J Public Health 
2001,91:1060-1068. 
342. Dennis AM, Napravnik S, Sena AC, Eron JJ. Late entry to HIV care among 
Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis 
2011,53:480-487. 
343. Yanik EL, Tamburro K, Eron JJ, Damania B, Napravnik S, Dittmer DP. Recent 
cancer incidence trends in an observational clinical cohort of HIV-infected 
patients in the US, 2000 to 2011. Infect Agent Cancer 2013,8:18. 
344. University of North Carolina. UNC Center for AIDS Research web site. In; 2007. 
345. Jose M, Gajardo R, Jorquera JI. Stability of HCV, HIV-1 and HBV nucleic acids in 
plasma samples under long-term storage. Biologicals 2005,33:9-16. 
346. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al. 
Low-abundance drug-resistant viral variants in chronically HIV-infected, 
antiretroviral treatment-naive patients significantly impact treatment outcomes. J 
Infect Dis 2009,199:693-701. 
347. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. 
Multiple sequence alignment with the Clustal series of programs. Nucleic Acids 
Res 2003,31:3497-3500. 
348. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: 
Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, 
Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol 
2011,28:2731-2739. 
349. Kimura M. A simple method for estimating evolutionary rates of base 




350. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. Accuracy and quality of 
massively parallel DNA pyrosequencing. Genome Biol 2007,8:R143. 
351. Williams RL. A note on robust variance estimation for cluster-correlated data. 
Biometrics 2000,56:645-646. 
352. Cox DR. Regression Models and Life-Tables. J R Stat Soc [Ser B] 1972,34:187-
220. 
353. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd 
ed. Hoboken, N.J.: J. Wiley; 2002. 
354. Efron B. The Efficiency of Cox's Likelihood Function for Censored Data. J Am 
Stat Assoc 1977,72:557-565. 
355. Breslow N. Covariance analysis of censored survival data. Biometrics 
1974,30:89-99. 
356. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in 
clinical trials: good practice and pitfalls. Lancet 2002,359:1686-1689. 
357. Allison PD, SAS Institute. "Heterogeneity, repeated events, and other topics". In: 
Survival Analysis Using the SAS system: A Practical Guide. Cary, NC: SAS 
Institute; 1995. pp. viii, 292 p.249-252. 
358. Buchacz K, Baker RK, Palella FJ, Jr., Chmiel JS, Lichtenstein KA, Novak RM, et 
al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort 
study. AIDS 2010,24:1549-1559. 
359. Moore RD, Keruly JC, Bartlett JG. Improvement in the Health of HIV-Infected 
Persons in Care: Reducing Disparities. Clin Infect Dis 2012,55:1242-1251. 
360. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates 
of forward transmission events after acute/early HIV-1 infection. J Infect Dis 
2007,195:951-959. 
361. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Gunthard HF, et al. 
The impact of transmission clusters on primary drug resistance in newly 
diagnosed HIV-1 infection. AIDS 2009,23:1415-1423. 
 183 
 
362. Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, et al. Impact of 
transmitted drug-resistance on treatment selection and outcome of first-line 
Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr 
2010,53:633-639. 
363. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. 
Effect of transmitted drug resistance on virological and immunological response 
to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint 
project): a European multicohort study. Lancet Infect Dis 2011,11:363-371. 
364. Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, et al. 
Low level of the K103N HIV-1 above a threshold is associated with virological 
failure in treatment-naive individuals undergoing efavirenz-containing therapy. 
AIDS 2011,25:325-333. 
365. Jakobsen MR, Tolstrup M, Sogaard OS, Jorgensen LB, Gorry PR, Laursen A, et 
al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on 
treatment outcome. Clin Infect Dis 2010,50:566-573. 
366. Johnson JA, Li JF, Wei X, Craig C, Stone C, Horton JH, et al. Baseline detection 
of low-frequency drug resistance-associated mutations is strongly associated 
with virological failure in previously antiretroviral-naive HIV-1-infected persons. 
Antivir Ther 2006,11:S79-S79. 
367. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence 
and clinical significance of HIV drug resistance mutations by ultra-deep 
sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE 
2010,5:e10952. 
368. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, et al. Prevalence 
of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants 
in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2011,50:156-
161. 
369. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, Liu T, et al. 
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance 
mutation. PLoS ONE 2010,5:e10992. 
370. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, 3rd, Shikuma C, 
et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors 
predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-
infected subjects. J Infect Dis 2008,197:867-870. 
 184 
 
371. Krueger F, Andrews SR, Osborne CS. Large scale loss of data in low-diversity 
illumina sequencing libraries can be recovered by deferred cluster calling. PLoS 
ONE 2011,6:e16607. 
372. Wang J, Bambara RA, Demeter LM, Dykes C. Reduced fitness in cell culture of 
HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations 
correlates with relative levels of reverse transcriptase content and RNase H 
activity in virions. J Virol 2010,84:9377-9389. 
373. Wang J, Li D, Bambara RA, Yang H, Dykes C. L74V increases the reverse 
transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase 
drug-resistant mutations L100I+K103N and K101E+G190S, which results in 
increased fitness. J Gen Virol 2013,94:1597-1607. 
374. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, Maenza J, et al. Prevalence 
and impact of minority variant drug resistance mutations in primary HIV-1 
infection. PLoS ONE 2011,6:e28952. 
 
 
 
